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Introduction 11
PERITONEAL DIALYSIS
Patients with chronic renal failure have an accumulation of extracellular fl uid and waste 
products (uremic toxins) which are normally excreted by the kidney. There are diff erent renal 
replacement therapies, which can partially correct these abnormalities. Peritoneal dialysis (PD) 
is one of these modalities. Since the introduction of continuous ambulatory peritoneal dialysis 
(CAPD) in 1976 1, the use of PD has increased steadily and is now used worldwide. On January 
1st 2009, 6292 patients were on dialysis in The Netherlands, of which 18.1 % (n=1139) were on 
PD (source:RENINE www.renine.nl).
In PD the peritoneal membrane is used as a dialyzer membrane. By gravity a sterile dialysis 
solution is instilled in the peritoneal cavity via an intra-abdominal catheter. Through a com-
bination of diff usion and convection waste products and fl uid are transported between the 
peritoneal capillaries and the dialysis fl uid. After a few hours an equilibration is reached, and 
the effl  uent is drained. In the regular CAPD scheme, this cycle is performed 4 times a day for 4 
hours with a long night dwell.
Dialysis solutions contain varying concentrations of glucose in order to provide an osmotic 
gradient necessary for the transport and removal of excess body water. The glucose is absorbed 
by the peritoneal capillaries, which leads to a decrease of the osmotic gradient. In the early 
nineties icodextrin was introduced as a new dialysis fl uid. This is a glucose polymer derived 
from starches, which is absorbed slowly by the capillaries. Therefore it is very eff ective for 
ultrafi ltration, particularly in long dwells 2. Although, the side eff ects of icodextrin appear to be 
limited, sterile peritonitis due to icodextrin has been reported 3.
Normal peritoneum comprises diff erent components; a thin layer of mesothelial cells and a 
submesothelial layer with vessels and fi broblasts. The inner abdominal wall is lined with a pari-
etal membrane, where as a visceral membrane covers the intestines. Continuous exposure to 
dialysis solutions and other exogenous factors results in changes of the peritoneal membrane. 
In long term PD there is mesothelial denudation, the submesothelial layer becomes thicker and 
new vessels develop 4.
The 5-years survival of the PD population is approximately 50 % 5. The main reasons of mor-
tality are cardiovascular disease, infections and malnutrition. The reports on the survival of PD 
and hemodialysis (HD) patients are somewhat confl icting. Some reports showed comparable 
mortality rates of PD and HD patients 6-7. There are also reports that show a slightly increased 
survival in the fi rst years of renal replacement therapy of PD compared to HD 8-9. This may be 
explained by the improved preservation of renal residual function in PD patients, which is an 
independent predictor of mortality 10-11.
Despite the fact that both patient and technique survival improved during the decades, 
the number of patients on PD is decreasing. In the Netherlands the proportion of dialysis 
patients on PD was 31.3% in 2002 and this decreased to 18.1% in 2010 (source: RENINE data-
base). The reason for this decline is not completely understood but appears to be a worldwide 
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phenomenon 12-13. It is probably because of multiple reasons; increasing transplantation 
numbers, reimbursement issues, lack of education and the fear of complications. Furthermore, 
the ESRD patient eligible for PD, is getting older. Subsequently, the likelihood of being able to 
perform PD without extra support decreases.
The main complications of PD are peritonitis, access related complications, hernias, ultrafi l-
tration failure and encapsulating peritoneal sclerosis (EPS). 
ENCAPSULATING PERITONEAL SCLEROSIS
One of the most feared complications of PD is encapsulating peritoneal sclerosis (EPS). Gandhi 
et al. was one of the fi rst to describe EPS 14. Five patients were described who were treated 
with PD during several years. At laparotomy a thick tissue covering the peritoneum was found. 
Subsequent microscopical investigation showed extensive formation of fi broconnective tissue. 
In the following years the diagnosis was reported more often with diff erent names such as 
abdominal cocooning and sclerosing encapsulating peritonitis (SEP). The current name is more 
appropriate given its chronic non-infl ammatory appearance at presentation. The prevalence 
varied from 0.7% in Australia 15, 2.5 % in Japan 16 to 3.3 % in a single center study from the UK 
17. In the past EPS was predominantly described and investigated in Japanese literature. Encap-
sulating peritoneal sclerosis (EPS) appeared to be a life threatening complication of peritoneal 
dialysis (PD) with a mortality rate as high as 50%. The majority of deaths occurred during the 
fi rst year after the diagnosis.
The diagnosis of EPS is diffi  cult, mainly because a uniformly used defi nition is lacking. The 
international society for peritoneal dialysis (ISPD) was the fi rst to make a defi nition of this 
complication 18. The ISPD stated that EPS is a clinical syndrome with signs of intermittent and 
persistent or recurring complaints of gastro-intestinal obstruction, with macroscopic and/or 
radiological confi rmation of sclerosis, calcifi cation, peritoneal thickening or encapsulation of 
the intestines. 
Even though this defi nition of EPS is not specifi c, the presence of a disturbed intestinal function, 
such as the clinical symptoms of partial or total obstruction, is essential for the diagnosis. The 
complaints may progress to severe abdominal pain, vomiting, anorexia, malnutrition, weight 
loss, and the development of an abdominal mass. The chronic and insidious nature of this 
developing clinical syndrome is specifi c for EPS 16. As a consequence, EPS is often recognized 
in a late stage.
Macroscopic inspection at laparotomy shows extensive peritoneal changes with a thickened 
brownish peritoneum with adhesions, which partially cover the intestines. In later stages there 
is a total encapsulating of the intestine with a dense sclerotic cover. Because of this thickened 
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fi brous membrane, it leads to the impression of an abdominal cocoon. An example is depicted 
in fi gure 1.
Although much basic research is done with respect to peritoneal remodeling, clinicians still 
struggle with various issues and questions concerning EPS. For instance, there is the notion 
of an increased incidence of EPS in the Netherlands. In addition, the risk factors for EPS have 
been poorly investigated and may have changed over time. These are important issues as both 
patient and doctor should be informed on the risk of EPS prior to the initiation and during PD 
treatment. Finally, there are no clear guidelines for diagnosing and treating EPS. Specifi cally the 
diagnostic tools to recognize the early stages of EPS development are lacking.
In this thesis these clinical relevant aspects of EPS are addressed.
HYPOTHESIS AND OUTLINE OF THE THESIS
In chapter 2 we explored the current knowledge on EPS. The last decade more attention has 
been focused on this complication. This attention mainly concerned the possible increase 
of incidence, new diagnostic tools and the therapeutical management of EPS. Recent 
Figure 1 | EPS at laparotomy
This patient with a history of PD had developed complaints of intestinal obstruction. At laparotomy there is a clear 
fi brotic and thickened membrane covering the bowel. There are also extensive adhesions.
Mario BW v4.indd   13 25-03-11   11:11
14 Chapter 1
developments led to a debate on an arbitrary expiry date for PD because of the risk of EPS. To 
investigate the disease various registries have recently been initiated.
In the years 2004-5 it was our distinct empirical impression that EPS was increasing in 
incidence. This observation appeared to be shared by other nephrologists in the Netherlands. 
Given the impressive clinical spectrum this caused concerns and led to a diminished enthusi-
asm to start PD as an initial choice for renal replacement therapy. 
In the fi rst part of the thesis the possible increase in incidence will be explored. Therefore we 
initiated an investigation in the university hospitals of Rotterdam and Utrecht. This is described 
in chapter 3.1. In this initial report the EPS patients in these centers were investigated, as was 
the hypothesized increasing incidence of EPS in the period 1996-2006.
After the fi rst report it could be hypothesized that in addition to PD duration, there might 
be novel independent risk factors associated with EPS and its increased incidence. This was 
more thoroughly investigated in a case-controlled multicenter study, in which eight large 
Dutch centers participated. This study is described in chapter 3.2. This study was intended to 
investigate the EPS incidence in a larger cohort. The chosen log linear statistical model enabled 
us further to investigate the hypothesis that besides PD duration other novel independent risk 
factors, as age, dialysis solutions, peritonitis, kidney transplantation and ultrafi ltration failure 
are associated with EPS and its increased incidence.
There is a great need for early detection of EPS in patients. This is hampered by the insidious 
nature of the disease. Patients slowly develop intermittent abdominal complaints, but the dif-
ferential diagnosis at the time of considering EPS is extensive. Additionally, the radiological 
establishment of EPS with abdominal CT scanning is not useful in early screening. In chapter 4 it 
was hypothesized that using Il-6, as a regulatory cytokine and CA125 as a marker for mesothelial 
cell mass, both measured in effl  uent, might have a predictive value for EPS. The ultrafi ltration 
capacity was also taken into account. This hypothesis was retrospectively investigated in EPS 
patients in whom longitudinal equilibration tests were done.
Currently there is no consensus on therapeutical management of EPS. Nutritional status is 
important. Surgery with extensive adhesiolysis is recommended, but this is rarely performed 
in Western Europe. There are anecdotal reports on the positive eff ect of tamoxifen in EPS, but 
there is a lack of controlled studies concerning tamoxifen. In chapter 5 it was hypothesized 
that tamoxifen may result in lower mortality in treated patients. We performed a retrospective 
study in the multicenter EPS study to investigate whether tamoxifen was associated with an 
improved survival in these patients.
EPS in general has a high mortality, but the impact of the recently described post-transplan-
tation EPS on mortality after kidney transplantation is yet unknown. We hypothesized that 
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post-transplantation EPS has a considerable impact on mortality of transplanted PD patients. We 
performed a study investigating this issue, which is described in chapter 6. Using the national 
transplantation database and the RENINE database, it is investigated what the mortality is of 
post-transplantation EPS and how this infl uences the survival of transplanted PD patients.
In chapter 7 the results of the studies are summarized and discussed in general.
It is known that with new fi ndings more questions and possible explanations concerning eti-
ology arise. In chapter 8 some of the possible future questions on EPS and post-transplantation 
EPS, in particular are explored. In the fi rst part of this chapter the developed initiative for the 
EPS registry is described. In the second part some future recommendations, pathophysiological 
hypothesis and possible research initiatives are described.
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Encapsulating Peritoneal Sclerosis; 
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INTRODUCTION
Encapsulating peritoneal sclerosis (EPS) is the most severe complication of long-term peritoneal 
dialysis (PD). A fi brous cocoon covers the intestines and causes gastrointestinal dysfunction 
and intestinal obstruction. This leads to malnutrition, weight loss, infections and death. The 
last decade more attention has been focused on this complication and several registries and 
study groups have been started 1-5 . The recent attention concerns the increased incidence of 
EPS in recent years and identifi cation of new risk factors. Although this search has given us 
more insight into the pathophysiology and possible risk factors of the development of EPS, we 
still do not know how to prevent or recognize the development of EPS in the early stages. As a 
consequence, there is much debate on whether there should be an arbitrary expiry date for PD 
because of the risk of EPS. 
In this review we will give an overview of the current status of EPS. Regarding the patho-
physiology of peritoneal fi brosis and EPS much progress has been made. Especially the role 
of diff erent growth factors is emerging. Finally, an update for clinicians on the diagnostic and 
therapeutical options will be given.
EPIDEMIOLOGY
The reported prevalence of EPS varies between 0.5 and 2.5% 2,6-10. The occurrence of EPS 
increases with the duration of PD therapy. An Australian registry study described an incidence 
of 19.4% after 8 years of PD treatment 9. This was confi rmed in a prospective Japanese study. 
The incidence of EPS increased with the duration of PD from 0.7% after 5 years, 2.1% after 8 
years, 5.9% after 10 years and 17.2% after 15 years of PD therapy 10. 
The last years an overall increase of EPS incidence has been reported of 0.9% in 1996 to 3.5% 
in 2005 despite the overall decrease in PD population 2,7-12. It seems unlikely that the increase 
in incidence is caused by over diagnosis or more attention for this complication. The clinical 
presentation of EPS is very severe and thus a missed diagnosis is implausible. Reported mortal-
ity rates of EPS are high, especially in the year of the diagnosis. They vary between 25% and 55% 
and increase with the time on PD 2,7,9-12. 
PATHOPHYSIOLOGY
Alterations of the peritoneum
The peritoneum is build upon a monolayer of mesothelial cells and its basement membrane. 
Between the mesothelial layer and the vascular plexus lays the submesothelial compact zone 
with fi broblasts , macrophages and blood vessels 1 3. 
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Several alterations of the peritoneum occur during the course of PD treatment 14-17. The 
mesothelial layer disappears (denudation). The peritoneal vasculature shows progressive signs 
of fi brosis and hyalinization of the media, due to the deposition of collagen IV (vasculopathy) 
17. New vessels develop (neoangiogenesis) and the more vessels develop, the more severe the 
interstitial fi brosis appears to be 15,18. The submesothelial compact zone thickening is caused by 
interstitial fi brosis and sclerosis that is composed of various types of collagen including collagen 
IV and myofi broblasts 15. Also advanced glycation end products (AGE) accumulate in the meso-
thelial layer, submesothelial layer and vascular wall with time on PD 19-20. The deposition of AGE 
is associated with the presence of peritoneal fi brosis and functional problems 19,21. In vitro AGE’s 
induce collagen and TGF-β expression in human peritoneal mesangial cells 22. Experimental stud-
ies showed that ligand binding of AGE to its receptor (RAGE) led to submesothelial fi brosis and 
interstitial collagen accumulation 23-24. It is unknown whether AGE’s cause peritoneal damage or 
are innocent bystanders. But it is hypothesized that AGE accumulation infl uences the vessel wall, 
which would explain the association between AGE accumulation and fast solute transport 25.
Simple sclerosis is a mild sclerosis that may develop during PD. It is described as thickening 
of the parietal peritoneum and vascular alterations in absence of encapsulation 26. When bowel 
encapsulation is present, clinical signs of EPS become manifest. In EPS the parietal peritoneal 
specimens show fi brin deposition, fi broblast swelling, capillary angiogenesis, and mononuclear 
cell infi ltration 27. Visceral peritoneal specimens show an excess of interstitial type IV collagen 
and a large number peritoneal vessels 15. Whether EPS is the natural consequence of simple 
sclerosis, or whether they are two diff erent disease entities remains a topic of debate. To study 
this, Garosi et al. compared the peritoneal thickness of peritoneal specimens of 224 patients 
with long term PD with peritoneal specimens of patients that developed EPS. Simple sclerosis 
was present in 180 of the 224 patients. In the EPS group the visceral and parietal specimens 
were 10 to 50 times thicker compared to the control group. They concluded that there was 
no intermediate stage between simple sclerosis and EPS and therefore they are two diff erent 
diseases 28. In contrast, a Japanese study compared peritoneal specimens of EPS patients and 
compared them to long-term PD patients. Angiogenesis, vasculopathy, new membrane for-
mation, fi brosis and degenerative changes of the compact zone layers were present in both 
groups. Only the thickness of the compact zone and positive fi brin stains were unique for the 
EPS group 29. The peritoneal changes may gradually develop from peritoneal remodelling asso-
ciated with long-term PD to simple sclerosis, and eventually EPS. However, no uniformity exists 
on this sequence, and not every patient progress from simple sclerosis to EPS.
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PATHOGENETIC FACTORS AT THE CELLULAR LEVEL
Growth factors, cytokines and enzymes
Several growth factors, cytokines and enzymes may be important for the development of 
fi brosis, neoangiogenesis and eventually EPS. Vascular endothelial growth factor (VEGF) plays 
an important role through proliferation and migration of endothelial cells 30. Several in vitro 
experiments have shown that human peritoneal mesothelial cells (HPMC) have the capacity to 
produce VEGF in response to diverse stimuli present in PD fl uids 31-32. An experimental model 
of EPS demonstrated the crucial role of VEGF in the development of EPS-like changes in rats. 
The EPS group treated with anti-VEGF showed a thinner compact zone and less vasculopathy 
compared to the EPS group not treated with anti-VEGF 33. This angiogenic inhibitory eff ect was 
confi rmed in other studies 34-35. VEGF has been demonstrated in peritoneal effl  uent, where it 
was locally produced or released by peritoneal tissues or cells. VEGF showed a linear relation-
ship with the duration of PD treatment 36-37. 
TGF-β appears essential in the formation of peritoneal fi brosis. TGF-β is important in diff er-
ent wound healing processes 38-40. Overexpression of TGF-β is associated with several fi brosing 
syndromes. In vitro stimulation of HPMC with TGF-β leads to more collagen mRNA expression 
41-42. The experimental model by Liu et al. demonstrated the role of TGF-β in the development 
of EPS in mice. This EPS model was developed by using a helper-dependent adenovirus that 
actively transformed TGF-β. The short term exposure to the adenovirus expressing TGF-β led 
to simple sclerosis while longer exposure led to neoangiogenesis, extensive adhesions and 
cocooning or encapsulation of the intestines, also present in EPS 43-45. When tissue TGF-β binds 
to the TGF receptor diff erent intracellular pathway signals are triggered. TGF-β signalling 
through SMAD seems to be a crucial element in the signal transduction pathways involved 
in wound healing and fi brosis 46-48. This was confi rmed in an experimental study with SMAD3 
knockout mice. These mice were resistant to peritoneal injury induced by TGF-β 46. 
Other growth factors may also play a role in the development of peritoneal fi brosis. A posi-
tive correlation has been reported between the thickness of the peritoneal membrane and the 
expression of mRNA connective tissue growth factor (CTGF). Effl  uent CTGF levels correlated 
with dialysate-over-plasma ratios of creatinine and the estimated local peritoneal produc-
tion of CTGF  49. An association between CTGF and fi brosis has not been demonstrated and 
needs to be studied. Fibroblast growth factor (FGF) participates in several fi brotic diseases and 
induces the proliferation of various cultured cells such as fi broblasts and endothelial cells 50. 
An in vitro study of mesothelial cells exposed to a high glucose concentration showed more 
mRNA expression of FGF 51. FGF has not been demonstrated in clinical PD studies. Therefore it 
is unknown whether FGF is involved in EPS. Platelet derived growth factor (PDGF) is involved 
in many wound healing processes. Daily addition of PDGF to cultured cells stimulated collagen 
production 52. The eff ect of PDGF expression on angiogenic and fi brotic eff ects in the mice 
peritoneum has also been studied. An adenovirus mediated gene transfer was used. The over 
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expression of PDGF led to a normal wound healing response with angiogenesis and fi broblast 
proliferation. However it did not lead to collagen protein expression. It can be concluded that 
PDGF is not responsible for the peritoneal membrane injury 53.
AGE accumulates in the peritoneal structures with time on PD. In vitro AGEs induce collagen 
and TGF-β expression in human peritoneal mesangial cells 22. Experimental studies showed that 
ligand binding of AGE to its receptor (RAGE) led to submesothelial fi brosis, interstitial collagen 
and fi bronectine accumulation 23-24. The peritoneal expression of RAGE is increased in settings 
of diabetes and uremia 54.
Plasminogen activator inhibitor 1 (PAI1) and tissue-type plasminogen activator (tPA) are 
involved in fi brogenesis of various organs and can be produced by mesothelial cells. An in vitro 
study showed that HPMC produce PAI1 and t-PA in response to glucose based PD solutions 55. A 
mouse model of peritoneal fi brosis showed that tPA aggravates peritoneal fi brosis, neoangio-
genesis and peritoneal infl ammation 56. It remains unclear whether plasminogen is involved in 
the development of EPS.
In addition to increased formation of fi brosis a decreased degradation of fi brous tissue also 
contributes to the accumulation of fi brosis in the peritoneum. Metalloproteases (MMP’s) are 
enzymes important in tissue destruction and excessive remodelling. Experimental EPS studies 
showed increased MMP2 levels in effl  uent, and inhibition of MMP2 led to less peritoneal injury 
56-58. A multicenter study investigated the MMP2 and MMP9 levels in effl  uent of EPS patients and 
PD patients with peritoneal injury. Patients with infectious peritonitis had high MMP9 levels. PD 
patients with mild peritoneal injury (ascites<100mL) had the highest MMP2 levels. EPS patients 
had moderate high levels of MMP2. However, half of the patients with MMP2>600ng/mL ended 
up with EPS (7 out of 15) 59. An in vitro study of HPMC exposed to glucose demonstrated that 
a decreased expression of MMP1, 8, 13 and an increased expression of tissue inhibitor metal-
loproteinase (TIMP) leads to ECM accumulation 60. Whether MMP’s play a role in the develop-
ment of EPS is uncertain. Mast cells produce tryptase, which has a fi brinolytic function. In an 
infl ammatory state an increased number of mast cells is present in the peritoneum. Also in 
PD patients without any complications an increase of mast cells is found. However a recent 
histochemical study demonstrated that the number of mast cells in the peritoneum of EPS 
patients is extremely low, comparable to patients without infl ammation 61.
Tumor necrosis factor-alpha (TNF-alpha) stimulates in vitro macrophages to induce neo-
angiogenesis and fi broblast proliferation 62. Zemel et al. measured TNF-alpha in effl  uent and 
demonstrated that it was only produced by peritoneal tissues or cells in case of peritonitis 63. A 
role of TNF-alpha in the development and early diagnosis of EPS is unclear. 
A scheme of these potentially relevant factors in EPS development is given in Table 1.
Epithelial to mesenchymal transition
Epithelial to mesenchymal transition (EMT) is a physiological process which occurs through-
out the body and in the peritoneum to repair damaged tissue. During EMT, mesothelial cells 
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that have been exposed to dialysate undergo a morphological and functional alteration that 
changes their epithelial phenotype to become fi broblastic. These fi broblasts then migrate to 
Table 1 | Potentially relevant factors for the development of EPS and their evidence in literature.
Relevant factors for the development of EPS at cellular level References
VEGF
In vitro 30-31
In animals 33-35
In humans 36-37
TGF-β
In vitro 41-42
In animals 43-45
SMAD
In animals 46-48,53
CTGF
In humans 49
FGF
In vitro 51
PDGF
In animals 52-53
AGE
In vitro 22,52
In animals 23,44
In humans 19,21
PAI1
In vitro 55
In animals 56
MMP
In vitro 60,64
In animals 56-58
In humans 59
Mast cells
In humans 61
TNF
In vitro 62
In humans 63
EMT – in vitro
TGF-beta 44,65
SMAD 66-67
VEGF 68
MMP2 59
AGE 69
HGF 70-72
VEGF: vascular endothelial growth factor; TGF-β: transforming growth factor beta; CTGF: connective tissue growth 
factor; FGF: fi broblast growth factor; PDGF: platelet derived growth factor; AGE: advanced glycation end products; 
PAI1:plasminogen activator inhibitor 1; MMP: metalloprotease; TNF: tumor necrosis factor.
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the submesothelial compact zone and may overproduce TGF-β. This process starts at the initia-
tion of PD treatment and continues with the duration of PD 73. EMT is necessary for tissue repair 
under normal conditions, but uncontrolled it may lead to fi brotic processes 70. Characteristics 
of EMT were present in fi brotic peritoneal tissue, predominantly in the submesothelial layer 
74. TGF-β plays a central role in EMT. The addition of TGF-β to HPMC leads to a myofi broblastic 
conversion of these cells 65. An experimental model demonstrated that TGF-β is a promoter of 
EMT 44. Although TGF-β signalling through the SMAD pathway seems crucial in the processes 
of wound healing and fi brosis, the role of SMAD in EMT remains controversial 66-67,75. Several 
growth factors and cytokines important for the development of fi brosis, are produced by meso-
thelial cells that have undergone EMT. An ex vivo experiment showed higher VEGF production 
in mesothelial cells with fi broblastic features compared to mesothelial cells with an epithelial 
phenotype 68. A Japanese study showed that MMP2 was produced by myofi broblast-like mes-
enchymal cells 59. Other important promoters of EMT and the subsequent peritoneal fi brosis are 
MMP2, Il-1, AGE and transcription factor SNAIL 69,73,76.
In a recent study EMT was detected in parietal peritoneum of early PD patients (up to 2 
years). In this study an association was suggested between fi brosis through EMT and a fast 
transport status without an increased vascular surface area 77. Fibrosis and fast transport status 
are both associated with EPS. Although EMT is generally being accepted, the full contribution 
of EMT to the processes of EPS remains unclear 14,66.
THEORIES ON THE PATHOGENESIS OF EPS
Two hit theory
The “two-hit theory” of EPS hypothesizes that 2 factors are required for the onset of EPS. The 
fi rst hit causes disruption of normal peritoneal and mesothelial physiology. This disruption 
generally occurs over a period of years and is a consequence of PD treatment. EMT takes care of 
the physiological repair process. During this time the patient may be predisposed to a second 
hit that triggers the development of EPS 78. The second hit may be a peritonitis, the discontinu-
ation of PD or perhaps a genetic predisposition 79-80. The second hit theory was fi rst described 
by Kawanishi et al. and is now generally accepted 80. 
Genetic predisposition
Most patients that start PD treatment will never develop EPS. A genetic predisposition may 
infl uence the development of EPS 81. Several polymorphisms of important factors in the devel-
opment of EPS are known such as TGF-β and VEGF 82. To study the genetic association with EPS 
a large DNA database has been started in Great Britain 5. The joint occurrence of EPS and Alport 
syndrome has also been described, suggesting that Alport syndrome may predispose to EPS 83. 
Mario BW v4.indd   26 25-03-11   11:11
State of aff airs 27
EPS AND CLINICAL PRACTICE
Clinical presentation
Gandhi et al. was one of the fi rst to describe EPS associated with intermittent PD, and the inter-
national society for peritoneal dialysis (ISPD) was the fi rst to make a defi nition of this complica-
tion 84-85. The ISPD stated that EPS is a clinical syndrome with signs of intermittent and persistent 
or recurrent complaints of gastro-intestinal obstruction, with macroscopic and/or radiological 
confi rmation of sclerosis, calcifi cation, peritoneal thickening or encapsulation of the intestines. 
Even though this defi nition of EPS is not specifi c, the presence of a disturbed intestinal func-
tion such as the clinical symptoms of partial or total obstruction, is essential for the diagnosis. 
The fi rst signs may be accompanied by increased parameters of infl ammation. At the time of 
EPS diagnosis, the obstruction often appears acute and non-infectious. However in hindsight, 
abdominal complaints like nausea, complaints of changing defecation, and passage problems 
are often present in earlier stages. The complaints may progress to severe abdominal pain, 
vomiting, anorexia, malnutrition, weight loss, and the development of an abdominal mass. The 
chronic and insidious nature of this developing clinical syndrome is specifi c for EPS 10. As a 
consequence, EPS is often recognized in a late stage. 
Blood-stained ascites may be present in the early stages of EPS; reports vary between 7 and 
50% 9. Peritoneal function often shows decreased net ultrafi ltration (UF) and increased small 
solute transport 86. A laparotomy reveals several peritoneal alterations, such as a thickened, 
brownish peritoneum with several adhesions, and intestines that are partially or totally encap-
sulated in a thick fi brous tissue. In the last phase a complete or total sclerotic layer may cover 
the intestines, which gives it the appearance of a cocoon.
Radiological diagnosis
The diagnosis of EPS is often confi rmed by diff erent radiological measures. Abdominal ultra-
sound may demonstrate a thick walled mass containing bowel loops, loculated ascites and, 
fi brous adhesions at the time of EPS 87. Plain abdominal fi lm may show gas fl uid levels and dila-
tion of the bowel lumen, indicating obstruction. In some patients, calcifi cations of the bowel 
wall are visible 88-89.
The CT scan is the most useful in confi rming the clinical diagnosis of EPS. Peritoneal 
enhancement, peritoneal thickening, peritoneal calcifi cations, adhesions of bowel loops, signs 
of obstruction and fl uid loculation/septation are visible at a CT scan at the time of EPS 90-93. 
The scan should be evaluated by a radiologist experienced in assessing scans of PD patients. 
Unfortunately the CT scan is not reliable for making an early diagnosis of EPS. Tarzi et al. studied 
13 CT scans taken at least 4 months before the diagnosis of EPS. Only 3 out of 13 scans showed 
abnormalities, indicating that the CT scan cannot be used as a screening too l 93. 
Two case reports on magnetic resonance imaging for the diagnosis EPS have been described. 
Dilatation of the intestines and circumscribed focal wall thickening, massive ascites with wall 
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enhancement of the loculated ascites and compression of the bowel were found 94-95. In conclu-
sion, all the above described radiological measures show signs of obstruction. The CT scan has 
been tested most frequently for the diagnosis EPS and appears to be the most reliable choice 
for the defi nite diagnosis, but is not useful as screening tool. 
RISK FACTORS
EPS is probably a multifactorial disease in which several risk factors must be considered. Many 
risk factors cause peritoneal changes and may play a role in the development of EPS. Recent 
studies have shown that besides PD duration there are novel risk factors associated with EPS 
development, such as age, dialysis solutions, ultrafi ltration failure and kidney transplantation 
3,86,96-97. 
Even before the initiation of PD chronic renal failure induces some signs of vasculopathy and 
thickening of the submesothelial compact zone 98. 
The duration of PD is the most important risk factor for peritoneal alterations and EPS 3,10. This 
is probably because it represents the exposure to damaging infl uences, especially the exposure 
to dialysis fl uids. PD fl uids contain glucose which is a major cause of peritoneal membrane 
injury. Peritoneal specimens of PD patients showed that a high glucose load is associated with 
more submesothelial fi brous tissue 18. Patients with EPS had been exposed to more glucose 
compared to controls with similar PD duration 86,99. Furthermore, glucose forms glucose degra-
dation products (GDP’s) during the heat sterilization process of PD fl uids. GDP’s accelerate the 
formation of advanced glycation end products (AGE’s), which leads to the described peritoneal 
changes 100. 
New PD fl uids contain less GDP’s. Also, diff erent dialysis solutions without glucose have 
been introduced such as icodextrin and amino acids 10 1-102. Icodextrin has been studied most, 
especially since it caused episodes of culture negative peritonitis. This was due to contamina-
tion with proteoglycans 103. Recently, some studies have described an association between 
icodextrin use and increased markers of local infl ammation such as, interleukin-6 (IL-6), hyal-
uronan, tumor necrosis factor (TNF), and fi brin degradation products (FDP), but this was not 
persistently found 1 04-108. Others argued that icodextrin preserves the peritoneal membrane 
function and mesothelial cell mass 108-109. Although diff erent studies showed that the majority 
of EPS patients used icodextrin, it is diffi  cult to determine whether this is due to the abundant 
ultrafi ltration failure in early EPS or this actually has a causative relation with EPS 2,86,96. A recent 
case controlled study showed no diff erence in prescription of icodextrin between EPS and non-
EPS patients 97. At present there is no convincing evidence that icodextrin causes structural 
alterations in peritoneal tissues or promote EPS. 
Since the fi rst reports on EPS, peritonitis episodes are considered risk factors for its develop-
ment 9,110-111. In particular episodes caused by the Pseudomonas spp, Staphylococcus Aureus, 
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Haemophilus Infl uenza or fungal peritonitis have been incriminated 9,112-113. The reports on the 
importance of peritonitis in the development of EPS remain, however, equivocal. The Japanese 
prospective study showed that 25% of the EPS cases were associated with bacterial peritonitis 
while a single center controlled study showed no relationship 10. Recent studies could not 
confi rm the association between peritonitis incidence and EPS 2,86,96. Nonetheless, the number 
of peritonitis episodes caused by Pseudomonas spp, Staphylococcus Aureus and fungal peri-
tonitis was higher in the EPS group compared to controls. This indicates that not the incidence, 
but the cause of the peritonitis may be relevant for the development of EPS 96.
Chlorhexidine was used in the past to sterilize tubing connections. A strong association was 
found between the use of chlorhexidine and the development of EPS 114. In the early seventies 
an association between practolol and 3 cases of EPS have been described 115. Other beta block-
ers have not been associated with EPS. Nowadays both are not used anymore.
Observational studies consistently showed that EPS patients are often young 3,12,99. This fi nd-
ing is diffi  cult to interpret. It could represent a bias by indication since older patients are less 
likely to remain on PD for a long time and thereby have less exposure risk than young patients. 
But it may also be considered a risk factor because younger people tend to have a more vivid 
repair process of damaged tissue. In case of peritoneal damage this may eventually lead to 
fi brosis.
Another common fi nding in patients with EPS is dysfunction of the peritoneal membrane. 
EPS patients almost always have a fast transport status and ultrafi ltration failure (UFF) 1,86,111,116-
117. The fast transport status refl ects the eff ective peritoneal surface area, which is increased 
due to neoangiogenesis. This may cause a quick disappearance of the osmotic gradient and as 
a consequence ultrafi ltration problems may develop 118. In half of the patients with at least 2 
years of PD treatment who developed UFF and continued PD therapy for three years or more, 
EPS developed. Therefore late UFF is sometimes considered a risk factor 119. However, because 
the alterations are the result of the development of the disease, it is probably more appropriate 
to consider UFF as an associated factor.
It is striking that most cases of EPS are diagnosed after the discontinuation of PD. In a pro-
spective study 69% of the Japanese EPS cases occurred after the termination of PD therapy 10. 
The most common reasons to switch to hemodialysis therapy were recurrent peritonitis and 
UFF. Perhaps the cause of EPS after PD discontinuation is the lack of washing out and removal 
of fi brin, growth factors and cytokines. Subsequent studies with peritoneal lavage after the 
discontinuation of PD showed no eff ect in preventing EPS, except for one 10,120-121.
Recent studies have described a high incidence of post-transplantation EPS 1,8,122. This form 
develops shortly after kidney transplantation and may be a frequent form of EPS in countries 
with a high transplantation rate. In the Pan-Thames study the median time after transplanta-
tion until EPS was 5.4 months 1. A Dutch EPS study confi rmed that EPS usually develops in 
the fi rst year after kidney transplantation 96. Diff erent causes for this phenomenon have been 
proposed. The profi brotic properties of calcineurin inhibitors (CNI’s) may be of infl uence on 
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the development of EPS. Both cyclosporin and tacrolimus cause an upregulation of TGF-β and 
other fi brogenic genes in animal models  123-124. An experimental study showed that the admin-
istration of cyclosporin in rats chronically exposed to a 3.86% glucose based dialysis fl uid led 
to peritoneal angiogenesis and fi br osis 125. Case-reports of EPS have been described in patients 
treated with tacrolimus after liver transplantation without chronic renal failure and without 
PD treatment 126. Furthermore, the introduction of CNI’s has also led to lower and shorter cor-
ticosteroid prescriptions after kidney transplantation. Corticosteroids may have a protective 
eff ect on the development of EPS, and have been prescribed for treatment of EPS 127. It remains 
unclear whether post-transplantation EPS is due to the discontinuation of PD or due to the 
transplantation itself. Figure 1 summarizes all these risk factors discussed above.
EARLY DIAGNOSIS
Making an early diagnosis of EPS could prevent the severe onset of this condition by starting 
therapy in an earlier stage. Between the stage of normal PD and EPS there must be a stage 
Figure 1 | A schematic representation of all the risk factors important for the development of EPS. All risk factors may lead 
to peritoneal changes and simple sclerosis and eventually EPS. However a minority of the PD patients undergo all stages.
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of pre-EPS. As mentioned previously, no radiological screening tools are available for early 
diagnosing EPS 93. Up to now pre-EPS is ill defi ned, the number of patients that progress to the 
pre-EPS stage and who do not develop EPS is unknown 128. Several attempts have been made to 
stage EPS, for instance Nakamoto 129, who divided the development of EPS in 4 clinical stages: 
a pre-EPS period, an infl ammatory period, encapsulating or progressive period and, complete 
bowel obstruction/ cocoon (table 2). Functional characteristic features of a pre-EPS stage are 
UFF and fast solute transport 85-86. Several diagnostic investigations for an early diagnosis have 
been studied; they will be discussed in the following paragraphs.
Functional parameters of the peritoneum 
The morphological changes of the peritoneum may infl uence peritoneal function. Verger et al. 
was one of the fi rst to describe the decrease in ultrafi ltration and hyperpermeability in a patient 
with EPS 130. Since then other studies have found similar results 1,116,131. However, these features 
are not specifi c for the development of EPS. In two recent case controlled studies a number of 
peritoneal function parameters were longitudinal followed in the years prior to the diagnosis 
EPS. Ultrafi ltration failure (UFF) appeared the predominant early change. This was associated 
with early loss of residual renal function and accumulative glucose exposure 86,119. This decrease 
of ultrafi ltration capacity was uncoupled of the also increasing small solute transport. It was 
Table 2 | Proposed stages in the development of EPS and their clinical manifestation adapted from Nakamoto et al. 129
Stage Pathological fi ndings Clinical symptoms and investigation
Pre-EPS/ Mesothelial denudation Ultrafi ltration failure
Asymptomatical period Vasculopathy Fast transport status
Peritoneal thickening due to 
fi brosis
Ascites
Peritoneal calcifi cations
Infl ammation period Infl ammation Loss of appetite, weight loss, diarrhea
Mononuclear cells Changes in defecation
Fibrin degradation products Fever
Blood-stained ascites
Increase in CRP levels, leukocytosis
Progressive or encapsulating period Infl ammation decreases
Adhesions and progressive 
encapsulating
Disappearance of the signs of 
infl ammation
Gastro-intestinal obstruction :
Nausea, vomiting
Abdominal complaints, obstipation
Ascites, abdominal mass
Blood stained effl  uent
Complete bowel obstruction/cocoon No infl ammation Anorexia and complete ileus
    Abdominal mass
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lower in EPS patients than in long term PD patients without EPS with comparable small solute 
transport status.
In long term PD treatment the small solute transport increases. In EPS patients this may 
change in the fi nal years prior to EPS when it decreases again. Free water transport decreased 
in the four years prior to EPS 132. The combination of an initial increase followed by a decrease 
in small solute transport, a declining free water transport, and the prominent UFF indicates 
a possible decreased osmotic conductance. This may refl ect a limited intrinsic transport 
through the interstitium in EPS and is possibly due to interstitial fi brosis 86. It is probably best 
to consider these alterations as parameters of the disease and thus as associated factors, rather 
than considering them as risk factors. In order to determine a fast transport state and UFF the 
peritoneal function could be assessed annually with a 3.86% glucose peritoneal function test. 
In combination with a reduced residual renal function and higher glucose exposure, this could 
identify patients prone to EPS and could suggest a modality switch to HD.
Effl  uent Markers
Several substances in PD effl  uent may serve as a surrogate marker for structural and functional 
alterations of the peritoneum. Some of these substances have been studied specifi cally for the 
diagnosis of EPS. Although there is no clear consensus, cancer antigen 125 (CA125) appears to 
be a marker for mesothelial cell mass 133-135. In the years prior to the EPS diagnosis CA125 values 
were extremely low, which could represent the denudation of mesothelial mass. IL-6 is a marker 
for infl ammation and 2 years prior to the diagnosis EPS values were very high. The combined 
appearance rates of CA125 and IL-6 had a sensitivity of 70% and a specifi city of 100% for the 
diagnosis of EPS in patients with UFF. This makes them potentially useful for an early diagnosis 
of EPS 136. 
All growth factors and cytokines involved in the process of peritoneal fi brosis and neoan-
giogenesis are potential (early) diagnostic markers for EPS. However, few studies investigated 
effl  uent markers. TGF-β appears important in the development of EPS. An inactive form of 
TGF-β has been demonstrated in peritoneal effl  uent, but the active form is not soluble 137. 
Besides, soluble TGF-β is diffi  cult to analyze in plasma or effl  uent and is therefore not useful 
in the diagnosis of EPS 36. Hyaluronan is an important substance in the extracellular matrix. 
Hyaluronan measured in effl  uent increases with the duration of PD and in patients with UFF. 
However, it was not increased in patients with peritoneal adhesions 138. Whether hyaluronan is 
an early diagnostic marker of EPS still needs to be studied. Hydroxyproline in tissue is a gold 
standard for the assessment of fi brosis. However, in an experimental study it appeared not use-
ful as a marker for peritoneal fi brosis 139. Effl  uent MMP2 has been studied as a diagnostic marker 
and seemed to correlate with profi brotic events, but has to be tested for EPS 59.
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THERAPY
Supportive care with either enteral or parenteral nutrition has been shown to be benefi cial and 
should be the mainstay of the treatment 140. Surgical treatment of EPS is mostly performed in 
Japan. Kawanishi et al. showed that enterolysis is a successful alternative to the treatment of the 
abdominal cocoon. 96% of the patients reached restoration of abdominal transition 141-142. Dur-
ing this time consuming operation (on average 6.9h) the fi brotic tissue is carefully peeled off  
the visceral and parietal peritoneum. Nowadays this operation is also conducted in Manchester 
79. Because of the risk of reoccurrence, patients are treated with high dose of immunosuppres-
sives immediately after operation.
The rationale behind immunosuppressive therapy in treatment of EPS is to treat the pre-
ceding infl ammatory state. Successful treatment of EPS with immunosuppressive therapy has 
been described with corticosteroids 85,127,143, azathioprine, mycophenolate mofetil (MMF) and 
sirolimus 144-148. These reports are mostly anecdotal and probably this is a biased view, because 
negative results are not likely to be reported. 
Tamoxifen is a nonsteroidal anti-estrogenic drug that showed to be successful in several 
fi brosing diseases such as retroperitoneal fi brosis 149. Several small case-series have described 
positive eff ects of this drug on the treatment of EPS with improvement of the intestinal function 
and a decrease of the infl ammatory features 150-151. A large English trial could not confi rm this 
eff ect, perhaps due to the patient selection, as only 33% had the clinical symptoms of severe 
EPS 1. Recently, an retrospective analysis of the Dutch EPS study showed a decreased mortality 
in EPS patients treated with tamoxifen 152. Adverse eff ects of tamoxifen in EPS patients, like 
tromboembolic events have been described by Eltoum et al. 151. The risks of these events are 
probably outweighed by the devastating consequences of EPS. Therefore a trial of corticoste-
roids and/or tamoxifen is recommended when EPS is diagnosed.
Angiotensin II (ATII) inhibitors may be important in the prevention and treatment of EPS. ATII 
has proinfl ammatory and profi brotic eff ects which act through transforming growth factor-
beta (TGF-β) 153-154. The antifi brotic features of ATII inhibitors have been shown in renal fi brosis 
155. In vitro studies revealed that the production of TGF- β induced by high glucose concentra-
tions in HPMC is inhibited by angiotensin converting enzymes inhibitors (ACEi) and angiotensin 
receptor blockers 153,156. Also in EPS models less fi brosis was found after ACE inhibition 157. In PD 
patients, ACE inhibitors appear to have a positive eff ect on the peritoneal function 158, but a 
protective eff ect for EPS has not been found 159. 
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CONCLUSIONS
What a nephrologist should know about EPS
The increased attention for EPS has led to more insight in the pathophysiology of this complica-
tion. It has an impressive time course. Although the prevalence of EPS may have increased, it 
remains a rare disease and contributes marginally to over-all mortality of PD patients.
A scheme linking the various proposed stages of EPS to pathological and clinical fi ndings is 
given in Table 2. The diagnosis of EPS is made on the presence of bowel obstruction and a CT 
scan. Identifying EPS in an early stage remains diffi  cult. Ultrafi ltration failure and the appear-
ance rates in effl  uent of CA-125 below 33mL/min and IL-6 above 350mL/min may be specifi c 
for the development of EPS. Patients with a prolonged PD therapy and high intraperitoneal 
glucose exposure, who develop ultrafi ltration failure are prone to EPS and should probably 
discontinue PD therapy.
There may be an association with transplantation, a phenomenon known as post-transplan-
tation EPS.
Patients have an increased risk of developing EPS when PD is discontinued, especially when 
UFF is present. The decision of switching patients to hemodialysis should take into account the 
high possibility of infection, the hemodynamic instability and diff erent quality of life. Although 
there are no data on the prospective change of PD to HD, it was concluded by an ISPD study 
group that changing PD to HD in order to prevent the development of EPS is unnecessary 160. 
Once EPS is suspected the outcome is poor. To date, there is no consensus on therapy, but 
besides supportive care a trial of corticosteroids and/or tamoxifen should be given. Adhesioly-
sis may be eff ective but only if performed by a surgeon familiar with EPS.
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Chapter 3.1 
Increasing incidence of severe 
Encapsulating Peritoneal Sclerosis 
after kidney transplantation.
Mario R. Korte, Marieke Yo, Michiel G.H. Betjes, Marien W. Fieren, 
Jan C.L.M. van Saase, Walther H. Boer, Willem Weimar, Robert Zietse.
Adapted from original article in Nephrology Dialysis Transplantation 2007 Aug;22(8):2412-4.
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ABSTRACT
Background
Encapsulating peritoneal sclerosis (EPS) is a rare complication of peritoneal dialysis (PD), with a 
high mortality. The reported overall prevalence of EPS varies between 0.7 % and 3.3 %. It is our 
impression that in recent years an increase in incidence of EPS has occurred. 
Methods
A retrospective analysis of the cases with severe EPS at two university hospitals in The Neth-
erlands. EPS was defi ned according the criteria of the ISPD. PD, transplantation and patient 
related variables were investigated.
Results
Eighteen cases (13 male / 5 female, age 39.8 ± 10.2 years) of severe EPS were identifi ed in the 
period 1998-2005 (mean time on PD of 71.2 ± 45.6 months). The majority of patients were on 
PD for a shorter period than fi ve years. Thirteen patients developed EPS in 2004 and 2005, 
compared to one or two patients in the previous years. The total number of patients on PD did 
not change in time. Fifteen patients had a kidney transplantation and eight patients developed 
EPS shortly after this (mean time from kidney transplantation to EPS diagnosis was 39.3 ± 71.1 
months). Seventeen patients used icodextrin and the mean time on icodextrin was 34.2 ± 22.2 
months. 
Conclusions
This study confi rms our impression that the incidence of EPS has increased in the recent years. 
The design of this study precludes conclusions on the cause of the increased incidence, but 
the remarkable preponderance of EPS patients with a functioning renal allograft suggests a 
pathogenetic role of kidney transplantation.
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INTRODUCTION
Encapsulating peritoneal sclerosis (EPS) is a life threatening complication of peritoneal dialysis 
(PD). Since the fi rst report in 1980 1, the reported overall prevalence of EPS has varied between 
0.7 % in Australia 2, 2.5 % in Japan 3 and 3.3 % in a single center study in Great Britain 4. Because 
of the slow progression of intestinal cocooning, it is frequently not recognized until it has devel-
oped into a severe stage. Often the diagnosis is made after an infective peritonitis, which recov-
ers slowly, despite adequate antibiotic treatment. Thereafter, the condition usually persists as 
a non-infectious infl ammatory abdominal condition 5. Because of progressive ultrafi ltration 
failure, patients are often switched to hemodialysis (HD). Remarkably, the majority of patients 
that develop progressive EPS do so after the cessation of peritoneal dialysis. It has been sug-
gested that this is due to the absence of continued lavage of fi brin 3.
The diagnosis of EPS is diffi  cult, mainly because a uniformly used defi nition is lacking. Most 
clinicians use the criteria defi ned by the Ad Hoc Committee of the International Society of 
Peritoneal Dialysis (ISPD) 6. This committee defi ned EPS as: “A clinical syndrome with persistent, 
intermittent or recurrent presence of intestinal obstruction with or without the existence of 
infl ammation parameters and the existence of peritoneal thickening, sclerosis, calcifi cations 
and encapsulation confi rmed by macroscopic inspection or radiological fi ndings”. It is our 
distinct impression that in recent years we are witnessing a marked increase in the incidence 
of EPS. In order to investigate whether this suspicion is justifi ed, we initiated an analysis of the 
occurrence of EPS in two university hospitals in The Netherlands.
METHODS AND DESIGN
Design 
This is a retrospective study at the dialysis and transplantation departments in two university 
hospitals in the Netherlands (Erasmus Medical University Center in Rotterdam and the Utrecht 
Medical Center in Utrecht). Both centers serve as regional transplantation centers. Cases were 
identifi ed by retrospective investigation of the medical records of both PD populations in the 
period 1998-2005. All medical records of patients with EPS were reviewed in detail.
Classifi cation of EPS
Encapsulating peritoneal sclerosis was defi ned according the criteria developed by the Ad 
Hoc Committee of the International Society of Peritoneal Dialysis 6. Using this defi nition of EPS 
limits the study population to severe forms of EPS presenting with intestinal obstruction, but 
minimises the possibility of missing patients in the retrospective analysis. The date of diagnosis 
of EPS was defi ned as the date at which the patient fulfi lled the diagnostic criteria of EPS. All 
patients underwent at least one abdominal CT scan.
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Variables
Several PD-related and patient-related variables were investigated. The total duration on PD 
was calculated by adding all separate episodes on PD. Whenever a patient was on some other 
form of renal replacement therapy for longer than a week, this time was not included in the 
time on PD. Ultrafi ltration failure (UFF) was defi ned by an ultrafi ltration volume of less than 
400 ml on a 4-hour dwell with a glucose concentration of 3.86 %. As an outbreak of icodextrin 
associated peritonitis occurred between November 2001 and July 2002 7, we also determined 
which patients had been treated with icodextrin during that period. 
When patients underwent a kidney transplantation, the time after the fi rst transplantation 
until EPS diagnosis was also calculated. 
Statistics
Data were entered in SPSS 12.0.1 datamanager (Chicago, USA). Statistical analysis was per-
formed using a Pearson’s chi-square test for trend analysis. A p-value below 0.05 was considered 
to indicate statistical signifi cance. All data are presented as mean ± SD.
RESULTS
Patients
Eighteen cases (13 male / 5 female, mean age 39.8 ± 10.2 years) of severe EPS were identi-
fi ed. All patients underwent abdominal CT scanning and had moderate to severe abdominal 
complaints of obstruction. All patients fulfi lled the ISPD criteria. Twelve of these patients were 
treated at the Erasmus Medical Center and six patients at the Utrecht Medical Center. Thirteen 
patients were not on PD at the time of diagnosis and were either on hemodialysis (4) or had 
received a functioning kidney graft (9). Patient’s characteristics are described in table 1.
Patients had a mean time on PD of 71.8 ± 44.9 months at the time of EPS diagnosis. Seventeen 
patients used icodextrin and the mean time on icodextrin was 34.2 ± 22.2 months. Seven 
patients were treated with icodextrin within the period between November 2001 and July 
2002, when an outbreak of icodextrin associated peritonitis occurred. In these patients there 
was no history of aseptic peritonitis. 
Sixteen patients (89 %) developed at least one episode of peritonitis during the treatment 
with PD (Table 1). The mean number of peritonitis episodes was 0.54 ± 0.73 for every 12 months 
of PD. There was no specifi c micro-organism responsible for the majority of the peritonitis 
episodes.
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Table 1 | Patient and PD characteristics
Case Gender Renal disease PD 
time
UFF Peritonitis
episodes
CT scan Outcome Therapy EPS 
related 
death
1 M Nephrolithiasis 120 Yes 3 Dilatation, 
peritoneal 
thickening
Deceased TPN Yes
2 M Alport’s Syndrome 48 Yes 1 Dilatation, 
peritoneal 
thickening, 
fl uid pocket, 
septation
Deceased TPN Yes
3 M MPGN II 71 NA 2 Fluid pocket, 
dilatation, 
peritoneal 
thickening
Deceased TPN Yes
4 F Chronic 
pyelonephritis 
50 No 13 Narrowing, 
calcifi cation, 
mesenterial 
thickening
Deceased TPN Yes
5 M FSGS 83 Yes 3 Air-fl uid levels, 
mesenterial 
thickening
Deceased NA Yes
6 M FSGS 222 Yes 3 Dilatation, 
peritoneal and 
mesenterial 
thickening
Deceased NA Yes
7 M Primary 
hyperoxalosis 
18 No 1 Fluid pockets Deceased Prednisone, 
TPN 
Yes
8 M Diabetic 
nephropathy 
43 NA 0 Fluid pocket, 
Dilatation, 
peritoneal 
thickening
Alive TPN 
9 M Alport’s syndrome 104 Yes 4 Dilatation, 
peritoneal 
thickening
Alive TPN 
10 F Atherosclerotic 73 Yes 1 Fluid pocket, 
septation, 
peritoneal 
thickening
Alive TPN 
11 M Glomerulopathy 54 NA 1 Dilatation Deceased TPN No
12 F MPGN 50 Yes 3 Fluid pocket, 
peritoneal 
thickening
Alive TPN 
13 F Preeclampsia 90 No 1 Peritoneal 
thickening, fl uid 
pockets
Alive none 
14 M Refl uxnephropathy 79 NA 2 Dilatation, 
peritoneal 
thickening, fl uid 
pockets
Deceased Prednisone, 
TPN 
Yes
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Fifteen patients (83 %) had a history of kidney transplantation, with eight patients having 
multiple transplantations. The mean time from the last kidney transplantation to the diagnosis 
of EPS was 39.3 ± 71.1 months. 
Incidence
The PD population, treated in the period 1998 to 2005, comprised of 418 patients (206 patients 
in Rotterdam and 212 in Utrecht). In both 1998 and 1999 there was one EPS case each year, in 
2000 and in 2001 no cases, in 2002 one case and in 2003 two cases. However, in 2004 and 2005 
we observed three and ten cases, respectively. The number of patients on PD did not change 
signifi cantly in time throughout the whole period in both centers. Given the great number of 
transplanted EPS patients, PD patients at risk for developing EPS were defi ned as either having 
previous PD treatment or patients with a history of PD having undergone renal transplanta-
tion no more than three years ago. Although there was a steady increase in patients alive with 
functioning kidney graft and a history of PD (in Rotterdam), the increasing incidence of EPS 
exceeded the increase in patients at risk (Figure 1, p = 0.038, using a Pearson’s chi-square test 
for trend analysis).
Outcome
Nine patients died, resulting in an overall mortality of 50 %. The cause of death was attributable 
to EPS in eight patients. These patients had progressive abdominal complaints with malabsorp-
tion, bowel obstruction, developing peritonitis or bowel perforation with subsequent sepsis. 
One patient died because of lung cancer. Therapy consisted of total parental nutrition (TPN), 
surgical therapy (minimal adhesiolysis and catheter extirpation in 7 patients) and medication. 
Six patients were treated with corticosteroids. Three patients received tamoxifen and one 
received colchicin. One patient received azathioprine.
Table 1 | Patient and PD characteristics (continued)
Case Gender Renal disease PD 
time
UFF Peritonitis
episodes
CT scan Outcome Therapy EPS 
related 
death
15 F Hypertensive 
nephropathy 
56 No 2 Dilatation, fl uid 
pockets
Alive Solumedrol, 
Prednisone 
16 M HUS 46 Yes 5 Calcifi cation Alive Prednisone, 
tamoxifen 
17 M Calcineurin toxicity 27 Yes 1 Peritoneal 
thickening, fl uid 
pockets
Alive Prednisone, 
tamoxifen, 
colchicin 
18 M Glomerulonephritis 
undetermined 
47 No 0 Ascites, 
dilatation, 
peritoneal 
thickening
Alive Prednisone, 
tamoxifen 
 
Time on PD in months, peritonitis expressed as total number of per patient, UFF means ultrafi ltration failure, TPN total 
parenteral nutrition.
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DISCUSSION
This study shows that in two Dutch university hospitals the incidence of severe EPS has 
increased signifi cantly in the period from 1998 to 2005 in stabile PD populations. Earlier reports 
also appeared to indicate an increased incidence of EPS 2,8. In these retrospective surveys the 
apparent increase was related to the duration of PD treatment, with a substantial increased 
prevalence after 5 years of PD 2. However, in our study the majority of patients were on PD for a 
considerably shorter period than fi ve years when they developed EPS.
The pathophysiology of EPS is unknown, but it appears EPS is not solely the result of pro-
gression of peritoneal remodelling that happens with PD. Remodelling may form a background 
on which intestinal encapsulation with the extensive fi brin depositions can develop. A second 
hit, has therefore been postulated to aggravate the damage to the peritoneum and to induce 
the further development of EPS 9. Although limited by the retrospective nature of this study, 
we investigated whether infection 2 or type of dialysis solution could be such a second hit 10-12. 
However, the mean number of peritonitis episodes was only 0.54 ± 0.73 for every year of PD 
and we found no increase of specifi c microorganisms in the EPS population. Almost all of the 
patients developing EPS used icodextrin. Since half of our patients were treated with icodextrin 
during the period, in which the outbreak with icodextrin related aseptic peritonitis occurred 7,13, 
a possible contribution of icodextrin to the development of EPS cannot be entirely excluded 
and has to be evaluated.
As the majority of EPS patients underwent a kidney transplantation at some point in time. 
Transplantation, with subsequent immunosuppressive treatment, could also be considered as 
Figure 1 | EPS cases and the population at risk for EPS in Rotterdam center in 1998-2005.
Population at risk is defi ned by patients with a kidney transplant and a history of PD (open boxes). EPS cases are shown 
(lined boxes) in Rotterdam. Signifi cant trend of increase of EPS independent of the increase in the defi ned population at 
risk (p = 0.038, chi square trend analysis).
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the second hit in the development of EPS. This suggestion is strengthened by the fact that, in 
some patients, EPS developed shortly after kidney transplantation. It remains unclear whether 
the transplantation procedure itself or the concomitant medication is responsible. Cessation 
of peritoneal lavage after transplantation could lead to diminished clearance of fi brin and may 
thus contribute to peritoneal fi brosing. Also, the known profi brotic eff ects of calcineurin inhibi-
tors (CNI’s) may have had an eff ect on the development of EPS 14-15. 
In conclusion, this study confi rms our impression that the incidence of EPS has increased 
in recent years. The design of this study precludes conclusions on the cause of the increased 
incidence, but the remarkable preponderance of EPS patients with a functioning renal allograft 
may point towards a pathogenetic role of kidney transplantation. A multicenter study is 
urgently needed to address this increasing threat to the patients on PD. 
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ABSTRACT
Objectives
Encapsulating peritoneal sclerosis (EPS) is a serious complication of peritoneal dialysis (PD) with 
a multifactorial pathophysiology and possible increasing incidence. The aims of the study were 
to investigate the incidence of EPS in recent years and to evaluate the independent associa-
tions of PD duration, age, dialysis fl uids and kidney transplantation with EPS.
Methods 
A multicenter case controlled study was performed in the Netherlands from January 1st 1996 
until July 1st 2007. The population comprised of 63 cases of EPS and 126 control cases. Control 
cases were selected from the national registry and matched for the date of start PD. Associa-
tions were analysed using a log linear regression model. Primary outcome was appearance of 
EPS.
Results
EPS incidence increased until 2005, despite a stable PD population. The increase in incidence 
appears to be followed by a small decrease in 2006. EPS patients were younger at start of PD, 
compared with controls (34.7 ± 15.4 vs. 51.5 ± 14.7 years, p<0.0001). The cumulative period on 
PD was longer in the EPS than in the control group (78.7 ± 37.8 vs. 32.8 ± 24 months, p<0.0001). 
The cumulative period on icodextrin was longer in EPS patients (32.7 ± 23.3 vs. 18.1 ± 15.7 
months, p=0.006). More EPS patients had kidney transplantations compared with the controls 
(47 vs. 59, p<0.0001). With regard to time after transplantation, the yearly probability of EPS 
increased in the year after transplantation from 1.75% to 7.5%. In multivariate regression 
analysis cumulative PD time, age at start PD, transplantation, time since last transplantation 
until EPS, calendar time, time on icodextrin and ultrafi ltration failure (UFF) were independently 
associated with EPS. Transfer from PD to hemodialysis, for other reasons then suspected EPS, 
could not be identifi ed as a risk factor for EPS. 
Conclusions
The incidence of EPS has increased until 2005. PD duration, age at start PD, kidney transplanta-
tion, time since last transplantation, UFF, and time on icodextrin were associated with a higher 
risk of EPS.
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INTRODUCTION
Encapsulating peritoneal sclerosis (EPS) is a rare but serious complication of peritoneal dialysis 
(PD) with a considerable morbidity and mortality. In EPS patients extensive fi brosing of the 
peritoneum leads to symptoms of malnutrition and intermittent bowel obstruction. Finally, 
encapsulation may result in a complete cocooning of the bowel with clinical symptoms of ileus.
The pathophysiology of EPS is probably infl uenced by multiple factors. The widely accepted 
second hit theory assumes a progressively damaged peritoneum by prolonged use of dialysis 
fl uids, whwich may be complicated by factors that aggravate the peritoneal sclerosis 1. The 
bioincompatibility of dialysis fl uids, in particular the unphysiologically high glucose concentra-
tions and the presence of glucose degradation products are thought to be key elements in this 
process 2. Some agents have been identifi ed as possible second hit, such as chloorhexidine 3 
and practolol 4, and are subsequently not used anymore. The data on the role of the presence 
of microbial peritonitis on the development of EPS remain equivocal 5-7. The incidence of EPS 
appears to increase with prolonged PD duration 8-9. This was also shown in recent cohort stud-
ies 10-11. However until recently the association of PD duration was previously not multivariate 
analysed using larger controlled studies. In recent years other candidate factors besides PD 
duration came forth from a number of observational single and multicenter studies. These 
included cessation of peritoneal lavage 12-13 and possibly factors associated with kidney trans-
plantation 14.
The reported prevalence of EPS ranges from 0.7 % to 3.3 % 5,10,12,15. The majority of the experience 
comes from Japan, where patients tend to be on PD for a longer period because the availability 
of kidney transplantation is limited 12. 
Recently, we reported an increased incidence of EPS over the last 10 years 16. Particularly 
striking was the occurrence of EPS shortly after kidney transplantation. More defi nite conclu-
sions could not be made due to the limited number of patients and the absence of a control 
group. 
Therefore, we designed this case controlled study in which eight large centers participated, 
giving 26% coverage of the total Dutch PD population in the period 1996-2007. This design 
enabled us to investigate the incidence of EPS and investigate the separate infl uences of PD 
duration, age, peritonitis episodes, dialysis fl uids and kidney transplantation on the develop-
ment of EPS.
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SUBJECTS AND METHODS
Design
The design of the study was a retrospective nested case controlled multicenter study. This 
is closest to a cohort study in which a defi ned cohort of PD patients is followed until some 
develop EPS. For each case two control patients were selected. We matched cases and controls 
for the start date of PD (calendar time) since the general changes in time (such as changes 
in surgical and nursing staff  or procedures could be confounders. This matching on calendar 
time brings the design close to a cohort study: each set of a case and its controls start PD at 
a certain time point on which they theoretically have the same probability to develop EPS. 
Patients and controls were deliberately not matched for PD duration to allow for an evaluation 
of this potential EPS risk factor, throughout the study period and in relation to other potential 
risk factors. To assure comparability of cases and controls in this case control design the cases 
and controls without EPS in our study were taken from the same source population, a clearly 
defi ned cohort of all PD patients in the Netherlands (RENINE, Registratie Nierfunctievervanging 
Nederland). In this registry all Dutch end stage renal disease (ESRD) patients with renal replace-
ment therapy are registered 17. This makes the study a nested case-control study. The matching 
of the cases was done by using an Access generated query in the RENINE database. The controls 
are matched on date start PD closest to the EPS case (one control before and one after start 
date PD). The participating centers were fi ve university hospitals and three large teaching 
hospitals. Cases in the period 1996 - 2007 were identifi ed. The study protocol was approved by 
the medical ethics committee of the Erasmus University Medical Center, Rotterdam.
Classifi cation and diagnosis of EPS
EPS was defi ned according the criteria developed by the International Society of Peritoneal 
Dialysis 18. It is defi ned as a clinical syndrome with persistent or recurrent presence of intestinal 
obstruction with or without the existence of infl ammation parameters and the existence of 
peritoneal thickening, sclerosis, calcifi cations and encapsulation confi rmed by macroscopic 
inspection or radiological fi ndings.
Using this defi nition the studied population was limited to severe forms of intestinal 
obstruction. This minimised the possibility of missing patients in the retrospective analysis. 
Medical records of patients with EPS were reviewed in detail. EPS diagnosis was retrospectively 
set at the date at which the diagnosis fulfi lled the defi nition of EPS and was confi rmed by two 
separate nephrologists. All patients underwent abdominal CT scanning. 
Investigated variables
Demographics, PD and patient related variables were investigated. The duration on PD was 
calculated by adding all separate episodes on PD. Whenever a patient was on other renal 
replacement therapy, for longer than a week, this time was not included. Follow-up time was 
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defi ned as the period from start PD until EPS diagnosis in the cases and death or end of study 
in the controls. Calendar time was defi ned as the years since the chosen reference date, close to 
which the fi rst patient in the study started PD (01-01-1983).
Small solute transport was analysed using the last available peritoneal equilibrium test. 
Ultrafi ltration failure was defi ned by ultrafi ltration volume of less than 400 ml on 4-hour 2000 
ml dwell with 3.86 % glucose concentration 19 or symptoms of overhydration and necessity 
of increasing glucose concentrations (one or more daily use of 3.86%). All ever used dialysis 
fl uids were reported. Since the introduction of icodextrin, the use of it was documented very 
accurate. Therefore the time on icodextrin could be assessed. 
To assess the eff ect of transfer from PD to HD on EPS development, patients transferring 
with a suspected EPS were excluded. This was because of possible confounding by indication. 
Suspected EPS was defi ned as having intermittent intestinal obstruction with ultrafi ltration 
failure and/or inconclusive evidence for EPS by radiological CT scanning (defi ned by Tarzi et 
al.20), without any other explanation for the symptoms. These criteria are also used in the cur-
rent Dutch EPS registry 21.
Variables related to kidney transplantation were also investigated. Time since transplanta-
tion until EPS was defi ned as the time from the last transplantation until EPS or end of study (in 
control patients).
Statistical analysis
Primary outcome was appearance of EPS. Means were compared using unpaired t-tests. Pro-
portions were compared with chi-square tests. 
We analyzed the data by using a piecewise exponential model 22-23. This model allows dif-
ferent time-dependent covariates, such as PD duration and time since transplantation to be 
taken into account. The theoretical model was implemented by fi tting a Poisson log-linear 
regression model in a dataset in which the follow up history of each patient was divided in 
steps of maximally one year. If during a year, for example, transplantation was performed, the 
year was divided in two pieces. For every piece the outcome was established (EPS or not at the 
end of the period) and values for all relevant predictors. So we constructed a new database 
with more than one line - at least one for each year of follow up - per patient. The fi tted Poisson 
model had EPS as outcome, the log of the length of follow up as off set variable and PD duration, 
age, transplantation, time since last transplantation, calendar time, follow up time, peritonitis 
episodes, transfer from PD to HD for other reasons than suspected EPS, time on icodextrin 
and presence of ultrafi ltration as pre-specifi ed predictors for the midpoint of the time step. All 
predictors were tested both univariate and multivariate.
The model estimates odds ratio’s (OR) given the other variables, so these estimates are valid 
and by defi nition cannot be caused by diff erences in other possible risk factors included in the 
model. 
Mario BW v4.indd   59 25-03-11   11:11
60 Chapter 3.2
There is an adjustment for the diff erences in other risk factors than the one of interest. All 
multivariate ORs are conditional on the diff erence in the other risk factors. For example, the OR 
for age at start PD is given considering the diff erences in cumulative PD time. That means that 
two patients with the same PD time, the one who started PD younger has a higher risk on EPS. 
Statistical tests were done in SPSS 15.0.1 datamanager (Chicago, USA) and R statistical 
software. If data were not available, these were reported as missing.
RESULTS
Incidence of EPS
In the period January 1st 1996 until July 1st 2007, 63 cases of EPS occurred in the participating 
centers. Within the study prevalence was calculated using only the number of patients in the 
period January 1st 1996 until January 1st 2007. In this period there were 61 patients diagnosed 
with EPS and 2022 patients were on PD in the participating centers. Six EPS patients were 
excluded from these 61 patients, because they had originally started PD in other PD centers 
than those participating, resulting in a prevalence of 2.7%.
The annual occurrence of EPS increased until 2005 (Figure 1). Thereafter a small decrease in 
2006 was present. The annual incidence in the PD population could not be calculated since the 
diagnosis of EPS was often made when PD was already discontinued. The overall PD population 
slightly decreased in the study period. 
Patient demographics
The 63 EPS patients with 126 controls resulted in a study population of 189 patients. Cases and 
controls were equally distributed among the centers. EPS patients were signifi cantly younger 
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Figure 1 | Annual occurrence of EPS and overall PD population in period 1996-2006.
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Table 1 | Patient characteristics
EPS
Yes (63) No (126) P-value
Gender (f/m) 21/42 43/83 NS
Age
Age at diagnosis EPS 43.4 ± 14.4
Age at start PD 34.7 ± 15.4 51.5 ± 14.7 0.0001
Age at death or end of study 45.1 ± 14.1 57.9 ± 13.4 0.0001
Periods 
Time until death after EPS diagnosis 20.5 ± 18.3
Follow-up 124.8 ± 60.6 74.5 ± 62.3 0.0001
End of study (%)
Deceased 34 (54.0) 83 (65.9) NS
Alive, functioning graft 12 (19.0) 32 (25.4) NS
Alive HD 17 (27.0) 8 (6.3) 0.0001
Alive, PD 0 3 (2.4) NS
Age and periods are reported in respectively mean years and months ± SD. F means female, m male, PD peritoneal 
dialysis, HD hemodialysis. Follow-up is defi ned as time since start PD until EPS, death or end of study. Means were tested 
using t-test, proportions were compared with chi-square tests. NS means not signifi cant.
Table 2 | Causes of end-stage-renal-disease
EPS Control 
63 (%) 126 (%)
Renal vascular disease due to hypertension 10 (15.8) 19 (15.0)
Chronic renal failure, aetiology uncertain 5 (7.9) 15 (11.9)
Glomerulonephritis, histologically examined 6 (9.5) 20 (15.8)
Pyelonephritis/Interstitial nephritis-cause not specifi ed 12 (19.1) 17 (13.5)
Focal segmental glomerulosclerosis 6 (9.5) 0
Polycystic kidneys 1 (1.6) 9 (7.1)
Diabetes Type II (non-insulin dependent) 1 (1.6) 10 (7.9)
Diabetes Type I (insulin dependent) 0 7 (5.5)
IgA nephropathy 3 (4.8) 3 (2.4)
Hereditary nephritis with nerve deafness 3 (4.8) 1 (0.8)
Lupus erythematosus 0 4 (3.2)
Haemolytic Uraemic Syndrome 3 (4.8) 0
Other identifi ed renal disorders 13 (20.7) 21 (16.9)
Causes were defi ned according the EDTA diagnosis defi nitions. Glomerulonephritis, pyelonephritis and renal vascular 
disease are composed of the related specifi ed renal disease diagnoses. Other identifi ed renal disorders are composed of 
various renal disease diagnoses.
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than controls when they started with PD (Table 1). Twenty-nine patients were diagnosed with 
EPS when they were on hemodialysis (HD) and eighteen patients had a functioning kidney 
transplant. Follow-up from start PD until EPS (or end of study) was longer in EPS patients 
compared with controls (Table 1). Mortality was not signifi cantly diff erent between the groups. 
From a total of 34 EPS patients who died, 30 deaths were attributable to EPS related factors. The 
ESRD causes are shown in Table 2.
PD related variables
The cumulative period on PD was signifi cantly greater in the EPS group in comparison to the 
controls (Table 3). EPS patients experienced more peritonitis episodes than controls (Table 3). 
Less peritonitis episodes occurred per patient year in the EPS group compared to the controls. 
From the various micro-organisms cultured during peritonitis only fungi were more often pres-
ent in EPS patients (8 vs. 3 episodes in total, p=0.02). Staphylococcus Epiderdimis was less often 
Table 3 | PD related variables
EPS
Yes No P-value
Time on PD 78.7 ± 37.8 32.8 ± 24 0.0001
Peritonitis
Peritonitis episodes 4.1 ± 3.8 2.4 ± 2.8 0.0020
Peritonitis per patient-year 0.7 ± 0.8 1.1 ± 1.4 0.0090
Transport status (%)
Slow 2 (3.2) 2 (1.6) NS
Slow Average 5 (7.9) 29 (23) 0.0010
Fast Average 17 (27) 33 (26.2) NS
Fast 25 (39.7) 12 (9.5) 0.0001
Unknown 14 (22.2) 49 (38.9)
Ultrafi ltration failure (%) 
Yes 38 (60.3) 19 (15.1) 0.0001
No 14 (22.2) 85 (67.5) 0.0001
Unknown 11 (17.5) 22 (17.5)
Dialysis fl uids
Dianeal 58 107 NS
Physioneal 31 20 0.0001
Icodextrin 49 28 0.0001
Time on icodextrin 32.7 ± 23.3 18.1 ± 15.7 0.0060
Icodextrin per patient-year 0.47 ± 0.3 0.53 ± 0.5 0.6
Periods and episodes of peritonitis are reported as mean ± SD. Time is reported as months. Other parameters are 
reported as number of patients (%). Ultrafi ltration failure is defi ned as < 400 ml ultrafi ltrate assessed with standard 
3.86% PET or the presence of clinical symptoms. Dialysis fl uids were scored if ever used in the period 1996-2007. Time on 
icodextrin is calculated as time (months) per patient using icodextrin. Icodextrin per patient-year is time on icodextrin 
calculated per year treated with PD. Means were tested using t-test, proportions were compared with chi-square tests. 
NS means not signifi cant.
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found in EPS patients (35 vs. 42 episodes, p=0.01). There was no diff erence in episodes with 
Pseudomonas, Staphylococcus Aureus or culture negative peritonitis. 
EPS patients were more often fast transporters, but a relatively large number of missing 
tests was present in the controls (Table 3). The majority of EPS patients had ultrafi ltration failure 
(60.3%). New dialysis solutions as a lactate/bicarbonate solution (Physioneal ®) and icodextrin 
(Extraneal ®) were more often used in EPS patients (Table 3). The cumulative period with use of 
icodextrin was signifi cantly longer in EPS patients (Table 3). For other solutions the time periods 
could not be assessed accurately and are therefore not shown. The accumulative glucose load 
could not be retrieved accurately.
Transfer from PD to HD
In total 34 patients with a fi nal diagnosis of EPS were transferred from PD to HD (54.0%). Of 
these, 22 were transferred to HD because of suspected EPS. Twelve patients transferred to 
HD for other reasons than suspected EPS (19.1%). Seven patients were transferred because of 
peritonitis, three patients because of ultrafi ltration failure, one because of exit site infections 
and in one patient the reason was not clearly documented. In the control group 37 patients 
(29.4%) transferred from PD to HD.
Table 4 | Kidney transplantation and immunosuppressive medication
EPS
Yes (63) No (126) P-value
Patients transplantated 47 59 0.0001
Number of transplantations 1.6 ± 0.9 1.3 ± 0.7 0.05
Age at last transplantation 36.4 ± 13.4 44.3 ± 13 0.0030
Time start PD - last transplantation 68.9 ± 60.5 25.6 ± 61 0.0001
Immunosuppressive medication
CNI 40 53 0.0080
tacrolimus 19 17 NS
CsA 27 37 NS
Prednisone 43 55 0.0001
MMF 27 27 NS
Age and time are reported respectively in mean years and months ± SD. Number of transplantations is reported in 
means ± SD per transplanted patient. Immunosuppressive medication is scored per patient, if ever used in the period 
1996-2007 for kidney transplantation. CNI means calcineurin inhibitors, CsA cyclosporin and MMF mycophenolate 
mofetil. Means were tested using t-test, proportions were compared with chi-square tests. All patients were used for 
calculation of p-values. NS means not signifi cant.
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Variables related to kidney transplantation
Relative more EPS patients had kidney transplantations in comparison to controls (47/63 vs. 
59/126, p<0.0001), with more transplantations per patient (Table 4). Twenty-one patients with a 
kidney transplant (44.7% of total transplanted EPS patients) developed EPS within 2 years after 
the last kidney transplantation. The median time from last transplantation to EPS was 12.4 months 
(IQR 39.4). Figure 2 shows the univariate relationship between time since the last transplantation 
and the yearly probability on the EPS development. Prior to the last transplantation the risk for 
developing EPS was 1.75% in the overall cohort. The year following the transplantation the risk 
increased to 7.5%. After the fi rst twelve months this decreased again with 7.0% per year.
Regression analysis
Univariate analysis showed that time on PD, age at start PD, transplantation, time since last 
transplantation until EPS diagnosis (or end of study in control patients), calendar time (years 
since the reference date close to which the fi rst patient started PD), period of using icodextrin, 
ultrafi ltration failure and follow up time were associated with EPS. Multivariate regression 
analysis showed that time on PD, age at start PD, transplantation, time since last transplantation 
Figure 2 | Eff ect of time after last transplantation on EPS.
Eff ect of time after last transplantation on development of EPS calculated with univariate analysis. After the last 
transplantation the yearly probability on EPS increased in this cohort from 1.75 % to 7.50 % in fi rst year after 
transplantation. Thereafter this risk decreased each year with 7%.
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until EPS diagnosis, calendar time, period of using icodextrin and ultrafi ltration failure were 
strongly associated with the presence of EPS (Table 5). In the multivariate analysis, using the log 
linear regression, follow up time, transfer from PD to HD for other reasons than suspected EPS 
and peritonitis episodes were not signifi cant because of strong associations with PD duration 
and age. Therefore these were excluded from the fi nal multivariate model. Since ultrafi ltration 
failure was missing in 17.5% of the patients, and is a possible confounder, we performed a 
sensitivity analysis and analyzed ultrafi ltration failure in two ways. First we coded it as yes, no 
or missing and estimated a separate odds ratio (OR) for the missing category. Subsequently we 
excluded patients with a missing value. Both approaches resulted in a similar signifi cance level 
of ultrafi ltration failure and similar OR’s for the other variables.
DISCUSSION
The fi rst aim of the present study was to investigate the incidence of EPS in recent years. The 
study shows an increasing incidence in a large representative Dutch PD population between 
January 1996 until January 2006, confi rming our previous fi ndings 16. This occurred despite 
a slight decrease in the PD population and a stable mean duration on PD. The increase in 
Table 5 | Univariate and multivariate regression
Univariate Multivariate 
OR P-value OR P-value
PD duration 1.49 <0.001 1.40 <0.001
Age at start PD 0.97 <0.001 0.96 <0.001
Transplantation 4.63 <0.001 2.47 0.010
Time since last transplantation until EPS 0.93 <0.001 0.85 <0.001
Time (calendar) 1.28 <0.001 1.37 <0.001
Icodextrin duration 1.92 <0.001 1.35 <0.001
Ultrafi ltration failure 4.55 <0.001 2.29 0.026
Follow up time 1.07 0.001
Transfer PD to HD other than suspected EPS 0.98 0.1
Peritonitis episodes 1.05 0.110
Data were analysed by a piecewise log linear model (Poisson regression) with EPS as outcome. Time since last 
transplantation until EPS is defi ned as the time from the last transplantation until EPS or end of study (in control 
patients). Calendar time was defi ned as the years since the chosen reference date, close to which the fi rst patient in the 
study started PD (01-01-1983). Follow up time was defi ned as the period from start PD until EPS, death or end of study. 
Odds ratios (OR) for time on PD, age at start PD, time since last transplant until EPS diagnosis, calendar time, time on 
icodextrin and follow up time are expressed per year. OR for transplantation and ultrafi ltration failure is given for these 
conditions. Follow up time, transfer PD to HD for other reasons than suspected EPS and episodes of peritonitis were 
not signifi cant in multivariate analysis and were therefore excluded from fi nal model. There is an adjustment for the 
diff erences in other risk factors than the one of interest. For example, the OR for age at start PD is given the diff erences in 
cumulative PD time. That means that two patients with the same PD time, the one who started PD younger has a higher 
risk on EPS. All multivariate ORs are conditional on the diff erence in the other risk factors.
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incidence appears to be followed by a small decrease in 2006. The reason for this is unclear. The 
most straightforward explanation for the increased incidence of EPS could be that increased 
awareness of the diagnosis led to subsequent inclusion of milder cases. However, this is unlikely, 
given the strict defi nition for inclusion. For instance, all patients had symptoms of intestinal 
obstruction. 
The second goal of the study was to investigate the separate associations of risk factors 
with EPS development. From the candidate risk factors we confi rmed the independent associa-
tions of PD duration and age with EPS development. In addition we were able to show novel 
independent associations as prolonged use of icodextrin, kidney transplantation and the time 
after kidney transplantation with the presence of EPS. We were not able to show an association 
with transfer from PD to HD. In contrast to others we found no signifi cant relationship with 
peritonitis 15,24. Despite these associations, there remains an unknown factor related to the 
recent increased incidence of EPS, as shown by the remaining independent association with 
calendar time. Currently we have no plausible alternative explanation for this.
The development of EPS is infl uenced by multiple factors and time is an important factor in 
the process of ongoing peritoneal remodelling and fi brosing. The second hit theory integrates 
individual predisposition with the time in which the peritoneal membrane is continuously 
exposed to conditioning agents and multiple hits, which result in the ultimate manifestation 
of EPS 1-2. With respect to predisposition, our data showed no diff erence in gender. As in other 
reports diabetic patients hardly develop EPS 8,25. 
The age at which PD was started, is associated with the presence of EPS. The younger a 
patient starts with PD the greater the chance to develop EPS. Given the independent signifi -
cance this is not simply due to longer time on PD or to longer follow-up time from the moment 
of initiating PD. Peritoneal remodelling is a process in which injury of the mesothelial cell plays 
a key role. In reaction to multiple insults, with for example glucose, mesothelial cells secrete 
cytokines subsequently leading to recruitment of macrophages and fi broblasts 26. Peritoneal 
fi brosing is then the result of disrupted repair with fi brin deposition on denudated mesothelial 
cell layer 2. Possibly this repair process is more vivid in younger patients, leading to earlier 
development of fi brosis.
From the studied candidate risk factors, duration of PD treatment is probably the strongest 
predictor of EPS. Although Japanese studies have shown that continuing PD for a longer 
period is associated with EPS development, this was until recently not previously analysed in 
a matched case controlled design 12. The Scottish Renal Registry showed that the incidence 
of EPS increased with PD duration 10. The current study confi rms these fi ndings. Each year of 
prolonged PD had an increased relative risk for EPS of 40%.
The associations of young age and PD duration are in accordance with a recent report of 
the ANZDATA registry 9. As in our study, this study has a controlled design with a multivariate 
Mario BW v4.indd   66 25-03-11   11:11
Incidence and risk factors 67
analysis. Although the designs diff ered, both studies used incident patients. The ANZDATA 
study used the whole cohort as reference group. This resulted in a signifi cant diff erence in the 
era in which dialysis was commenced. Because we controlled at start date of PD we excluded 
this possibility. It appears that the EPS patients of both studies were not entirely comparable. 
For instance, there were no post-transplantation EPS patients in the ANZDATA report and their 
EPS related mortality was much less.
Novel fi ndings of the current study are the associations of EPS with icodextrin and kidney 
transplantation. Solutions containing icodextrin permit good ultrafi ltration during long time 
dwells and their use avoids the potential harmful eff ects of glucose 27-28. As a result, the use 
of icodextrin has increased 29. In Dutch practice icodextrin is not only used for patients with 
apparent ultrafi ltration failure. Our study showed that, independent of ultrafi ltration failure, 
prolonged use of icodextrin was associated with the presence of EPS. Recently, concerns have 
been raised about the increased levels of markers of peritoneal infl ammation in icodextrin 
treated patients. The effl  uent showed a higher cell count and higher concentration of IL-6, TNF, 
hyaluronan, and fi brin degradation products 30-33. This led the authors to suggest that these 
patients were possibly at risk for EPS 34. Others argued that icodextrin preserves the peritoneal 
membrane function and mesothelial cell mass 28,33. A recent case controlled study showed 
no diff erence in prescription of icodextrin between EPS and non-EPS patients 13. A possible 
confounder, for which we were unable to correct, is cumulative intra-peritoneal glucose load, 
which might be higher in EPS patients 35. Although our data show an association with icodex-
trin, it is premature to identify it as a risk factor for EPS. Further studies are certainly warranted 
to address this important issue. 
Previously, we described a case series of patients who developed EPS shortly after kidney 
transplantation. We hypothesized that kidney transplantation could also be considered as a 
candidate factor for enhancing the EPS development 14,16. Others also described post-transplant 
EPS cases 10,36-37. We established kidney transplantation as a variable independently associated 
with EPS. The yearly probability on EPS after the last kidney transplantation increased from 
1.75% to 7.5%. Each subsequent year after transplantation this risk decreased again. A pos-
sible explanation is the profi brotic property of calcineurin inhibitors (CNI’s). Cyclosporin and 
especially tacrolimus have been shown to upregulate TGF-β in transplanted patients 38. TGF-β is 
thought to be of major importance in the development of peritoneal fi brosis 39. Recently, it was 
also shown that administration of cyclosporin to an experimental animal model with peritoneal 
exposure to a 3.86% glucose dialysis solution augmented peritoneal fi brosis and angiogenesis 
40. We were not able to identify the introduction of CNI’s as a risk factor for EPS, because the large 
majority of patients was treated with either cyclosporin or tacrolimus. Finally, not the kidney 
transplantation itself, but rather the cessation of the PD, might be the risk factor for developing 
EPS 12,41. This is underlined by results from other studies, which showed a number of patients 
diagnosed with EPS after switching to HD 13. We were not able to show an association with 
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transfer from PD to HD. Instead, we found that the majority of patients switching from PD to HD 
already were suspected of having EPS. These patients had symptoms of (intermittent) bowel 
obstruction but did not fulfi l the CT-scan criteria for EPS prior to transfer. Our data suggest that 
clinical symptoms and ultrafi ltration failure dominate in the early phase of EPS development, 
and diagnostic CT-scan abnormalities are mainly found at the later stages of disease. This is in 
accordance with the fi ndings of Tarzi et al. who showed that CT-scanning has no additional 
value for identifi cation of EPS early in the course of the disease 20. However, it remains an open 
question whether transferring PD patients with suspected EPS to HD accelerates the process of 
encapsulation.
The strength of the study is the large size of the EPS group and the controlled design, without 
premature controlling for PD duration. The multivariate analysis enabled us to investigate and 
quantify novel additional factors besides the PD duration. However, due to the design of the 
study and the RENINE registry, the study has some limitations. Recently, two studies described 
the increasing small solute transport status and decreased osmotic conductance in patients 
with developing EPS 42-43. The current study also shows increased small solute transport in EPS 
patients, but has considerable missing results concerning the transport status. This is due to the 
fact that in the past annual evaluation was not common. 
The risk ratio’s are given in yearly risks and this might suggest a contradiction with the known 
exponential increase of EPS incidence within every year of PD treatment 12. However, in any 
given PD population, a yearly calculated increase of a given risk factor for EPS will mathemati-
cally lead to an exponential increase in EPS incidence per year of PD treatment. The exponential 
nature of the model is demonstrated by the fi gure on the risk for EPS in univariate relation to 
time after transplantation. 
It is interesting to speculate on the clinical consequences of these fi ndings. Our data support 
the assumption that PD induced peritoneal damage underlies the post-transplantation EPS. A 
typical patient with EPS after kidney transplantation has started with PD at relatively young age 
(< 50 years), has been on PD for a prolonged time, with development of ultrafi ltration failure 
and has been exposed to icodextrin. Instead of an arbitrary overall expiry date of PD, a timely 
switch of young PD patients to HD at the appearance of ultrafi ltration failure, while waiting on 
renal transplantation, can be considered. Such a prudent policy might reduce EPS incidence.
In conclusion, we confi rmed that the incidence of EPS has increased in recent years, followed 
by a decrease in 2006. We identifi ed signifi cant independent associations of PD duration, age, 
kidney transplantation, ultrafi ltration failure and the use of icodextrin with EPS development. 
In particular the possible role of icodextrin needs to be further evaluated.
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ABSTRACT
Background 
Encapsulating peritoneal sclerosis (EPS) is a life threatening complication of long-term peri-
toneal dialysis (PD). No tests are available to make an early diagnosis of EPS. Effl  uent cancer 
antigen 125 (CA125) is a marker of mesothelial cell mass, interleuking-6 (IL-6) is a marker of 
infl ammation, potassium (K+) is released during hypertonic cell shrinkage and vascular endo-
thelial growth factor (VEGF) is a growth factor for the formation of new vessels. The aim of the 
present case-control study was to analyze the time course of the above described peritoneal 
membrane markers in patients who developed EPS and in those matched for the duration of 
dialysis that did not progress to this complication. 
Methods
Dialysate and serum samples of 11 EPS patients and 31 control patients all treated with PD 
for at least 57 months were longitudinally collected during a standard peritoneal permeability 
analysis (SPA) performed once a year. The 4 most recent samples were analyzed. CA-125 and 
IL-6 were measured in dialysate alone, K+ and VEGF were measured in both dialysate and serum. 
To correct for the eff ect of the drained volume, values of CA-125 and IL-6 are expressed as 
appearance rates (AR). Dialysate over serum (D/S) K+ was divided by the D/S creatinine in order 
to correct for diff usion. The local production of VEGF was calculated by taking the diff erence 
between the measured and expected D/S VEGF, based on diff usion. The linear mixed model 
was used to analyze the time courses of the various markers. The sensitivity and specifi city of 
the diff erent markers were calculated based on the results of the last two time points.
Results
EPS patients were younger than controls (35 versus 53 years, p=0.05) and had a longer PD 
duration (104 months versus 72 months, p=0.01). No signifi cant diff erences in time courses 
of the diff erent markers were present between groups. However AR CA-125 was signifi cantly 
lower in the last three years prior to EPS (p<0.05) and AR IL-6 was higher two years prior to EPS 
(p=0.09). Locally produced VEGF showed no diff erences among the groups. The combination of 
AR CA-125<33 U/min and AR IL-6>350 pg/min had a sensitivity of 70% and a specifi city of 89%.
Conclusions
AR of CA-125 showed lower values and AR of IL-6 showed higher values during the last years 
prior to the diagnosis of EPS compared to controls. The sensitivity and specifi city of the combi-
nation of CA-125 and IL-6 indicate the potential use for an early diagnosis of EPS.
Mario BW v4.indd   76 25-03-11   11:11
Early diagnostic markers 77
INTRODUCTION
Encapsulating peritoneal sclerosis (EPS) is a life threatening complication of long-term perito-
neal dialysis (PD). No tests are available to make an early diagnosis of EPS. Typically, patients 
present with bowel obstruction, after which the diagnosis is made, either by laparotomy or CT 
scanning 1-2. Ultrafi ltration failure (UFF) is always present, but this is not diagnostic. Peritoneal 
solute transport is often fast, but may decrease before the diagnosis is made 3-4.
Peritoneal effl  uent contains a number of substances that are locally produced or released, 
additionally to their transport from the circulation 5. These include potassium 6, cyto kines 7-8, 
growth factors 9 and the mesothelial cell marker cancer antigen 125 (CA-125) 10. 
The aim of the present case-control study was to analyze the time course of the above 
described peritoneal membrane markers in patients who developed EPS and in those matched 
for the duration of dialysis that did not progress to this complication. Our research question 
was whether any of the above mentioned effl  uent markers could be used as early diagnostic 
marker for EPS.
PATIENTS AND METHODS
Patients
All EPS patients who were diagnosed in our department between 1995 and October 2008 were 
selected for this study. The diagnosis of EPS was based on predefi ned criteria 2. These included 
clinical features like bowel obstruction, ascites and blood stained effl  uent in combination with 
UFF, confi rmed either by fi ndings at radiology, laparotomy or autopsy, and reviewed by two 
experienced nephrologists.
All PD patients with at least 57 months of PD in the same period were included in this study 
as controls.
Samples
The effl  uent and serum samples of EPS patients and controls were obtained during a Standard 
peritoneal Permeability Analysis (SPA) 11. None of the patients had peritonitis at time of the SPA 
or the four preceding weeks. The presence of ultrafi ltration failure (UFF) was made based on the 
recommendation of the International Society for Peritoneal Dialysis 12. PD patients undergo a 
SPA to assess the functional condition of the peritoneum once a year. Remaining effl  uent and 
serum samples are frozen and stored after centrifugation. Therefore several effl  uent and serum 
samples of diff erent time points were available for all patients with an average interval of one 
year. The average interval between the diagnosis EPS and the time of the last available sample 
was 10 months. This allowed us to express the time points as years prior the diagnosis of EPS, 
whereas time point zero was the time of the diagnosis of EPS.
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Markers
K+ was measured in effl  uent and serum directly after the SPA with an ion selective electrode 
(Roche Diagnostics, Almere, The Netherlands). CA-125 levels in effl  uent were analyzed by using 
an enzyme labeled sandwich immunoassay (Roche Diagnostics, Almere, the Netherlands). 
Interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) were measured in effl  uent 
with commercially available enzyme-linked immunosorbent assays (human IL-6 and human 
VEGF, RandDsystems, Minneapolis, USA). Prior to the measurement of VEGF the effl  uent samples 
were concentrated 10 times through ultrafi ltration by using an ultra-15 centrifugal fi lter with a 
molecular cut off  point of 10,000 Da (Millipore, Molsheim, France). The concentration factor was 
defi ned as the albumin concentration in the concentrate divided by the albumin concentration 
in the original effl  uent sample.
Creatinine was measured with an enzymatic method on an automated analyzer (Hitachi 
H911, Boehringer, Mannheim, Germany). Albumin (Alb), immunoglobulin G (IgG) and alpha-
2-macroglobulin (A2M) were all measured by nephelomethry (BN100, Behring, Marburg, 
Germany) with commercial antisera (Dakopatts, Glostrupp, Denmark). Beta-2-microglobulin 
(B2m) was determined with a microparticle enzym immunoassay with an IMX system (Abbott 
Diagnostics, North Chicago, IL, USA).
Calculations and Statistics
Data are presented as medians and ranges unless stated otherwise. In order to correct for peri-
toneal transport, dialysate over plasma ratio (D/P) of K+ was divided by the D/P creatinine. Due 
to their size, diff usion of CA-125 and IL-6 is negligible and only effl  uent appearance rates (AR) 
were calculated to correct for the eff ect of the drained volume on their concentration.
Peritoneal handling of the macromolecules beta-2-microglobulin, VEGF, albumin, IgG and 
alpha-2-macroglobulin was expressed as the dialysate over serum ratio (D/S). A peritoneal 
transport line was computed for each patient based on the least squares regression analysis 
of the D/S ratio of B2m (MW=11,800 Da), Alb (MW=69,000 Da), IgG (MW=150,000 Da) and A2m 
(MW=820,000 Da) and their molecular weights when both were plotted on a double logarith-
mic scale 13. By interpolation of the MW of VEGF (MW= 34,000 Da) in the regression equation 
the expected D/S ratio was calculated assuming that the effl  uent concentration would only be 
determined by transport from the circulation. The concentration of VEGF attributed to local 
production was defi ned as the diff erence between measured and expected effl  uent concentra-
tion.
The linear mixed model was used to analyze the time courses of the various effl  uent mark-
ers. A Mann-Whitney-U test was used to analyze the diff erences between groups on diff erent 
time points. Sensitivity and specifi city of all markers were calculated at one and two years prior 
to the diagnosis of EPS or prior to the discontinuation of PD in the control group. Cutoff  values 
for these calculations were based on literature for K+ 6, CA-125 14, IL-6 15, and VEGF 9.
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RESULTS
Patients
Patient characteristics are listed in Table 1. We included 11 EPS patients and 31 controls. Patients 
who developed EPS were younger and the duration of PD treatment was longer. Reasons for 
discontinuation of PD treatment in EPS patients were: ultrafi ltration failure (6), infection (2), 
transplantation (1) and EPS (2). Reasons for stopping PD treatment in controls were death (12), 
infection (2), transplantation (7), UFF (4) and other (1). Five patients were censored at October 
2008. None of the control patients developed EPS in the three years of follow-up.
Markers
The time course of the various effl  uent markers is shown in Figure 1 for D/P K+/ D/P creatinine, in 
Figure 2 for the CA-125 appearance rate, in Figure 3 for the IL-6 appearance rate and in Figure 4 
for the effl  uent concentration of locally produced VEGF. For none of the markers a signifi cant dif-
ference was found in the time courses, but lower values for CA-125 were found in the EPS patients 
compared to controls. This group also showed a tendency for a higher IL-6 appearance rate.
Table 1 | Patients characteristics of EPS patients and their time matched controls. 
EPS 
(n=11)
Controls 
(n=31)
Age (years) 35 (21-73) 53* (32-87)
Gender (Male/female) 7/4 19/12
PD duration (months) 104 (57-149) 72* (57-112)
Net UF at last SPA (mL/4h) 121 (-113-308) 494**(73-920)
Number of peritonitis episodes (total episodes since 
start of PD)
4 (0-15) 3 (0-11)
Peritonitis incidence (episodes / year) 0.47 (0-2.61) 0.41 (0-1.66)
Data are presented as medians and ranges. *p<0.05, **p<0.01
Figure 1 | Linear mixed model estimations (mean and SEM) of the time 
course of D/P K+/ D/P creatinine in the EPS group (—♦—) and in the 
control group (- -- -). The number of patients at each time point 
is given on the horizontal axis. The time course was not diff erent 
between the groups (p=0.085), but lower values were found for EPS 
patients (p=0.029). This was mainly based on the diff erence at -3 
years.
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Sensitivity and Specifi city
Results are presented in Table 2. Sensitivity and specifi city of the separate effl  uent markers were 
calculated at timepoint -1 plus -2. The combined sensitivity and specifi city of AR IL-6 and AR 
CA125 was also calculated at these time points. This parameter had a sensitivity of 70% and a 
specifi city of 89%. In patients with UFF, the combination of AR CA-125 <33 U/min and AR IL-6 
> 350 pg/min had a sensitivity of 70% and a specifi city of 100% for the development of EPS.
Figure 2 | Linear mixed model estimations (mean and SEM) of 
the time course of the CA-125 appearance rate in the EPS 
group (—♦—) and in the control group (- -- -). The number of 
patients at each time point is given on the horizontal axis. The 
time course was not diff erent between the groups (p=0.68), 
but lower values were found for EPS patients (p=0.045). 
Signifi cant diff erences were found at the timepoints -3, -2 and 
-1 years.
Figure 3 | Linear mixed model estimations (mean and SEM) of 
the time course of the IL-6 appearance rate in the EPS group 
(—♦—) and in the control group (- -- -). The number of 
patients at each time point is given on the horizontal axis. The 
time course was not diff erent between the groups (p=0.414), 
but higher values were found for EPS patients (p=0.06). This 
was mainly based on the diff erence at -2 years.
Figure 4 | Linear mixed model estimations (mean and SEM) of 
the time course of the local production of VEGF in dialysate 
in the EPS group (—♦—) and in the control group (- -- -). 
The number of patients at each time point is given on the 
horizontal axis. The time course was not diff erent between the 
groups (p=0.97), and similar values were found for EPS patients 
and controls (p=0.89).
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DISCUSSION
Encapsulating peritoneal sclerosis is a serious complication of long-term PD that should be tried 
to avoid. Therefore identifi cation of patients at risk for its development is important. Almost all 
EPS patients have ultrafi ltration failure 4,16, but its prevalence in long-term PD patients is much 
higher than the occurrence of EPS 17. Therefore the current analysis of substances present in 
peritoneal effl  uent was performed. It appeared that until one year prior to the diagnosis of EPS, 
no diff erences were present between pre-EPS patients and time matched controls in the time 
courses of the various markers. However, effl  uent CA-125 was lower and effl  uent IL-6 tended 
to be higher in patients who developed EPS. The combination of an appearance rate of CA-125 
<33 U/min and an IL-6 appearance rate >350 pg/min had a sensitivity of 70% and a specifi city 
of 100% in patients with ultrafi ltration failure.
The choice of the biomarkers was based on results from previous investigations and their 
interpretation. Effl  uent K+ during a hypertonic 4 hour exchange is partly due to diff usion, but 
also to local release from cells 6. Hypertonic cell shrinkage causing K+ effl  ux is the most likely 
mechanism. This phenomenon is especially present in patients during the fi rst few years of PD, 
while it is absent in long-term patients with UFF. The amount of local release was not related to 
effl  uent CA-125 18. Low values were found in both groups without an obvious trend, which may 
be caused by a lower number of cells or by impaired function of cellular K+ channels.
Effl  uent CA-125 is a marker for mesothelial cell mass or turn-over 10,19. It decreases with the 
duration of PD 19. This is in accordance with the loss of mesothelium in PD as found in the perito-
neal biopsy registry 20. Complete loss of mesothelium has been described in EPS 21. Our analysis 
showed lower values for effl  uent CA-125 in the pre-EPS patients at various time points when 
compared to the control group. This is in line with the alterations in peritoneal morphology.
Effl  uent IL-6 is considered a marker for local infl ammation 15,22. Also in the present analysis 
an increase with the duration of PD was found. This is in accordance with the infl ammatory 
changes described in some EPS patients 23.
Table 2 | Sensitivity and specifi city of diff erent markers for the development of EPS 
Measurepoint -1 and -2 year
Sensitivity (%) Specifi city (%)
D/P K / D/P creatinine >1 10/11 (91%) 8/29 (28%)
AR CA-125 <33 (U/min) 7/10 (70%) 14/21 (66%)
AR IL-6 >350 (pg/min) 8/10 (80%) 10/20 (50%)
VEGF >15 (ng/L) 6/9 (33%) 3/12 (25%)
AR CA-125<33 (U/min) and AR IL-6>350 (pg/min) 7/10 (70%) 17/19 (89%)
AR CA-125<33 (U/min) and AR IL-6>350 (pg/min) 
in UFF patients
7/10 (70%) 8/8 (100%)
Sensitivity and specifi city of diff erent markers for the development of EPS at 1 year and 2 years prior to the diagnosis. 
The numbers before the slash refer to the number of positive fi ndings; those behind the slash to the number of analyzed 
samples. The percentage refers to the sensitivity or specifi city.
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Soluble VEGF in effl  uent is partly derived from diff usion and partly by local production 9. 
Locally produced VEGF is related to the mass transfer area coeffi  cient of creatinine 9, which 
refl ects the surface area of peritoneal microvessels 24-25. Patients with EPS have high solute 
transport rates and an increased number of vessels. Yet, no high effl  uent concentration of 
locally produced VEGF was found in the present analysis. We speculate that neoangiogenesis 
occurs in an earlier stage than fi brosis during the development of EPS.
Some biomarkers were not analyzed, because of various reasons. Effl  uent transforming 
growth factor beta was not analyzed because we previously found that it was present in a 
non-active form and the results were not related to the duration of PD or any other parameter 
9. Similarly, effl  uent hydroxyproline was not informative 26. Tumor necrosis factor alpha was not 
analyzed because it is only locally produced during acute peritonitis 13. Fibrinolytic proteins 
were not measured, because no citrate or EDRA plasma was collected. Yet, these are potentially 
interesting because local peritoneal production has been shown for tissue plasminogen activa-
tor inhibitor type 1 antigen 27. Methods for the measurement of collagen IV and alpha smooth 
muscle actin are not commercially available.
The sensitivity and specifi city of the combination of effl  uent CA-125 and IL-6 in patients 
with UFF suggest that it is possible to identify those at risk for clinically established EPS. This is 
important, because preventive interventions to reduce morbidity and mortality might be more 
eff ective at this stage than after the establishment of the diagnosis. Besides discontinuation of 
PD, such interventions could include peritoneal  resting 28, steroids and immunosuppressives 
29-30 and also tamoxifen 31. These interventions could potentially be monitored by effl  uent 
CA-125 and IL-6, but these would require further studying.
A potential weakness of the study is the diff erence in PD duration between both groups. 
Intentionally the shortest duration of PD in the control group was 57 months, similar to the 
observed shortest duration in the EPS group. It illustrates the importance of the duration of 
PD therapy in the development of EPS. Nevertheless six out of eleven EPS patients had an 
overlapping PD duration with the control group. The EPS patients were also younger. This may 
be relevant for the development of EPS, because it was also present in a diff erent EPS cohort 
2. Another shortcoming is that not all analyses could be done in all patients, because of the 
limited number of available serum and effl  uent samples. However, the number of samples in 
the EPS group averaged 8 and was never smaller than 5.
It can be concluded that the dialysate appearance rate of the combination CA-125 and IL-6 is 
potentially useful for an early diagnosis of EPS, especially in patients with UFF. Both can be mea-
sured easily without specifi c preparation of the effl  uent sample. Further studies are required to 
confi rm our fi ndings and to investigate whether the effl  uent CA-125/IL-6 combination can be 
used for monitoring of interventions.
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Tamoxifen is associated with lower mortality 
of Encapsulating Peritoneal Sclerosis; results of 
the Dutch multicenter EPS study.
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ABSTRACT
Background
Encapsulating peritoneal sclerosis (EPS) is a serious complication of peritoneal dialysis (PD) with 
an increasing incidence. There is no clear consensus on the treatment of EPS, but anecdotal 
reports indicate improvement in EPS patients treated with tamoxifen. At present there is no 
evidence for the eff ect of tamoxifen treatment in EPS patients. This study investigates the eff ect 
of treatment with tamoxifen on survival in EPS patients.
Methods
Retrospective analysis of survival in EPS patients as part of Dutch multicentre EPS study in the 
period January 1996 – July 2007. Sixty-three patients with severe EPS were followed up until 
August 2008. Demographic, patient and PD related variables of EPS patients were investigated. 
Patients treated with tamoxifen were compared to patients not treated with tamoxifen. Survival 
was analyzed with multivariate Cox regression analysis.
Results
Twenty-four patients were treated with tamoxifen and 39 were not treated with tamoxifen. The 
clinical and demographic characteristics were similar for the tamoxifen treated and non-treated 
group. The mortality rate was signifi cantly lower in tamoxifen treated patients compared to EPS 
patients not treated with tamoxifen (45.8% vs. 74.4%, p=0.03). Survival in tamoxifen treated 
patients, adjusted for calendar time, age, use of corticosteroids, presence of functioning trans-
plantation, use of parental nutrition and centre infl uences was longer in comparison to not 
treated patients (HR 0.39, p=0.056).
Conclusions
Tamoxifen treatment in EPS patients is associated with lower mortality and shows a trend to 
an increased multivariate-adjusted survival. This supports additional use of tamoxifen to treat 
patients with severe EPS.
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INTRODUCTION
Encapsulating peritoneal sclerosis (EPS) is a clinical syndrome characterized by intestinal encap-
sulating and subsequent obstruction of the intestinal tract by formation of excessive peritoneal 
fi brosis tissue 1. Although EPS can be found in diff erent clinical settings, the condition is most 
frequently seen in patients treated with peritoneal dialysis (PD).
Although rare, EPS has come to be recognized as a serious complication of PD with a high 
morbidity and a mortality of approximately 50% 2. The development of EPS is insidious and 
probably starts with sterile visceral peritoneal infl ammation with neovascularisation, followed 
by massive deposition of fi brous scar tissue that encases part or all of the bowels. As such, EPS 
is diff erent from the sclerotic thickening of the peritoneum that appears after many years of 
peritoneal dialysis, a condition often referred to as simple sclerosis 3. The infl ammatory stage of 
EPS may be recognized clinically by the appearance of bloody ascites, ultrafi ltration failure and 
signs and symptoms of chronic infl ammation. When fi brous tissue progressively encapsulates 
the bowels, intermittent or defi nite intestinal obstruction will ensue, leading to severe mal-
nutrition 4-5. The symptoms of intermittent intestinal obstruction are mild in the beginning of 
encapsulation and often not appreciated as early signs of EPS.
Due to the slow nature of progression and the aspecifi c criteria for the EPS diagnosis there 
is often a delay in diagnosing the disease. Eventually, the diagnosis is primarily confi rmed by 
radiological fi ndings or by the macroscopical image of peritoneal encasement. Recently, crite-
ria for abdominal CT scanning have been established, which can be of help in diagnosing EPS 6. 
Supportive care with either enteral or parenteral nutrition has been shown to be benefi cial and 
should be the mainstay of the treatment when intestinal obstruction with malnutrition is pres-
ent 7. Encouraging results from Japan have been reported with surgical enterolysis, releasing 
the complete small intestine 8. However, there is little experience with this procedure outside 
Japan and it is rarely performed in Western-Europe. There is no uniform medical management 
strategy for EPS, as the effi  cacy of the intervention is not proven. Usually patients are treated 
with intestinal rest and additional treatment, such as immunosuppressive medication 9-11 or 
tamoxifen 12.
Tamoxifen is a selective estrogen receptor modulator (SERM) 13, predominantly used for the 
treatment of breast cancer 14-16. Tamoxifen also infl uences the activity of the profi brotic cytokine 
TGF-β and has shown to be eff ective in fi brotic diseases as retroperitoneal fi brosis 17 and Riedels’ 
thyroiditis 18. The reported eff ects of tamoxifen in EPS are equivocal and result from a limited 
number of case reports and small series of patients 12,19-20. A controlled study investigating the 
eff ect of tamoxifen on survival in a larger population is lacking.
Recently we performed a large Dutch multicentre study to investigate the incidence of EPS 
in the past years 21, preceded by an initial report indicating a possible increase of EPS 22. As part 
of this study we investigated the survival of EPS patients treated with tamoxifen in comparison 
with not treated patients in the period of 1997-2007.
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METHODS
Design and setting
The design of the study was a retrospective multicentre study. The participating centres were 
fi ve university hospitals in the Netherlands and three large teaching hospitals. All cases in the 
participating centres in the study period 1996-2007 were identifi ed by investigating the medi-
cal records. The university centres are the primary transplantation centres for their region. 
The study protocol was approved by the medical ethics committee of the Erasmus University 
Medical Centre, Rotterdam.
Classifi cation and diagnosis of EPS
Encapsulating peritoneal sclerosis was defi ned according the criteria developed by the Ad Hoc 
Committee of the International Society of Peritoneal Dialysis (ISPD) 23. It is defi ned as a clinical 
syndrome with persistent or recurrent presence of intestinal obstruction with or without the 
existence of infl ammation parameters and the existence of peritoneal thickening, sclerosis, 
calcifi cations and encapsulation confi rmed by macroscopic inspection or radiological fi ndings.
Using this defi nition of EPS the studied population was limited to severe forms of intestinal 
obstruction that lead to persistent clinical problems, the necessity of surgical intervention, 
immunosuppressive therapy and/or the necessary use of total parental nutrition (TPN). 
Participants
Patients with EPS diagnosed in the period January 1st 1996 - July 1st 2007 were included. Medical 
records of patients with EPS were reviewed in detail by the investigating nephrologist, who was 
not the primary treating physician. Data were entered into the case report form and database. 
The date of diagnosis of EPS was retrospectively set at the date at which the diagnosis fulfi lled 
the defi nition of EPS and confi rmed by two separate nephrologists. All patients underwent 
abdominal CT scanning. 
Outcomes and Follow-up
Demographics, patient and PD related variables were investigated. The duration on PD was 
calculated by accumulating all separate episodes on PD. Whenever a patient was on other renal 
replacement therapy, for longer than a week, this time was not included in the calculated time 
on PD. The follow-up of the included patients was extended to August 2008.
Renal replacement therapy was scored at the time of diagnosis of EPS. All episodes of perito-
nitis were scored. Variables related to kidney transplantation were also investigated. All dates of 
kidney transplantations were noted. The time after last transplantation until EPS diagnosis was 
calculated. All immunosuppressive medication was scored as ever used.
To ensure a complete record of medication, all medical records, including electronic 
prescription software (when used in the hospital) were investigated. Tamoxifen used for the 
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treatment of EPS was scored if the use was longer than two weeks. The use of prednisone both 
intended for treatment of EPS or as part of post-transplant regimen was scored if it was used 
at the moment of EPS diagnosis or after the diagnosis of EPS was made. The use of parenteral 
nutrition and azathioprine because of EPS was also scored as ever used.
Statistical Methods
Data were entered and statistical tests were done in SPSS 15.0.1 datamanager (Chicago, USA). 
Means were compared using unpaired t-tests. Proportions were compared with chi-square 
tests. A two sided p-value of less than 0.05 was considered to be statistical signifi cant. 
Survival was further analyzed with Kaplan Meier and Cox regression analysis. In a multivari-
ate Cox model we adjusted for the possible confounders age, year of diagnosis, presence of a 
functioning kidney transplant at time of diagnosis, PD centre, use of concomitant prednisone 
and the use of total parenteral nutrition. 
RESULTS
Patient characteristics
In the period January 1st 1996 until July 1st 2007, 63 cases of EPS occurred in the participating 
centres. Within the EPS multicentre study prevalence was calculated using only the number 
of patients in the period January 1st 1996 until January 1st 2007. In this period there were 61 
patients diagnosed with EPS and 2022 patients were on PD in the participating centres. Six EPS 
patients were excluded from these 61 patients, because they had originally started PD in other 
PD centres than those participating, resulting in a prevalence of 2.7% 21. 
For the remaining tests all 63 EPS patients were used. All 63 patients had objective symp-
toms of bowel obstruction, underwent abdominal CT scanning and were diagnosed with EPS 
according the ISPD criteria. Twenty-four patients were treated with tamoxifen and thirty-nine 
patients were not treated with tamoxifen.
There were no signifi cant diff erences between the two groups in ages at start of PD, at EPS 
diagnosis, at last kidney transplantation or at death. The groups were also comparable concern-
ing follow up time and the type of renal replacement at the time of the diagnosis (Table 1).
PD and kidney transplantation related variables
There were no signifi cant diff erences between the treated and not treated groups of EPS 
patients with regards to the cumulative period on PD, the episodes of peritonitis, the number of 
transplanted patients and the number of transplantations per transplanted patient. Overall, 47 
transplanted patients developed EPS after the last kidney transplantation with a mean of 50.8 ± 
69.8 months after the last kidney transplantation. Mean age at the last transplantation was 36.4 
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± 13.4 years. Twenty-one patients with a kidney transplant (44.7% of the total 47 transplanted 
patients) developed EPS within 2 years after the last kidney transplantation (Table 2). 
From the 47 patients with EPS after transplantation 18 patients had a functioning kidney 
transplant at the time of EPS diagnosis (Table 1). None of the patients was transplanted because 
of EPS symptoms.
Table 1 | Patient characteristics.
Tamoxifen P-value
Total (n=63) Yes (n=24) No (n=39)
Gender (f/m) 21/42 6/18 15/24 NS
Age
Age at diagnosis EPS 43.4 ± 14.4 44.7 ± 13.6 42.7 ± 15.1 NS
Age at start PD 34.7 ± 15.4 36.0 ± 14.6 34.3 ± 16.4 NS
Age at death or end of study 45.1 ± 14.1 46.4 ± 13.2 44.3 ± 14.8 NS
Age at last transplantation 36.4 ± 13.4 39.9 ± 15.1 34.0 ± 12.0 NS
Periods 
Time until death after EPS 27.3 ± 20.6 30.8 ± 18.6 25.2 ± 21.7 NS
Follow-up 129.4 ± 60.5 134.8 ± 65.6 126.0 ± 57.7 NS
Renal replacement when EPS
PD 16 7 9 NS
HD 29 8 21 NS
Functioning graft 18 9 9 NS
End of study
Deceased 40 11 29 0.03
EPS related death 35 11 24 NS
Alive, functioning graft 9 6 3 0.07
Alive HD 14 7 7 NS
Alive, PD 0 0 0 NS
Data shown as means ± SD. F female, m male. Age expressed in years. Time periods expressed in months. Renal 
replacement therapy expressed in number of patients. Means were compared using unpaired t-tests. Proportions were 
compared with chi-square tests. A two sided P-value of less than 0.05 was considered to be statistical signifi cant. NS 
means not signifi cant.
Table 2 | PD and transplantation related variables in EPS patients.
Tamoxifen P-value
Total (n=63) Yes (n=24) No (n=39)
PD
Time on PD 77.4 ± 38.1 69.9 ± 35.1 82.0 ± 39.5 NS
Episodes of peritonitis 4.1 ± 3.8 3.9 ± 3.6 4.2 ± 3.9 NS
Transplantation
Number of patients 47 19 28 NS
Number of transplantations 1.6 ± 0.9 1.4 ± 0.9 1.7 ± 0.9 NS
Time periods and episodes of peritonitis shown as means ± SD. PD peritoneal dialysis. Time periods expressed in months. 
Number of transplantations expressed in means ± SD per transplanted patient. Means were compared using unpaired 
t-tests. Proportions were compared with chi-square tests. A two sided P-value of less than 0.05 was considered to be 
statistical signifi cant. NS means not signifi cant.
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EPS treatment
There were no diff erences between the groups of EPS patients with respect to the treatment 
with TPN or prednisone. The total number of patients using prednisone (patients using pred-
nisone for the treatment of EPS or as part of post-transplant regimen combined) was also not 
diff erent between the groups. In each group one patient was also treated with azathioprine 
(Table 3). Treatment with tamoxifen was started by the treating physician. Dosages of tamoxifen 
varied in time from 10 mg once a day to 20 mg twice a day. All patients in the treatment group 
were treated with tamoxifen for at least 4 weeks. There was no extensive enterolysis performed 
in any of the patients.
Outcome
The overall mortality rate was lower in tamoxifen treated patients compared to patients not 
treated with tamoxifen, respectively 11 out of 24 and 29 out of 39 patients (45.8% vs. 74.4%), 
p=0.03. Estimated survival analyzed with Kaplan Meier showed better survival in the group 
treated with tamoxifen (p=0.07, Figure 1). Univariate Cox regression analysis confi rmed this 
trend with a hazard risk (HR) of 0.54 (p= 0.08). Multivariate Cox regression analysis with adjust-
ment for age, year of diagnosis, presence of a functioning kidney transplant at time of diagnosis, 
PD centre, use of concomitant prednisone and the use of total parenteral nutrition also showed 
a trend to an improved survival in the tamoxifen treated group, although the level of statistical 
signifi cance did not reach the predefi ned limit of less than 0.05 (HR 0.39, p=0.056). 
DISCUSSION
The present study shows that mortality rate is lower in tamoxifen treated EPS patients compared 
to EPS patients not treated with tamoxifen with both groups having comparable demographic 
and clinical characteristics. More importantly, treatment of EPS patients with tamoxifen was 
associated with a trend to an improved survival, independent of other possible benefi cial treat-
Table 3 | Treatment of EPS.
Tamoxifen P-value
Yes (n=24) No (n=39)
Treatment for EPS
Parenteral nutrition 14 21 NS
Prednisone 11 9 NS
Azathioprine 1 1 NS
Prednisone total use 12 14 NS
Data shown as number of patients. Prednisone total use means patients treated with prednisone because of EPS and 
because of renal transplant after the moment of EPS diagnosis. Proportions were compared with chi-square tests. A two 
sided P-value of less than 0.05 was considered to be statistical signifi cant. NS means not signifi cant.
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ment options. In accordance with previous studies, the results identify EPS as a life-threatening 
condition with a very high mortality.
At present there are no randomized controlled trials that have shown the effi  cacy of any given 
drug for EPS. Because there is a presumed infl ammatory response in the early development of 
EPS, corticosteroids are often given. Other immune suppressive agents like azathioprine, MMF 
or sirolimus have been given on a smaller scale. The benefi cial eff ects of this immune suppres-
sive therapy are predominantly anecdotal 10,24-29 and undoubtedly this is a biased view, because 
negative results are not likely to be reported.
In addition, a benefi cial eff ect of immune suppressive medication appears to be in contrast 
with our fi nding that EPS is more likely to develop in the fi rst year after renal transplantation, 
when patients are already immunosuppressed 22,30. In this study we could not identify a benefi -
cial eff ect of prednisone on survival of EPS patients. Therefore, the eff ect of immunosuppressive 
medication for the treatment of EPS remains to be proven.
Similar to immune suppressive medication, various anecdotal experiences and small case series 
have been reported on the eff ects of tamoxifen in EPS patients 12,19,31-40 and are summarized in 
Table 4. All reports show improvement of the intestinal function and a decrease of infl ammatory 
markers, except for a recently published large case series from England 19. In this latter study 
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Figure 1 | Survival of EPS patients with and without treatment tamoxifen.
Kaplan Meier analysis showing survival of 24 patients treated with tamoxifen (- - -) and 39 patients without tamoxifen 
(—). Time after diagnosis means time in months after EPS diagnosis. + Means censored in analysis. P-value was 0.077.
Mario BW v4.indd   94 25-03-11   11:11
EPS and tamoxifen 95
survival time in various treatment groups, including in 31 patients treated with tamoxifen was 
not diff erent compared to patients not given any drug treatment. This apparent discrepancy 
to our results may result from inclusion of less severe cases of EPS in the English study. For 
instance, only 33% of the English patients had a clinical diagnosis of bowel obstruction, while 
all patients in the present study had objective signs of severe bowel obstruction, necessitating 
parenteral nutrition in 35 of the 63 EPS patients.
In addition, the comparison appears inappropriate due to a possible diff erence in aetiology 
of EPS. In the UK study only 14 out of 111 patients developed EPS with a functioning renal trans-
plant compared to 18 out of 63 in our study (out of the total of 47 transplanted patients). The 
latter refl ects our previous reported high incidence of EPS shortly after renal transplantation 
22. From the other reports on the eff ect of tamoxifen only Moustafellas et al. reports patients 
with post-transplant EPS 34. A diff erent response of post-transplant EPS to tamoxifen is not 
implausible, considering that in this condition the peritoneal infl ammatory-fi brotic processes 
may be accelerated 30. 
Our study was not randomized. Although we did take into account all available possible 
confounders by including them into a multivariate analysis, it is possible that the results are 
infl uenced by ‘confounding by indication’.
Recently, EPS received more attention than before and subsequently there might be an 
improved strategy or increased use of tamoxifen in time. It is unlikely that this acts as a con-
founder, because the year of diagnosis was included in the analyses. A limitation of the study is 
Table 4 | Reports on tamoxifen in EPS.
Study Report N Dose of tamoxifen Steroids Outcome
Turner et al.40 case 1 10 mg b.i.d. No Improvement
Allaria et al.31 case 1 10 mg q.d. No Improvement (3 months FU)
Pollock et al.32 case 1 10 mg q.d. Yes Improvement
Del Peso et al.39 series 9 20 mg b.i.d. NR Survival benefi t
Evrenkaya et al.33 case 1 10 mg q.d. Yes Improvement (2 months FU)
Korzets et al.38 series 2 20 q.d.- 40 mg b.i.d. Yes Deceased
Moustafellas et al.34 series 2 20 mg b.i.d. Yes Improvement (3-4 months 
FU)
Dogan et al.36 case 1 10 mg q.d. Yes Resolved
Mesquita et al.37 case 1 20 mg b.i.d. Yes Improvement
Eltoum et al.12 series 4 20 mg b.i.d. No Resolved
Thirunavukasara et al.35 series 2 20 mg q.d. No Improvement (6 months FU)
Gupta et al.20 case 1 20 mg b.i.d. No Improvement
Balasubramaniam et al.19 series 31 NR Yes (12) No survival benefi t
Korte et al. (present study) Series 
controlled 
24 10 mg q.d. - 20 mg b.i.d. Yes (12) Survival benefi t (p = 0.056)
N means number of EPS patients treated with tamoxifen, b.i.d. means twice daily, q.d. means once daily, NR means not 
reported and FU means follow-up. The additional use of steroids is mentioned with number of patients when available. 
In the report of Eltoum et al. all 4 patients had restored intestinal function.
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the fact that treated patients were retrospectively compared to patients who were not treated. 
Perhaps physicians are more likely to prescribe or retain certain drugs in more severe cases. 
Another possible confounder is the fact that non-tamoxifen treated patients tend to have more 
HD at the time of EPS diagnosis. This could imply that patients on HD are sicker and are less 
likely to receive tamoxifen. We minimized these possibilities by using strict defi nitions of EPS, 
with including only severe cases with intestinal obstruction.
Due to the nature of the study we were not able to report the median dosage or cumulative 
exposure to tamoxifen. In the present study we could not include the infl uence of enterolysis, 
since such a procedure was not applied in our study population.
During the development of peritoneal sclerosis, in which an infl ammatory state develops 
into a fi brotic stage, neoangiogenesis and the transition of mesothelial cells with epithelial 
phenotype to mesenchymal type (EMT) with fi broblast like characteristics are essential 41. In 
this process TGF-β and vascular growth factors have a pivotal role. TGF-ß is regarded to be a 
central mediator of EMT 42. Overexpression of TGF-β in an animal model with chronic high glu-
cose PD fl uid exposure resulted in peritoneal fi brosis and neoangiogenesis 43. Myofi broblasts 
originating from the epithelial phenotype mesothelial cell produce vascular growth factors 
leading to neoangiogenesis and vasculopathy. In long-term PD these vascular changes with 
upregulation of vascular growth factors were shown 44. Blockade of these factors and inhibition 
of angiogenesis showed reduced angiogenesis and slowed the peritoneal fi brosis, confi rming 
the important role of vascular growth factors in peritoneal fi brosis and possibly EPS 45-47.
The antifi brotic eff ects of tamoxifen seem to be related to the infl uence of TGF-β and inhibi-
tion of angiogenesis. In other diseases with excessive collagen deposition and involvement 
of TGF-β, like Dupuytren’s, tamoxifen was able to down regulate the TGF-β production 48. In 
oncology, levels of VEGF are associated with the extent of angiogenesis and have prognostic 
value. Tamoxifen decreased extracellular VEGF level in solid tumours 49 and attenuated VEGF 
mediated angiogenesis 50. Extrapolating these fi ndings, tamoxifen might ameliorate the 
process of peritoneal fi brosis by downregulating TGF-β and decreasing VEGF levels thereby 
inhibiting angiogenesis. 
Patients with EPS development are historically treated with transfer to HD, nutritional sup-
port or more recently with enterolysis. Given the clear pathophysiological rationale for using 
tamoxifen in EPS patients combined with the encouraging results from this study, this may be a 
promising additional treatment option for a condition with a high mortality. To further establish 
our fi ndings a randomized controlled trial has to be performed. Given the low frequency of EPS 
such a study should be performed in a large research collaboration 51.
When tamoxifen is considered as part of the treatment of EPS potential adverse eff ects of 
the drug must be taken into account. Most reported adverse eff ects are thromboembolism, 
endometrial carcinoma or strokes 15. Only Eltoum et al. reported on the adverse events 12. They 
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observed three episodes of thromboembolic disease in four EPS patients. Our retrospective 
design of the study did not allow for an adequate evaluation of possible tamoxifen-related 
adverse events. Due to the morbidity and the limited life expectancy of EPS patients, the ben-
efi ts of tamoxifen probably outweigh the potential risks.
In conclusion, this study shows that tamoxifen treatment is associated with a lower mortality 
and shows a trend to a higher multivariate-adjusted survival of EPS patients. In addition to 
supportive therapy tamoxifen may therefore improve the prospect of this severe condition.
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Post-transplantation Encapsulating Peritoneal 
Sclerosis contributes signifi cantly to mortality 
after kidney transplantation.
M.R.Korte, S.M.Habib, H. Lingsma, W.Weimar, M.G.H.Betjes .
American Journal of Transplantation 2011 in press
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ABSTRACT
Background
Encapsulating peritoneal sclerosis (EPS) is a severe complication of peritoneal dialysis (PD) and 
may present after kidney transplantation, a condition known as post-transplantation EPS. The 
prevalence and impact of post-transplantation EPS on survival after kidney transplantation is 
unknown.
Methods
From January1st 1996 until July1st 2007 1241 PD patients were transplanted in participating 
centers. Thirty-eight cases of post-transplantation EPS (3%) were identifi ed from the Dutch 
multicenter EPS study. In EPS patients the mean pre-transplant dialysis duration was longer 
than in the controls (71.4 ± 37.5 months vs. 34.7 ± 25.5, p<0.0001). The majority of EPS cases 
were observed within the fi rst two years after transplantation, but some cases appeared many 
years after transplantation.
Results
Two-hundred-and-one (16.2%) patients died after transplantation, of which seventeen EPS 
patients. After infection (23.9%), cardiovascular disease (21.9%) and malignancy (10.9%), 
EPS (8.5%) was the fourth known cause of death after transplantation. Kaplan-Meier analysis 
showed a signifi cant decreased survival for transplanted patients with post-transplantation EPS 
compared to transplanted patients without EPS.
Conclusions
Post-transplantation EPS is rare but carries a high mortality. A prolonged clinical vigilance and 
a high index of suspicion for the diagnosis are warranted, specifi cally in PD patients with a 
relatively long cumulative pre-transplant duration of PD.
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INTRODUCTION
Peritoneal dialysis (PD) is a well-established renal replacement therapy, preferred by many 
young patients with end-stage renal disease in good clinical condition. Most PD patients are 
eligible for kidney transplantation and there is no apparent diff erence in rate of infections or 
patient survival between transplanted PD and hemodialysis (HD) patients 1-2. Early transplant 
function may even be improved in former PD patients receiving deceased donor kidney trans-
plantation 3-4. 
Common identifi ed causes for death after kidney transplantation are primarily cardiovascu-
lar events followed by infections and malignancy 5-6.
Encapsulating peritoneal sclerosis (EPS) is a clinical syndrome characterized by intestinal 
encapsulating and subsequent obstruction of the intestinal tract by formation of excessive 
peritoneal fi brosis tissue 7. EPS is most frequently seen in patients treated with or having a 
history of peritoneal dialysis (PD). EPS has come to be recognized as a serious complication of 
PD with a high morbidity and a mortality of approximately 50% 8. 
A substantial proportion of EPS cases present after renal transplantation, an entity known 
as post-transplantation EPS. The pathophysiology of EPS is probably infl uenced by multiple 
factors. The widely accepted second hit theory assumes a progressively damaged peritoneum 
by prolonged use of dialysis fl uids, which may be complicated by factors that aggravate the 
peritoneal sclerosis 9. In support of this theory is the fi nding that EPS is related with longer PD 
duration 10-11. The use of calcineurin-inhibitors after transplantation may promote EPS, as these 
drugs are considered profi brotic.
Recently, we showed an increasing incidence of EPS in the last decade with a surprisingly 
high frequency of EPS in the fi rst years after renal transplantation 12-13. The prevalence and 
impact of post-transplantation EPS on survival after kidney transplantation is unknown. We 
hypothesized that post-transplantation EPS may have a signifi cantly contribution to the mor-
tality after kidney transplantation, which has previously gone unrecognized. 
To test this hypothesis we analyzed the mortality due to EPS of transplanted PD patients in 
the Netherlands in the period 1996 to 2007. 
MATERIALS AND METHODS
Design and setting
The design of the study was a retrospective multicenter study in the period January1st 1996 until 
July1st 2007. All data analyzed are from patients transplanted in the four participating university 
hospitals in the Netherlands; Erasmus Medical Center Rotterdam, University Medical Center 
Utrecht, University Medical Center Nijmegen and the Academic Medical Center, Amsterdam. 
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The study protocol was approved by the medical ethics committee of the Erasmus University 
Medical Center, Rotterdam.
Participants
All post-transplantation EPS cases in the study period January1st 1996 until July1st 2007 were 
previously identifi ed by investigating the medical records and were described in the Dutch 
multicenter EPS study 13. Medical records of patients with EPS were reviewed in detail by the 
investigating nephrologist, who was not the primary treating physician. The date of diagnosis 
of EPS was retrospectively set at the date at which the diagnosis fulfi lled the defi nition of EPS 
and confi rmed by two separate nephrologists. All EPS patients underwent abdominal CT scan-
ning.
Variables
Two compatible national registries were used for collecting the additional data. Information 
regarding renal replacement therapy in the Netherlands was retrieved from RENINE. This is 
a clearly defi ned cohort of all patients with renal replacement in the Netherlands (RENINE, 
Registratie Nierfunctievervanging Nederland) 14. Information regarding the kidney transplanta-
tion was retrieved from the Dutch Transplantation Foundation, a registry for all transplanted 
patients in the Netherlands. 
From these two databases all transplanted PD patients were identifi ed. All demographic, 
dialysis and transplantation related variables were investigated using these databases and the 
medical records of patients. Pre-transplant peritoneal dialysis period is calculated by adding all 
separate peritoneal dialysis periods prior to the last transplantation for each patient. 
Death due to EPS is defi ned as any cause related to the underlying EPS, for instance: ileus, 
abdominal infection and catheter (in case of parenteral nutrition) related sepsis.
Immunosuppressive medication is reported in the transplantation database as induction 
therapy, at three months, 1 year and 2 years after kidney transplantation. For the statistical 
analysis the use of immunosuppressive medication at three months after the last kidney trans-
plantation was used when part of the maintenance therapy. Tacrolimus and cyclosporin were 
grouped as calcineurin inhibitors (CNI’s).
Classifi cation and diagnosis of EPS
Encapsulating peritoneal sclerosis was defi ned according the criteria developed by the Ad Hoc 
Committee of the International Society of Peritoneal Dialysis (ISPD) 15. It is defi ned as a clinical 
syndrome with persistent or recurrent presence of intestinal obstruction with or without the 
existence of infl ammation parameters and the existence of peritoneal thickening, sclerosis, 
calcifi cations and encapsulation confi rmed by macroscopic inspection or radiological fi ndings.
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Using this defi nition of EPS the studied population was limited to severe forms of intestinal 
obstruction that lead to persistent clinical problems, the necessity of surgical intervention, 
immunosuppressive therapy and/or the necessary use of total parental nutrition (TPN).
Statistical Methods
Data were entered and statistical tests were done in SPSS 17.0.1 datamanager (Chicago, USA). 
Means were compared using unpaired t-tests. Medians were compared with non-parametric 
tests (Mann Whitney). Proportions were compared with chi-square tests. A two sided p-value 
of less than 0.05 was considered to be statistical signifi cant. Survival was further analyzed with 
Kaplan-Meier statistics.
RESULTS
Demographics
In the period January 1st 1996 - July 1st 2007 1241 PD patients were transplanted. Thirty-eight 
(3%) patients developed a severe EPS after kidney transplantation. All EPS patients had 
abdominal complaints of intestinal obstruction and were diagnosed with EPS according the 
ISPD guidelines. EPS patients were previously described in the Dutch multicenter EPS study 13.
Table 1 | Patient characteristics. 
Variable Controls EPS patients P-value 
Number of patients 1203 38
Gender
Female (%) 474 (39.4) 15 (39.5) NS
Male (%) 729 (60.6) 23 (60.5) NS
Cause of renal disease: (%)
Glomerulonephritis 299 (24.9) 9 (23.7)
Interstitial nephritis and pyelonephritis 125 (10.4) 5 (13.2)
Cystic kidney diseases 129 (10.7) 2 (5.3)
Congenital and hereditary kidney diseases 48 (4.0) 5 (13.2)
Renal vascular disease, excluding vasculitis 165 (13.7) 5 (13.2)
Diabetes mellitus 70 (5.8) 1 (2.6)
Other multisystem disease 109 (9.1) 5 (13.2)
Others 31 (2.6) 1 (2.6)
Unknown 161 (13.4) 4 (10.5)
Missing 66 (5.5) 1 (2.6)
Time on pre-transplant peritoneal dialysis (months) 31.1 ± 22.6 65.8 ± 30.7 0.0001
Deceased patients (%) 184 (15.3) 17 (44.7) < 0.0001
Months on pre-transplant dialysis as mean ± SD. Proportions were compared with chi-square tests. Means were tested 
with t-tests.
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Patient’s characteristics and the transplantation related variables are shown in table 1 and 
table 2, respectively. In EPS patients, pre-transplant PD duration was signifi cantly longer than 
in the controls and they tended to be younger at last kidney transplantation. Ten EPS patients 
(26.3%) had a total PD duration shorter than 48 months.
EPS patients had more kidney transplantations and more overall transplant failures com-
pared to non-EPS patients. There was no signifi cant diff erence in cause of transplant failure of 
the last kidney transplantation between the EPS and non-EPS group.
Figure 1 shows the prevalence of EPS patients in time after the last kidney transplantation. 
EPS patients were diagnosed with EPS with a median time of 12.4 months (IQR 6.2 – 45.6) after 
transplantation. Sixty percent of the patients were diagnosed with EPS in the fi rst 2 years after 
the last kidney transplantation. Three patients developed EPS more than 6 years after the last 
transplantation. The mean PD duration of these three patients was not signifi cantly diff erent 
(mean 56.2 ± 18.2 (SD) months) from patients with post-transplantation EPS within 6 years 
after transplantation (67.6 ± 32.6 months, p-value 0.6). There was no diff erence in number of 
transplants and graft failures between these groups.
Table 2 | Transplantation characteristics.
Variables Control patients (1203) EPS patients (38) P-value
Number of transplantations 1.20 ± 0.5 1.50 ± 0.8 < 0.0001
Donor last transplantation Deceased: 767 (63.8%)
Living: 436 (36.2%)
Deceased:32 (84.2%)
Living: 6 (15.8%)
< 0.0001
Mean age at last transplantation (years) 46.1 ± 14.7 42.0 ± 14.2 0.09 
Overall transplant failure 0.32 ± 0.6 1.05 ± 1.1 < 0.0001
Transplant failure last transplantation yes 139 (11.6%) yes 21 (53.7%) < 0.0001
Data as means ± SD, except for transplant failures of last transplant which are reported as number of patients. Means 
were tested using t-test, proportions were compared with chi-square tests. Medians were tested with non-parametric 
tests (Mann-Whitney).
Figure 1 | EPS after kidney transplantation.
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CNI’s were the mainstay of immune suppressive therapy in both EPS and non-EPS patients 
(respectively 85% and 95% of patients at 3 months after transplantation, p-value>0.1). There 
was no signifi cant diff erence in use of corticosteroids, azathioprine, mycophenolate mofetil 
or sirolimus as maintenance therapy between EPS patients and the non-EPS group (data not 
shown). 
Mortality
During the ten-years follow-up 201 patients died after transplantation. Infections and cardio-
vascular events are the most important causes of death after kidney transplantation. Seventeen 
EPS patients died due to EPS related causes, 184 non-EPS patients died due to other reasons. 
EPS patients died with a median time of 15.2 months, (IQR 7.6 – 35.0), after the EPS diagnosis. 
Specifi c details about causes of death in the fi rst two years after kidney transplantations are 
shown in table 3. 
Overall EPS related mortality after kidney transplantation is 8.5%, which results in the fourth 
known cause of mortality after kidney transplantation (fi gure 2). There remains a large group of 
death due to unknown cause. 
Kaplan-Meier analysis showed that patients with post-transplantation EPS had a signifi cantly 
decreased survival after transplantation compared to patients without EPS (fi gure 3).
Table 3 | Diagnosis of death after kidney transplantation.
Cause of death Overall Percentage occurring 
within one year of 
transplantation
Percentage occurring 
within two years of 
transplantation
Infections 48 (23.9%) 15 (31.3%) 19 (39.6%)
Cardiovascular disease 44 (21.9%) 24 (54.5%) 26 (59.1%)
Malignancy 22 (10.9%) 4 (18.2%) 5 (22.7%)
Encapsulating Peritoneal Sclerosis 17 (8.5%) 6 (35.3%) 8 (47.1%)
Gastrointestinal 11 (5.5%) 7 (63.6%) 7 (63.6%)
Cerebrovascular accident 6 (3.0%) - 2 (33.3%)
Social 6 (3.0%) 2 (33.3%) 2 (33.3%)
Pulmonary embolus 5 (2.5%) 3 (60.0%) 3 (60.0%)
Hemorrhage 3(1.5%) 1 (33.3%) 1 (33.3%)
Other 8 (4.0%) 1 (12.5%) 3 (37.5%)
Unknown 31 (15.4%) 4 (12.9.0%) 7 (22.6%)
Total number 201 (16.2%) 67 (33.3%) 83 (41.3%)
Data in numbers of patients (%). One and two-years post-transplantation represents deaths at one and two years after 
kidney transplantation (% of total of each cause of death).
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DISCUSSION
Post-transplantation EPS is a rare but severe complication in transplanted PD patients. Next to 
already known causes of death, like infections and cardiovascular events, EPS was identifi ed 
as the fourth known cause of death after kidney transplantation and was associated with a 
decreased survival in these patients.
The contribution of EPS to mortality after kidney transplantation was previously not investi-
gated and our fi ndings can therefore not be compared to other studies. However, our general 
results, showing the various proportions of diff erent causes of death after kidney transplanta-
tion, are comparable to other reports 16. 
In accordance with other studies, there remains a large group of unknown causes of death 
5. In the past the EPS related mortality was possibly included in this group or in a group with 
gastro-intestinal causes. 
Post-transplantation EPS appears to be a new phenomenon in transplantation practice. A 
recent Scottish study showed that the contribution of post-transplantation EPS might be even 
as much as 50% of the total EPS patients 17. It diff ers from the classic form of EPS, which is 
predominantly associated with long term PD (longer than 5 years) and changed peritoneal 
membrane function, resulting in ultrafi ltration failure. This latter form is extensively described 
in Japan, where patients tend to stay on PD longer, because kidney transplantation is limited 
10. In contrast, post-transplantation EPS patients tend to be younger when initiating PD and do 
Figure 2 | Overall causes of death after kidney transplantation.
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not necessarily have a prolonged PD duration 13,18. In this study, patients with post-transplan-
tation EPS had a signifi cantly longer PD duration compared to transplanted patients without 
EPS. The longer cumulative duration of PD may be partly explained by a higher frequency of 
transplant failure in this group. As pre-transplant PD duration is implicated as a risk factor for 
post-transplantation EPS, this information should be part of the informed consent procedure 
before transplantation. However, one must realize that there is a large variation in PD duration. 
This is shown in the current study, where a considerable number of EPS patients (26%) had a 
PD duration shorter than 48 months. The study design did not allow for a reliable multivariate 
analysis of this large variation and/or the impact on the incidence of post-transplantation EPS.
The post-transplantation EPS patients usually become symptomatic shortly after kidney trans-
plantation, as was also shown in a recent study from the UK 19. In this study, 21 post-transplan-
tation EPS patients (identifi ed from a total of 111 EPS patients) were diagnosed with a mean 
time from transplantation of only 5.4 months (1-19 months). In the current study the majority of 
EPS cases were also observed within the fi rst two years after transplantation. However, in some 
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Figure 3 | Infl uence of EPS on ten-year survival of PD transplanted patients.
Cox regression analysis with time after last transplantation, with analysis censored for ´time until end of study or death´. 
Data presented as univariate analysis, P-value < 0.001.
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patients the diagnosis was even made after a number of years after transplantation. The clinical 
implication is that a prolonged clinical vigilance and a high index of suspicion for the diagnosis 
are warranted. Furthermore, our fi ndings contribute to the ongoing discussion whether young 
PD patients should prematurely be transferred to hemodialysis after a few years of PD while 
awaiting transplantation or after transplant failure 20-21.
The etiology of post-transplantation EPS is yet unknown. But there are several hypotheses. The 
current accepted pathophysiological theory on EPS in general, is that the peritoneal membrane 
is preconditioned by damaging PD solutions. In reaction to this a repair process develops with 
an increased infl ammation. After a second hit, such as a fungal peritonitis, this might result in 
an uncontrolled fi brosing process with an encapsulating of the intestines. 
In post-transplantation EPS the relationship with the moment of transplantation is striking, 
suggesting that transplantation might impose the second hit. A possible explanation of the 
association with transplantation might be the discontinuation of peritoneal lavage of profi brotic 
factors after successful kidney transplantation. Another hypothesis is that post-transplantation 
EPS might be related to the concomitant use of profi brotic CNI’s. In the damaged peritoneum 
there is already an upregulation of TGF-β which leads to fi brosis and neoangiogenesis 22. Both 
tacrolimus and cyclosporin also lead to enhanced TGF-β expression and subsequent fi brosis 23. 
The additional administration of cyclosporin to an experimental rat model of chronic peritoneal 
exposure to dialysis solutions indeed leads to EPS like abnormalities 24. 
Furthermore, the introduction of CNI’s has led to a trend to lower corticosteroids after kidney 
transplantation. Corticosteroids may, however, have a benefi cial eff ect on the infl ammatory 
state during the development of EPS. The role of CNI’s in post-transplantation EPS remains 
unclear and given the evidence it is premature to conclude that the use or absence of CNI’s are 
associated with EPS development. 
The current study has a retrospective design, with its obvious limitations. One might argue 
that this design could lead to an underestimation of diagnoses, other than EPS. This is partially 
diminished because the used registries collect their data at the actual time of treatment with 
only a slight delay. There were some missing values in the use of maintenance immunosuppres-
sive medication. These were equally distributed among both groups and it mainly concerned 
patients with kidney transplantation in the early nineties.
Once EPS has been diagnosed the therapeutical options are limited. Surgical treatment with 
extensive enterolysis might be successful, but it requires an experienced surgeon and has a 
high risk of recurrence and complications 25. Successful treatment of EPS with immunosuppres-
sive medication such as high dose steroids, azathioprine and MMF has been described 10,26-27, 
but these reports are anecdotal. Finally, we recently showed that tamoxifen treatment of EPS is 
associated with an increased patient survival 28. 
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In conclusion, post-transplantation EPS occurs infrequently but contributes signifi cantly to a 
decreased survival in transplanted PD patients. A prolonged clinical vigilance and a high index 
of suspicion for the diagnosis is warranted, specifi cally in PD patients with a relatively long 
cumulative pre-transplant duration of PD.
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INTRODUCTION
This thesis describes the incidence of encapsulating peritoneal sclerosis (EPS) in the Nether-
lands, its risk factors and clinical consequences. It is primarily intended to provide the clinician 
with novel fi ndings and associations with EPS.
In chapter 2 of the thesis a global overview of the current understanding of EPS is given. Encap-
sulating peritoneal sclerosis (EPS) is a severe complication of long-term peritoneal dialysis (PD) 
with a high mortality (50%). A fi brous cocoon covers the intestines and causes dysfunction 
leading to intestinal obstruction. The last decade more attention has been focused on this 
complication. Although it is still rare, the incidence of EPS has possibly increased in recent years 
despite a stable PD population. The reported prevalence of EPS varies between 0.5 and 2.5% 1-6. 
The occurrence of EPS increases with the duration of PD therapy. A registry study from Australia 
described an incidence of 19.4% after 8 years of PD treatment 5. 
Several alterations of the peritoneum occur during the course of PD treatment. The meso-
thelial layer disappears (denudation). The peritoneal vasculature shows progressive signs of 
fi brosis and hyalinization of the media, neoangiogenesis with vasculopathy. The more vessels 
develop, the more severe the interstitial fi brosis appears to be. The submesothelial compact 
zone thickening is caused by interstitial fi brosis and sclerosis. In EPS this appears to be even 
more pronounced. 
The pathophysiology is proposed as a “two-hit theory”, which hypothesizes that 2 factors are 
required for the onset of EPS. The fi rst hit causes disruption of normal peritoneal and mesothe-
lial physiology and is mainly due to the incompatible features of the dialysis fl uids. The second 
hit may be a peritonitis episode, the discontinuation of PD treatment or perhaps a genetical 
predisposition. In the primary process of repair of damaged peritoneum TGF-β plays a central 
role. It is associated with more fi brosis and angiogenesis. Epithelial to mesenchymal transition 
(EMT) may also be important 7. EMT is a physiological process which occurs throughout the 
body and in the peritoneum to repair damaged tissue. During EMT, mesothelial cells that have 
been exposed to dialysate undergo a morphological and functional alteration that changes 
their epithelial phenotype to become fi broblastic. These fi broblasts then migrate to the 
submesothelial compact zone and may overproduce TGF-β. This process starts at the initiation 
of PD treatment and continues with the duration of PD. EMT is necessary for tissue repair under 
normal conditions, but uncontrolled it may lead to fi brotic processes. Other important players 
are vascular growth factors (e.g. VEGF), AGE’s, cytokines (IL-6), metalloproteases, transcription 
factor snail and mast cells. 
Besides prolonged PD duration novel independent associations with EPS as age, increased 
small solute transport, ultrafi ltration failure, kidney transplantation and dialysis solutions might 
be present. 
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Recently radiological criteria for diagnosing EPS were developed 8. It is however still diffi  cult 
to prevent or recognize EPS in the early stages. Abdominal CT scans are not useful at this stage. 
Peritoneal functional parameters are probably useful. Ultrafi ltration failure (UFF) appeared the 
predominant early change 9. This was associated with early loss of residual renal function and 
accumulative glucose exposure. There usually is an increased small solute transport, which 
refl ects the eff ective peritoneal surface area. 
To date, there is no consensus on treatment. This should consist of supportive care and, 
when it is available, surgery. Corticosteroids and tamoxifen may be benefi cial. Recent devel-
opments resulted in concerns among nephrologists and subsequently led to a debate on an 
arbitrary expiry date for PD because of the risk of EPS. 
INCIDENCE AND RISK FACTORS OF EPS
Chapter 3 describes the two studies investigating the possible increasing incidence of EPS and 
the risk factors associated with EPS. The initial report is described in chapter 3.1.
It was our distinct impression that in recent years we were witnessing a marked increase in 
the incidence of EPS. In order to investigate whether this suspicion was justifi ed, we initiated 
an analysis of the occurrence of EPS in two university hospitals in The Netherlands (Erasmus 
Medical University Centre in Rotterdam and the Utrecht Medical Centre in Utrecht). Cases were 
identifi ed by retrospective investigation of the medical records in the period 1998-2005. This 
study shows that the incidence of severe EPS had increased signifi cantly in the last few years in 
stabile PD populations. There was a remarkable preponderance of EPS patients with a function-
ing renal allograft which may point towards a pathogenetic role of kidney transplantation.
Due to the limited numbers it was impossible to draw fi rm conclusions on risk factors associ-
ated with EPS and its increased incidence. Therefore we performed an additional study. 
This study is described in chapter 3.2. This is a multicenter study in which eight large hospi-
tals in the Netherlands participated, which resulted in a representative study, as it covered 26% 
of all PD patients in the Netherlands in this period. The design is a retrospective nested case 
controlled study. It comprises of 63 EPS and 126 control patients. Control patients were selected 
from the national registry (RENINE) and controlled for start date PD with the controls closest to 
the start date of the EPS patients. In order to be able to investigate the association of PD dura-
tion in a controlled manner there was deliberately no matching for PD duration. Associations 
were analysed using a log linear regression model. PD duration, age, transplantation, time since 
last transplantation, calendar time, follow up time, peritonitis episodes, transfer from PD to HD 
for other reasons than suspected EPS, time on icodextrin and presence of ultrafi ltration were 
pre-specifi ed predictors.
Mario BW v4.indd   120 25-03-11   11:11
Summary and general discussion 121
The study showed that the incidence increased in the years 2003-2005, confi rming our earlier 
results. This is probably not due to an increased awareness or a change in diagnostic criteria 
which could lead to inclusion of milder EPS stages. The presence of the severe EPS symptoms 
makes it unlikely that the diagnosis was missed in the past.
There also appeared to be a decrease of the incidence in 2006. This might suggest that the 
increase was just a temporary issue. We did not analyse the incidence in the years after 2006. 
However when the recent reports are interpreted, it can be concluded that the incidence is still 
increasing. For example, a recent observational study from London showed at most 1 patient a 
year until 2003 and in the years 2004-2008 respectively 5,6,4,6 and 11 EPS patients 10. Although 
there is no information on the general PD population in this cohort, it appears unlikely this has 
increased with the same proportion.
In the multivariate regression analysis we confi rmed the independent associations of PD dura-
tion, ultrafi ltration failure (UFF) and age with EPS development. Each year of prolonged PD had 
an increased relative risk for EPS of 40%. The associations of young age and PD duration are in 
accordance with another recent report of the ANZDATA registry 11. In addition we were able to 
show novel independent associations as prolonged use of icodextrin, kidney transplantation 
and the time after kidney transplantation with the presence with EPS.
Icodextrin permits good ultrafi ltration during long time dwells and avoids the potential 
harmful eff ects of glucose. The association with EPS is somewhat surprising and deserves more 
attention in the future. The association with EPS appeared not be caused by the abundant pres-
ence of ultrafi ltration failure in EPS.
Consistent with the fi rst report there was an independent association with kidney transplan-
tation. A possible explanation is the profi brotic feature of calcineurin inhibitors (CNI’s). However, 
we were not able to identify the introduction of CNI’s as a risk factor for EPS. With regard to time 
after transplantation, the yearly probability of EPS increased in the year after transplantation 
from 1.75% to 7.5% in the univariate analysis. Finally, not the kidney transplantation itself, but 
rather the cessation of the PD, might be the risk factor for developing EPS 6,12. We were not able 
to show such an association with transfer from PD to HD. Instead, we found that the majority of 
patients switching from PD to HD already were suspected of having EPS.
EARLY DIAGNOSTIC MARKERS
Chapter 4 described the use of effl  uent substances as possible diagnostic markers of early EPS. 
Effl  uent cancer antigen 125 (CA125) is a marker of mesothelial cell mass, interleuking-6 (IL-6) is 
a marker of infl ammation, and vascular endothelial growth factor (VEGF) is a growth factor for 
the formation of new vessels. In this case-controlled study the time course of these peritoneal 
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membrane markers in patients who developed EPS and in those matched for the duration of 
dialysis who did not develop EPS, was analyzed. 
Dialysate and serum samples of 11 EPS patients and 31 control patients all treated with PD 
for at least 57 months were longitudinally collected during a standard peritoneal permeability 
analysis (SPA) performed once a year. Again, EPS patients were younger than controls and had 
a longer PD duration (104 months versus 72 months, p=0.01). No signifi cant diff erences in time 
courses of the diff erent markers were present between groups. However appearance rate (AR) 
of CA-125 was signifi cantly lower in the last three years prior to EPS (p<0.05) and AR of IL-6 was 
higher two years prior to EPS (p=0.09). Locally produced VEGF showed no diff erences among 
the groups. 
The combination of AR CA-125<33 U/min and AR IL-6>350 pg/min had a sensitivity of 70% 
and a specifi city of 89% for predicting EPS diagnosis. Recent reports showed that ultrafi ltration 
failure is a predominant sign in developing EPS 9,13. When the presence of ultrafi ltration failure 
was added to the predictive model it gained more strength. The specifi city increased to 100%, 
indicating the potential use for an early diagnosis of EPS. In daily practice this might be useful 
to identify those at risk for clinically established EPS. This is important, because preventive 
interventions to reduce morbidity and mortality might be more eff ective at this stage than 
after the establishment of the diagnosis. It is therefore recommended to longitudinally monitor 
the peritoneal function with 3.86% glucose peritoneal equilibration tests. 
There are some limitations of the study which concern the fact that not all the analyses could 
be done in all patients. Despite intended matching for PD duration there also appeared a slight 
diff erence in overall mean PD duration.
TAMOXIFEN AND SURVIVAL BENEFIT
Chapter 5 describes the possible use of tamoxifen in EPS therapy. Currently there is no con-
sensus on therapeutical management of EPS. Nutritional status is important 14 and surgery 
with extensive adhesiolysis is recommended. The latter is rarely performed in Western Europe, 
probably because of fear of complications 15-16. At present there are no randomized controlled 
trials that have shown the effi  cacy of any given drug for EPS, including tamoxifen. Tamoxifen 
infl uences the activity of the profi brotic cytokine TGF-β and has shown to be eff ective in fi brotic 
diseases as retroperitoneal fi brosis 17. It was hypothesized that tamoxifen may result in lower 
mortality in treated patients. We performed a retrospective study in the multicenter EPS study 
to investigate whether tamoxifen was associated with an improved survival in these patients. 
EPS patients treated with tamoxifen and not treated with tamoxifen were compared. The study 
shows that mortality rate was lower in tamoxifen treated EPS patients compared to EPS patients 
not treated with tamoxifen (45.8% vs. 74.4%, p=0.03) with both groups having comparable 
demographic and clinical characteristics. More importantly, treatment of EPS patients with 
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tamoxifen was associated with a trend to an improved survival, independent of other possible 
benefi cial treatment options (HR 0.39, p=0.056). Although all available possible confounders 
were taken into account by including them into a multivariate analysis, it is possible that the 
results are infl uenced by ‘confounding by indication’. When considering tamoxifen for the 
treatment of EPS the possible adverse events like thromboembolism or endometrial carcinoma 
have to be considered. Due to the morbidity and the limited life expectancy of EPS patients, 
the benefi ts of tamoxifen probably outweigh the potential risks. The clear pathophysiological 
rationale for using tamoxifen in EPS patients combined with the encouraging results from this 
study supports the recommendation to use tamoxifen as an additional treatment option for 
EPS.
MORTALITY AFTER KIDNEY TRANSPLANTATION DUE TO EPS
Chapter 6 describes the impact of post-transplantation EPS on mortality after kidney trans-
plantation. EPS frequently presents after kidney transplantation, a condition known as post-
transplantation EPS. The prevalence and impact of post-transplantation EPS on survival after 
kidney transplantation is unknown. It was hypothesized that post-transplantation EPS may 
have a signifi cantly contribution to the mortality after kidney transplantation, which has previ-
ously gone unrecognized.
From January1st 1996 until July1st 2007 1241 PD patients were transplanted in four participat-
ing university hospitals in the Netherlands. Thirty-eight cases of post-transplantation EPS (3%) 
were identifi ed from the Dutch multicenter EPS study. Two-hundred-and-one (16.2%) patients 
died after transplantation, of which seventeen EPS patients. After infection (23.9%), cardiovas-
cular disease (21.9%) and malignancy (10.9%), EPS (8.5%) was the fourth known cause of death 
after transplantation. Kaplan-Meier analysis showed a signifi cant decreased survival for trans-
planted patients with post-transplantation EPS compared to transplanted patients without EPS. 
The majority of EPS cases were observed within the fi rst two years after transplantation, but 
some cases appeared many years after transplantation. In conclusion, post-transplantation EPS 
is rare, but carries a high mortality. Therefore, a prolonged clinical vigilance and a high index 
of suspicion for the diagnosis are warranted, specifi cally in PD patients with a relatively long 
cumulative pre-transplant duration of PD. Furthermore, our fi ndings contribute to the ongoing 
discussion whether young PD patients should prematurely be transferred to hemodialysis after 
a few years of PD while awaiting transplantation or after transplant failure 18-19.
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CONCLUSIONS
1. The incidence of severe EPS has increased signifi cantly in the period 1996-2006 in the Dutch 
PD population.
2. PD duration, age, kidney transplantation, time after kidney transplantation, prolonged use 
of icodextrin and ultrafi ltration failure (UFF) are independently associated with EPS devel-
opment. Each year of prolonged PD had an increased relative risk for EPS of 40%.
3. The combination of AR CA-125<33 U/min and AR IL-6>350 pg/min had a sensitivity of 70% 
and a specifi city of 89% for predicting EPS diagnosis.
4. Tamoxifen reduces mortality in tamoxifen treated EPS patients compared to EPS patients 
not treated with tamoxifen. Treatment of EPS patients with tamoxifen was associated with a 
trend to an improved survival, independent of other possible benefi cial treatment options.
5. After infection (23.9%), cardiovascular disease (21.9%) and malignancy (10.9%), EPS (8.5%) 
was the fourth known cause of death after transplantation. Survival for transplanted 
patients with post-transplantation EPS is signifi cantly decreased compared to transplanted 
patients without EPS.
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The Dutch EPS registry: increasing the 
knowledge of Encapsulating Peritoneal 
Sclerosis.
M.R. Korte, E.W. Boeschoten, M.G.H. Betjes on behalf of the EPS registry.
 Netherlands Journal of Medicine 2009 Sep;67(8):359-62
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ABSTRACT
Encapsulating peritoneal sclerosis (EPS) is a rare condition characterized by fi brotic thickening 
of the visceral peritoneum, leading to encapsulating of the intestines with partial or total intes-
tinal obstruction. EPS is a serious complication of peritoneal dialysis (PD) with high morbidity 
and a mortality exceeding 50%. At present, there is uncertainty concerning the incidence and 
the risk factors involved in the development of EPS. To address these questions a nationwide 
registry has been initiated.
Primary goals of the registry are to record the incidence of EPS and investigate the asso-
ciation of diff erent variables, such as PD duration, medication, dialysis solutions and kidney 
transplantation with EPS.
The registry will improve the knowledge of EPS and will serve to develop guidelines and 
necessary management strategies. From the registry diff erent research activities can be initi-
ated. A major challenge lies in the establishment of criteria that allow for a timely diagnosis of 
EPS. At present, there are no diagnostic tools that can accurately detect EPS at an early stage. 
For this reason, besides patients with proven EPS, the clinical suspicion of EPS will be a suffi  cient 
criterium for inclusion in the registry. 
This nationwide EPS registry is currently enrolling patients.
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INTRODUCTION
Encapsulating peritoneal sclerosis (EPS) is a clinical syndrome characterized by intestinal 
encapsulating and subsequent obstruction of the intestinal tract 1. EPS can be found in many 
diff erent clinical settings, but the condition is most frequently encountered in patients treated 
with peritoneal dialysis.
Although rare, encapsulating peritoneal sclerosis (EPS) has come to be recognized as a seri-
ous complication of peritoneal dialysis (PD) with a high morbidity and a mortality of approxi-
mately 50% 2.
Reported prevalences for EPS range from 0.7 to 3.3 % 2-4. Recently, more attention has been 
given to this complication, as several reports have suggested an increased incidence of EPS 
during the last years 5-6. 
Peritoneal dialysis (PD) is an excellent modality of renal replacement therapy (RRT) and may 
have a superior patient survival compared to hemodialysis 7, due to a better preservation of the 
renal residual function 8. In the period 1996-2006 approximately 7800 patients with end stage 
renal disease were treated with PD in the Netherlands (Renine database). However, in recent 
years a worldwide trend of treating fewer patients with PD has been noted. Among other rea-
sons, an increased fear of EPS may be an incentive for the nephrologist to favor hemodialysis 
over PD when starting renal replacement therapy 9.
There is much uncertainty concerning the true incidence of EPS in the Netherlands. In addi-
tion, the clinical factors associated with the development of EPS seem to diff er from previous 
reports, as we found a substantial number of severe cases of EPS after renal transplantation 6. 
Given the severity of the condition and the current lack of data collaboration was started 
among Dutch nephrologists, which has resulted in the initiation of a nationwide registry for 
EPS. 
DISCUSSION
Clinical spectrum of EPS
EPS, formerly known as sclerosing peritonitis, is characterized by progressive fi brosis of the 
visceral peritoneum resulting in a partially or total encasement of the bowel by a thickened 
and fi brotic membrane (Figure 1). 
The development of EPS is insidious and initially there are only vague abdominal complaints. 
With progressive fi brosis, symptoms as nausea, vomiting, appetite loss, weight loss and consti-
pation appear. Usually, ultrafi ltration failure has developed and signs of a systemic infl amma-
tory syndrome may be present. Eventually, in the last stage of abdominal cocooning there is 
partial or complete intestinal obstruction. At this stage there is a high morbidity and mortality. 
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Recently, we performed a multicenter study in which we analyzed the data of 2022 PD patients 
in the period 1996-2006. The results showed a high mortality-rate of EPS, in accordance with 
studies from other countries (Figure 2) 10. 
The diagnosis of EPS is diffi  cult because the criteria defi ned by the ISPD (Table 1) are rather 
aspecifi c 11. The key feature of EPS is the presence of a clinical syndrome of intermittent or 
recurrent presence of intestinal obstruction, with or without infl ammation parameters. The 
existence of peritoneal thickening, sclerosis, calcifi cations and encapsulation is confi rmed by 
macroscopic inspection or radiological fi ndings.
There is however a large overlap with simple sclerosis when patients are on PD for a longer 
time and CT scanning is not useful as a screening tool for early stages of EPS 12. The use of 
macroscopic evidence of EPS is the only appropriate tool serving as golden standard for the 
diagnosis EPS. However, this approach is not always feasible in a clinical setting and macro-
scopic evidence of EPS is only obtained in the minority of cases. 
Pathophysiology
The peritoneum of patients treated with PD is daily exposed to various dialysis fl uids. This 
leads to changes of the peritoneal membrane over time characterized by mesothelial cell loss, 
Figure 1 | Macroscopical EPS.
This patient with a history of PD has developed complaints of intestinal obstruction. At laparotomy there is a clear 
fi brotic and thickened membrane covering the bowel. There are also extensive adhesions.
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epithelial to mesenchymal transition of mesothelial cells, neovascularisation and vasculopathy 
13-17. These changes are probably induced by conventional dialysis fl uids with bio-incompatible 
characteristics, high glucose concentrations, glucose degradation products, lactate buff ers and 
acid pH. This process during long term PD with fi brosis of parietal peritoneum is sometimes 
referred to as simple sclerosis 18. It is generally assumed that the abundant fi brosis of the 
visceral peritoneal as seen in EPS has a diff erent etiology than simple sclerosis. The complete 
pathophysiology of EPS is yet unclear, but is probably multifactorial. The duration of PD is 
recognized as the single most important risk factor for EPS, as EPS within 3 years of treatment is 
rarely observed. Therefore, the most generally accepted theory assumes a progressively dam-
aged peritoneum by prolonged use of incompatible dialysis fl uids, which may be complicated 
by factors that aggravate the peritoneal sclerosis 4,19. In recent years candidate factors came 
forth from a number of observational studies. These included cessation of peritoneal lavage 3, 
peritonitis 20-21 and factors associated with kidney transplantation 6.
Why a nationwide registry?
To date, there are still large gaps in our knowledge of EPS. This can be largely attributed to the 
lack of systemic prospective data collection, specifi cally necessary in the case of a condition 
Figure 2 | Survival of EPS patients.
In a Dutch multicenter study in the period 1996-2007 there were 63 patients with severe EPS in a total of 2022 PD 
patients 10. This fi gure shows the cumulative survival (Kaplan Meier analysis) of these patients after the diagnosis of EPS 
was made.
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encountered less than once a year in an average dialysis center. Such a data collection is even 
more important as we reported a possible increased incidence of EPS 5. Therefore, the fi rst goal 
of this registry should be to record the current incidence of EPS and investigate whether it is 
still increasing. 
Secondly, the registry needs to investigate the association of diff erent variables, such as PD 
duration, medication, dialysis solutions and kidney transplantation. For instance, our case-
controlled analysis of EPS cases in the Netherlands over the last 10 years showed a strikingly 
high percentage of EPS (50%) shortly after renal transplantation and suggested that the use 
of icodextrin was independently associated with EPS 10. In addition, the statistical modeling 
indicated that large part of the variation was not accounted for by the clinical and demographi-
cal variables used for analysis. These observations, that may have major consequences for the 
management of the PD patients, need to be verifi ed in a prospective database. Furthermore, in 
an eff ort to document early stages of EPS we will also include cases of suspected EPS. This also 
allows for identifi cation of risk factors for progression and discovery of biomarkers for establish-
ing EPS at an early stage.
Table 1 | Criteria for the diagnosis of encapsulating peritoneal sclerosis (EPS).
ISPD1 Criteria 
EPS Intestinal obstruction2
and
Radiological or macroscopical evidence3
EPS registry 
Macroscopical EPS (golden standard) Intestinal obstruction2
and
Macroscopically identifi ed EPS
Clinical EPS Intestinal obstruction
and
Radiological EPS3
Suspected early EPS Intestinal obstruction
or
Two or more fi ndings of:
− weight or appetite loss
− bloody ascites
− radiological suggestion of EPS
− fast transport status or ultrafi ltration failure
No EPS Intestinal obstruction
but
Other cause than EPS identifi ed with certainty
1Criteria as used in the defi nitions by the ISPD (International Society of Peritoneal Dialysis) and the EPS registry of EPS 
in a patient that is currently being treated or has been treated with PD 11. 2Intestinal obstruction means any sign and 
symptom of persistent, intermittent or recurrent intestinal obstruction. 3Radiological evidence for EPS means fulfi lment 
of the criteria for EPS with CT scanning with fi ndings such as peritoneal calcifi cation, bowel thickening, bowel tethering, 
bowel dilatation, ascites or peritoneal thickening 12.
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In a recent survey among Dutch nephrologists it appeared that 16% of the responders feared 
EPS and subsequently considered to withhold PD as a fi rst choice of RRT 9. Given the rarity 
of the disease and good overall survival on PD this decision is unlogical, but illustrates the 
need for a registry recording data and yielding evidence-based guidelines to the treating 
physicians. As such, these data are currently not available and there is a lack of prospective 
studies on EPS. The majority of the experience comes from Japanese observational studies, 
where patients tend to be on PD for a longer period because the limited availability of kidney 
transplantation 8. It is not clear whether the Japanese fi ndings can be extrapolated to the PD 
population of Western Europe.
An important part of the guidelines is the development of an uniform management strategy 
for EPS. Given the presence of malnutrition in the presence of intestinal obstruction, supportive 
care with either enteral or parenteral nutrition is the mainstay of the treatment 22. Immune 
suppressive medication and others agents, like tamoxifen have been suggested 23-26. But the 
level of evidence is low as the data are from anecdotal reports or small case series. Encourag-
ing results from Japan have been reported with surgical enterolysis, releasing the complete 
small intestine 27. However, there is yet little experience with this procedure in Western-Europe. 
Finally, the registry will function as a central organization from which diff erent research activi-
ties, for example genetic and marker studies can be initiated. To strengthen the importance of 
the registry there will be extensive collaboration within Europe, for instance with the UK EPS 
study group. 
Design
Collaboration of all university centers and the Hans Mak institute resulted into a steering com-
mittee, which has initiated the nationwide EPS registry. Patients with a history of PD with a 
diagnosis of EPS or suspicion of EPS will be prospectively included. Ideally, the registry would 
include all patients treated with PD. This way, all data could be accurately registered. However, 
giving the low prevalence of EPS, inclusion of all PD patients would be time consuming and 
requires a very large, expensive database. 
Every 6 months an e-mail will be sent to all Dutch nephrologists inquiring whether they can 
report a patient (suspected of ) having EPS. In the registry patients are divided into four groups 
by the steering committee; macroscopically defi nite EPS, clinical EPS, possible EPS and no EPS, 
by the criteria shown in Table 1. As multiple factors may infl uence the development of EPS, 
there will be an extensively reviewing of all possible diagnostic, prognostic and therapeutically 
variables. Demographics, PD, HD, transplantation related factors of all included patients will be 
reviewed. In addition, a sample of peritoneal effl  uent and plasma will be taken and stored for 
later analysis.
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An easy accessible website (www.epsregistry.com) is developed to give more detailed 
information on EPS and the EPS registry. The registry is made so that it can easily be extended 
to a European format. 
For professionals it also has the opportunity to submit a patient with EPS There will be a 
yearly update on the progress of the registry. In the future research developments and guide-
lines will be published on the website.
CONCLUSION
EPS is a potential devastating disease with a high mortality. Recently, it was shown that the 
prevalence of EPS may increase in the Netherlands. The low prevalence of EPS has hampered 
the research in this area, which has resulted in a lack of knowledge about natural history, 
pathophysiology and risk factors, and treatment options. A nationwide registry is required to 
collect data prospectively. Such an EPS registry has recently been initiated. The database of 
this EPS registry will allow establishment and monitoring of the prevalence of EPS, identifying 
risk factors, basic research of the pathophysiology of EPS and development of management 
guidelines. The EPS registry is currently enrolling patients. We kindly call upon all nephrologists 
to cooperate with the registry in order to obtain a representative registry and thus contribute 
to a better understanding of EPS. 
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INTRODUCTION
In this thesis we described the results of studies on risk factors of EPS, showed new diagnostic 
markers and evaluated tamoxifen as a possible therapy. Furthermore, we evaluated the entity 
post-transplantation EPS and its clinical consequences. These observations have raised new 
questions and revealed potential areas of interest for future research. In this section some of 
these future questions and possible research initiatives on EPS and post-transplantation EPS, 
in particular, are explored. In addition, recommendations for diagnostics and therapeutical 
approach are given.
IN WHAT WAY IS POST-TRANSPLANTATION EPS DIFFERENT FROM “CLASSIC” 
EPS?
Post-transplantation EPS appears to be diff erent in comparison with the “classic form of EPS”. 
The latter is found in association with prolonged PD and mainly reported in Japanese literature. 
The post-transplantation EPS is characterized by the appearance of EPS shortly after kidney 
transplantation and seems to be triggered by either cessation of PD treatment and/or the 
transplantation procedure itself.
Classical EPS can be seen as a result of an exaggerated healing response of the peritoneum, 
which has been exposed for a prolonged time to “toxic” dialysis fl uids. At the early stage of 
development of EPS this process is probably associated with local infl ammation to a variable 
degree1. It is unknown to what extent infl ammation is involved in post-transplantation EPS. It 
is possible that post-transplantation EPS is in fact occurring in patients that are already at the 
early stage of EPS. In post-transplant EPS patients there appear to be no abdominal complaints 
prior to the kidney transplantation, but this has not been thoroughly investigated. Possibly, 
there are also signs of enhanced peritoneal infl ammation present, indicative of an early stage 
of EPS. On the other hand, post-transplantation EPS may have a very diff erent etiology, e.g. CNI-
induced fi brosis (see below), without the presence of infl ammation. We will need to understand 
the natural clinical course of post-transplantation EPS better and investigate to what extent 
post-transplantation EPS diff ers from the classical form of EPS. The answers to these questions 
are relevant as they could be important to identify patients prone for EPS after transplantation.
In the study on post-transplantation EPS it became clear that there is also a small number of 
patients who develop EPS much longer after kidney transplantation. It needs to be investigated 
in what way these patients diff er from patients with EPS presenting shortly after kidney trans-
plantation. For example, did these patients have a more prolonged PD treatment compared to 
the patients with EPS shortly after kidney transplantation?
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WHAT IS THE ETIOLOGY OF POST-TRANSPLANTATION EPS?
Post-transplantation EPS has only recently gained interest as an important clinical entity and 
the question concerning the etiology is still open for debate. Various possibilities are plausible.
As stated before, it is possible that post-transplantation EPS occurs in patients already hav-
ing the early stage of EPS, which has gone unrecognized. Another possibility is the use of CNI’s 
that are known to have profi brotic features. Although we were unable to show an association 
with CNI’s in the described studies, this does not exclude an infl uence of this class of immuno-
suppressive drugs on the development of EPS. There are two main reasons for this statement. 
First, the increase in the number of EPS patients seems to coincide with the increasing number 
of transplantations and the subsequent use of CNI’s. Second, the pro-fi brotic quality of CNI’s has 
been documented in an animal model of EPS 2. 
However, at present the evidence for the involvement of CNI’s in post-transplantation EPS is 
not fi rm enough to propose a change of CNI’s into e.g. sirolimus as part of immunosuppressive 
regimen after kidney transplantation. In addition, post-transplantation EPS has been reported in 
patients that were given a CNI-free drug regimen 3. To answer this question a large randomized 
prospective trial comparing a CNI-free drug regimen with a standard CNI-containing regimen 
after transplantation needs to be performed. Given the low incidence of post-transplantation 
EPS this would require a multicenter, international study design.
Hypothetically the development of post-transplantation EPS might be infl uenced by certain 
viruses. It is well known that fi brosing polyoma viruses are more present shortly after kidney 
transplantation and cause chronic allograft failure due to fi brosis 4-5. A comparable reaction 
could also happen in the peritoneum. The course of post-transplantation EPS with the absent 
symptoms prior to the transplantation and the relation with the transplantation could suggest 
such an association. 
Finally, it has to be established what the contribution is of discontinuation of PD treatment 
on EPS development. With the cessation of peritoneal dialysis the peritoneal lavage of fi brin, 
possible profi brotic and pro-infl ammatory mediators is decreased, which results in an increased 
peritoneal concentration of these mediators. Furthermore the abdominal structures are more 
closely aligned because of the absence of the fl uid, which possibly facilitates the formation of 
adhesions. Perhaps the impact of kidney transplantation on EPS development is overestimated 
because it coincides with the termination of PD? We tried to answer this question in the study 
described in chapter 3.2, analyzing the role of termination of PD treatment in all our cases of 
EPS. However, the majority of EPS cases without prior kidney transplantation discontinued 
PD treatment because of signs of developing EPS. The number of PD patients developing EPS 
after terminating PD treatment, without previous symptoms of EPS, is therefore quite small. 
Therefore, this important question appears diffi  cult to answer and requires a prospective study 
in a very large cohort of PD patients.
Mario BW v4.indd   142 25-03-11   11:11
Future perspectives and recommendations 143
IS THERE A GENETIC SUSCEPTIBILITY FOR EPS?
There are patients who are on PD for many years and never develop EPS. This is an intriguing 
observation and suggest the possibility of interindividual diff erences for the risk of developing 
EPS. Are these patients in some way protected for EPS development or do EPS patients have 
certain susceptibility for EPS? In the near future this will probably gain more attention. Registries 
are already collecting effl  uent and serum samples of EPS patients 6-7. Gene polymorphisms of all 
important players in peritoneal remodeling and in the EPS development will be investigated. 
For instance, an association between EPS and a polymorphism of the RAGE receptor, one of the 
main players, has already been described 8. Other candidate polymorphisms include vascular 
growth factors, TGF-β and its downstream mediators, metalloproteases and PAI-1. 
HOW CAN THE DIAGNOSTICAL APPROACH BE IMPROVED?
Laparoscopy?
There is a lack of diagnostic criteria for the early stages of EPS, which may present with rather 
a-specifi c abdominal complaints or in patients with inconclusive radiological evidence. This 
often leads to a substantial delay in the diagnosis of EPS. Subsequently a possible benefi cial 
therapy is withheld at the early stage of the disease. Given the high morbidity of EPS it is justi-
fi ed to be more aggressive in the diagnostic approach. In the view of the author there should be 
more focus on laparoscopy with performing biopsies. There is some reluctance to perform such 
a procedure. This is because of the possibility of complications such as perforation of the bowel. 
This is however likely to be overestimated. In general the risk of perforation on laparoscopy is 
low 9. In the specifi c case of emerging EPS an abdominal CT scan is performed. When this shows 
a retracted bowel at the dorsal side of the abdomen there is usually an overlying fl uid collection 
which minimizes the risk of perforation even more. A diagnostic laparoscopy can provide the 
diagnosis when there is a clinical suspicion of EPS, but the CT scan is not yet conclusive. A 
laparoscopy also facilitates peritoneal biopsies for the diff erential diagnosis of malignancies, 
tuberculosis or fungal peritonitis. Furthermore it provides biopsy material for future research. 
MRI and ultrasound
Although abdominal CT scanning is useful for diagnosing EPS, it has some limitations. Two of 
the most important ones are that it is useless as screening tool and it has to be interpreted by 
an experienced radiologist. The radiological reports on EPS are scarce 10, but there is ongoing 
research to the contribution of MR imaging in case of EPS. There may be an enhanced contrast 
between overlying structures 11. One limitation is the motility of the bowel which interferes 
with the imaging. Ultrasound might be more promising. With the improving quality of the 
ultrasound early changes might be detected. Perhaps this should be monitored on a regular 
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basis to be able to compare the abdominal images and learn on the natural course of peritoneal 
remodeling. Additionally, ultrasound is easily accessible and can be learned by an enthusiastic 
nephrologist.
SHOULD THERE BE PRE-EMPTIVE TRANSFERRING FROM PD TO HD?
There is much debate on the subject of a fi xed expiry date of PD. As the development of EPS 
is associated with long term PD, it is sometimes suggested to discontinue PD after 3 to 4 years 
and switch to HD. In two recent commentaries on this subject it was postulated that there is 
currently little evidence to transfer patients from PD to HD, because of a chance of EPS 12. One 
of these commentaries concerned a statement from an ISPD working group 13.
However, the arguments given in these commentaries can be criticized.
First, one of the main reasons used by the authors to not transfer patients is the fact that 
EPS is not common. It is indeed true that, although the incidence of EPS is possibly increas-
ing, it still has a low overall incidence. However, summarizing the diff erent studies/registries 
of EPS, one notices that although EPS has a low incidence in the general PD population, this 
increases to 19.4% after 8 years of PD treatment 14. In order to make a correct judgment towards 
the individual risk of EPS the survival on PD has to be taken into account. From the RENINE 
database (registry of all Dutch ESRD patients with renal replacement therapy) it can be shown 
that in the period 1996-2006, 5604 patients started on PD (www.renine.nl). After 4 years only 
slightly less than 20% of these patients was still on PD. The incidence of EPS after 4 years of PD 
is approximately 5%. In the period 1996-2006 this would have resulted in approximately 1120.8 
patients still on PD for 4 years of which 56 patients would have developed EPS. Thus, although 
the absolute numbers of PD patients developing EPS are small, this is largely because relatively 
few patients are on PD for more than 5 years. 
Second, the complications of HD such as infections and cardiovascular risks are frequently 
mentioned as reasons to not transfer patients to HD. Additionally, the switch to HD could have 
important implications on the quality of life. Although these arguments are true, they primarily 
focus on the downside of HD. There are also other modalities of HD, which are reported to have 
good results concerning quality of life and outcome, such as home dialysis or nocturnal dialysis 
15-16.
The third argument concerns the limited knowledge on the EPS pathophysiology. The 
majority of the data regarding EPS incidence and pathophysiology has originated from the era 
where conventional dialysis fl uids were used. The newer more biocompatible are supposed to 
have less damaging eff ects and subsequently lead to less EPS. However the infl uence of these 
new dialysis solutions on EPS development has not been investigated.
It appears that EPS may develop after discontinuation of PD, therefore a switch could 
actually provoke an EPS exacerbation. This is possibly true for patients with long-term PD and 
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already having some early symptoms. It is unknown whether a pre-emptive switch to HD would 
prevent further peritoneal deterioration when it is done early enough. The exclusion of the 
damaging infl uence of dialysis fl uids may in the end result in less peritoneal changes. 
Finally, the majority of authors advocate a more individualized assessment of patients at risk 
for developing EPS. The primary focus should be on identifying patients using the current data 
on risk factors and markers in early stages of EPS. However, it is also recognized that there is 
a current lack of biomarkers or clinical features that are able to reliable identify the patients 
at risk for EPS. This is used as an argument against pre-emptive transfer from PD to HD. When 
using the most recent data two risk factors, ultrafi ltration failure and kidney transplantation, 
can be useful for such an individualized approach. Although it is not discriminating between 
long-term PD and EPS, ultrafi ltration failure is an universal fi nding in EPS patients. Recently the 
group of Davies et al. showed that EPS patients have on average a rapid decrease of ultrafi ltra-
tion failure in the fi rst years of PD treatment. This decrease of ultrafi ltration capacity in EPS 
patients was uncoupled from the also increasing small solute transport, which distinguishes 
them from the other PD patients 17. Our data show that on average 3% of all transplanted PD 
patients develop EPS and this percentage is probably signifi cantly higher in the subgroup of 
patients that had ultrafi ltration failure prior to transplantation. After kidney transplantation, the 
long-term survival and quality of life of these relatively young PD patients without EPS are very 
well, which can be dramatically changed by EPS. 
Therefore, it seems that in the Dutch population it is justifi ed to switch each PD patient 
eligible for kidney transplantation to HD, if he develops ultrafi ltration failure within the fi rst 2 
to 3 years after starting PD. This decision would probably result in a relatively modest impact 
on the total number of patients on PD, as the number of PD patients fulfi lling these criteria is 
rather small. 
In conclusion, the life expectancy of older patients and patients with co-morbidities is limited. 
Few patients will therefore not survive long enough to develop EPS. With the decision to switch 
the modality to HD, the risk of EPS must also be weighed against the tolerance to HD and pos-
sible associated complications. But in the end, the decision to transfer to HD will be made by 
the nephrologist and the patient, provided he is well informed. The most important question to 
be answered is whether a patient is to be exposed to the risk of disease with a high morbidity 
when he has had a few years of PD, develops ultrafi ltration failure and awaits a kidney trans-
plantation within a few years. 
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THERAPEUTICAL MANAGEMENT
Once a patient is diagnosed with EPS the therapeutical options are limited. There are numerous 
case reports on diff erent therapies in EPS patients, but these lack appropriate comparisons. At 
this stage we need to reach a clear consensus on management based on the current data and 
rationale. In the future uniform management algorithm the mainstay of the therapy should 
be adequate nutrition. In early stages corticosteroids may be applied, provided an infectious 
cause is excluded. In addition tamoxifen should be applied. In case of intestinal obstruction 
an adhesiolysis, performed by an experienced surgeon, can be considered. The latter is mainly 
performed in Japan and has shown promising results 18. Nowadays these operations are also 
conducted in the UK, but they have not reported any fi ndings yet 19.
In my view there needs to be more focus on an integrated approach with multiple disci-
plines, like dialysis nephrologists, transplantation nephrologists, dieticians, radiologists and 
surgeons. At this moment there is not a single specialized center in the Netherlands, which also 
has the surgical experience in these cases. The achievement of guidelines on therapy and at 
least one specialized center with surgical expertise should be one of the main priorities of the 
Dutch working group on EPS 20.
IS A PREDICTIVE MODEL FOR EPS POSSIBLE?
PD is a well tolerated choice of renal replacement therapy with a fair prognosis 21. Although 
EPS is increasing in incidence, it is still rare. This calls for a well-balanced decision when to 
initiate treatment and when to stop treating patients with PD with respect to the risk of EPS. 
The clinician is best helped with an algorithm. In this algorithm the choice of possible kidney 
transplantation should also be included. When one summarizes the fi ndings of the recent stud-
ies, one may conclude that we are probably close to such a predictive model.
Therefore, an important goal for the near future is to design a predictive model for EPS 
development. In the specifi c case of predicting the risk of post-transplantation EPS this should 
ideally include; the time on PD, the age at which the patient started with PD, the presence of 
ultrafi ltration failure, the longitudinal results of small solute transport tests, the expected date 
of transplantation, the possible availability of effl  uent markers and the use of icodextrin.
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INTRODUCTIE
Dit proefschrift beschrijft de incidentie van encapsulating peritoneal sclerosis (EPS) in Neder-
land, de risico factoren en de klinische consequenties. Het is in eerste instantie bedoeld om de 
nieuwe resultaten en associaties met EPS te presenteren aan de klinisch praktiserende dokter.
In hoofdstuk 2 van dit proefschrift wordt een algemeen overzicht gegeven van de huidige 
kennis omtrent EPS. Encapsulating peritoneal sclerosis (EPS) is een ernstige complicatie van 
langdurige peritoneaal dialyse (PD) met een hoge mortaliteit (50%). Een fi breuze membraan 
bedekt de darmen en veroorzaakt een intestinale obstructie. In de laatste tien jaar is er meer 
aandacht geweest voor deze complicatie. Hoewel het nog zeldzaam is, lijkt de incidentie van 
EPS toegenomen te zijn, ondanks dat er een stabiele PD populatie is. De gerapporteerde preva-
lentie van EPS varieert tussen 0.5 tot 2.5%. Het voorkomen van EPS neemt toe met het langer 
continueren van de PD. Een registratie studie vanuit Australië liet een incidentie zien van 19.4% 
na 8 jaar PD. 
Er treden verschillende peritoneale veranderingen op tijdens de PD behandeling. De 
mesotheliale laag verdwijnt (denudation). De peritoneale vasculatuur vertoont tekenen van 
progressieve fi brose en hyalinisatie van de media, neoangiogenese met vasculopathie. Hoe 
meer vaten worden ontwikkeld, des te meer interstitiële fi brose er is. De verdikking van de sub-
mesotheliale compact zone wordt veroorzaakt door interstitiële fi brose en sclerose. In EPS is dit 
nog nadrukkelijker aanwezig. De pathophysiology wordt voorgesteld als een “two-hit theory”, 
welke veronderstelt dat er minimaal twee factoren noodzakelijk zijn voor de ontwikkeling van 
EPS. Het eerste insult veroorzaakt een verstoring van de normale peritoneale en mesotheliale 
fysiologie en wordt voornamelijk veroorzaakt door de incompatibele eigenschappen van de 
dialysevloeistoff en. Het tweede insult kan dan een peritonitis, het stoppen van de PD behande-
ling of een genetisch predispositie zijn. In the primaire herstel proces van het beschadigde 
peritoneum speelt TGF-β een centrale rol. Het is geassocieerd met meer fi brose en angioge-
nese. Epitheliale tot mesenchymale transitie van de mesotheel cel (EMT) kan een belangrijke 
rol spelen. EMT is een fysiologisch proces wat plaats vindt in het gehele lichaam, zo ook in 
het peritoneum om beschadigd peritoneum te herstellen. Tijdens EMT, ondergaan mesotheel 
cellen, welke bloot gesteld zijn aan dialysaat, morfologische en functionele veranderingen. Het 
epitheliale fenotype wordt meer fi broblastisch. Vervolgens migreren deze fi broblasten naar de 
compacte submesotheliale zone en hebben mogelijk een overmatige productie van TGF-β. Dit 
proces start bij het begin van de PD behandeling en gaat door gedurende de behandeling. EMT 
is noodzakelijk voor herstel van beschadigd weefsel, maar ongecontroleerd kan het leiden tot 
fi brotische processen. Andere belangrijke spelers zijn de vasculaire groeifactoren (bv. VEGF), 
AGE’s, cytokines (IL-6), metalloproteases, transcriptie factor snail and mestcellen. 
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Naast verlengde PD duur zijn er nieuwe onafhankelijke risico factoren geassocieerd met EPS, 
zoals leeftijd, toegenomen transport van “small solutes”, ultrafi ltratiefalen, niertransplantatie en 
dialyse vloeistoff en. 
Recent zijn er radiologische criteria ontwikkeld voor de diagnostiek van EPS. Het is echter 
nog steeds moeilijk om EPS te voorkomen of in een vroeg stadium te herkennen. Abdominale 
CT scans zijn nog niet bruikbaar in dit stadium. Functionele peritoneale parameters kunnen 
wellicht bruikbaar zijn. Ultrafi ltratie falen (UFF) is een overheersende vroege verandering. Dit 
was geassocieerd met een vroeg verlies van residuale nierfunctie en de cumulatieve perito-
neale glucose blootstelling. Gewoonlijk is er een toegenomen “small solute transport” wat 
representatief is voor de eff ectieve peritoneal oppervlakte. 
Tot op heden is er geen consensus over de behandeling van EPS. De therapie moet in ieder 
geval bestaan uit ondersteunende therapie en wanneer beschikbaar chirurgie. Corticosteroï-
den en tamoxifen kunnen eveneens eff ectief zijn. 
Recente ontwikkelingen hebben een onrust teweeg gebracht onder de nefologen en heb-
ben geleid tot een discussie omtrent een mogelijke arbitraire grens van staken PD vanwege het 
risico op EPS bij langdurige PD.
INCIDENTIE EN RISICO FACTOREN VAN EPS
Hoofdstuk 3 beschrijft de twee studies die de incidentie en risicofactoren van EPS onderzoch-
ten. Het eerste onderzoek is beschreven in hoofdstuk 3.1.
In de afgelopen jaren hadden we sterk de indruk dat er een toename was in incidentie van 
EPS. Om deze verdenking nader te onderzoeken initieerden we een analyse naar het voorko-
men van EPS in twee Nederlandse academische ziekenhuizen (Erasmus MC in Rotterdam en 
Universitair Medisch Centrum Utrecht). De patiënten werden geïdentifi ceerd met behulp van 
een retrospectieve analyse van de medische dossiers in de periode 1998-2005. Deze studie 
toonde dat de incidentie van ernstige EPS signifi cant was toegenomen. Daarnaast was er een 
opmerkelijke voorkomen van EPS patiënten met een functionerend niertransplantaat. Wellicht 
kan er een pathogenetische rol worden verondersteld van een nier transplantatie in de ontwik-
keling van EPS.
Wegens de beperkte aantallen was het niet mogelijk om duidelijke conclusies te maken 
aangaande risicofactoren en de toegenomen incidentie van EPS. Daarom werd een aanvul-
lende studie verricht.
Deze studie wordt beschreven in hoofdstuk 3.2. Dit is een multicenter studie waarin acht 
grote ziekenhuizen in Nederland participeerden. Dit resulteerde in een representatieve stu-
die, aangezien het in totaal 26% van alle PD patiënten in Nederland betrof. Het design is een 
retrospectieve “nested” case gecontroleerde studie. Het bestond uit 63 EPS en 126 controle 
patiënten. Controle patiënten werden geselecteerd uit de nationale registratie (RENINE) en 
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gecontroleerd voor de start datum van PD, controles voor en na de start datum van de EPS 
patiënten. Om de associatie van PD duur in een gecontroleerde opzet te onderzoeken was 
er opzettelijk geen controle voor PD duur. Associaties werden onderzocht met een log lineair 
regressie model. PD duur, leeftijd, transplantatie, tijd sinds transplantatie, kalender tijd, follow-
up tijd, peritonitis, overgaan van PD naar HD om ander redenen dan EPS, tijd op icodextrin en 
de aanwezigheid van ultrafi ltratie falen waren van te voren gedefi nieerde voorspellers. 
De studie laat zien dat de incidentie toenam in de jaren 2003-2005, en bevestigde hiermee 
de vorige studie. Dit is waarschijnlijk niet het gevolg van een toegenomen aandacht voor 
het ziektebeeld of een verandering van de inclusie criteria welke zouden leiden tot inclusie 
van mildere vormen van EPS. De aanwezigheid van symptomen van ernstige EPS maakt het 
onwaarschijnlijk dat de diagnose gemist werd in het verleden. 
Daarnaast leek er een afname van de incidentie in 2006. Dit kan suggereren dat de toe-
name slechts een tijdelijk fenomeen was. Wij onderzochten de incidentie niet in de jaren na 
2006. Maar uit nadere bestudering van recente artikelen kan geconcludeerd worden dat de 
incidentie nog steeds toeneemt. Bijvoorbeeld, een recente observationele studie in London 
rapporteert tot 2003, maximaal 1 patiënt per jaar. In de daarop volgende jaren (2004-2008) 
worden er respectievelijk 5,6,4,6 en 11 EPS patiënten per jaar gerapporteerd. Hoewel er geen 
informatie is omtrent de hele PD populatie in deze studie, lijkt het onwaarschijnlijk dat deze in 
vergelijkbare mate is toegenomen.
In de multivariate regressie analyse hebben we de onafhankelijke associatie met PD duur, 
ultrafi ltratiefalen en leeftijd met de ontwikkeling EPS bevestigd. Elk jaar van verlengde PD 
duur heeft een relatief risico van 40% op EPS. De associaties van leeftijd en PD duur worden 
ook gevonden in een recente beschrijving van de ANZDATA registratie. Hiernaast konden wij 
nieuwe onafhankelijke associaties met de ontwikkeling van EPS laten zien, namelijk verlengd 
gebruik van icodextrin, niertransplantatie en de tijd na niertransplantatie.
Icodextrin maakt een goede ultrafi ltratie mogelijk en voorkomt het overmatig gebruik van 
glucose met potentieel schadelijke gevolgen. De associatie met EPS is dan ook verrassend 
en dient in de toekomst beter geanalyseerd te worden. De associatie lijkt niet veroorzaakt te 
worden door het veelal aanwezige ultrafi ltratie falen in EPS.
Consistent met het eerste onderzoek was er ook nu een onafhankelijke associatie met 
niertransplantatie. De profi brotische eigenschappen van calcineurin inhibitoren (CNI’s) vormen 
een mogelijke verklaring. In dit onderzoek bleek het echter niet mogelijk om de introductie van 
de CNI’s te identifi ceren als mogelijk risicofactor voor EPS. Met betrekking tot de tijd na trans-
plantatie nam de jaarlijkse kans op EPS in het jaar na de transplantatie toe van 1.75% tot 7.5%. 
Tenslotte zou niet de niertransplantatie de risicofactor kunnen zijn, maar wellicht het hiermee 
samenhangende staken van de PD. In deze studie waren we niet in staat om een dergelijke 
associatie aan te tonen. In tegendeel, we vonden dat de meerderheid van de patiënten, die 
overgingen op HD al verdenking hadden op EPS.
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VROEGE DIAGNOSTISCHE MARKERS
Hoofdstuk 4 beschrijft hoe effl  uente markers gebruikt zouden kunnen worden als vroege 
markers van EPS. Effl  uent cancer antigen 125 (CA125) is een marker van mesotheel cel massa, 
interleuking-6 (IL-6) is een marker of infl ammatie, en vascular endothelial growth factor (VEGF) 
is een groei factor voor vaatnieuwvorming. In deze case gecontroleerde studie werd het tijdsbe-
loop van deze peritoneale markers onderzocht in EPS patiënten en in patiënten gecontroleerd 
voor PD duur, die geen EPS ontwikkelden.
Dialysaat and serum afnames van 11 EPS patiënten en 31 controle patiënten, allen behan-
deld met PD voor tenminste 57 maanden werden longitudinaal verzameld gedurende een 
jaarlijkse standaard peritoneale permeabiliteits analyse (SPA). Zoals eerder waren EPS patiënten 
jonger en hadden ze een langere PD duur (104 maanden versus 72 maanden, p=0.01). Tussen 
de groepen was er geen signifi cant verschil in het tijdsverloop van de verschillende markers. 
De appearance rate (AR) van CA-125 was echter signifi cant lager in de laatste drie jaren voor 
het ontwikkelen van EPS (p<0.05) en de AR of IL-6 was in de laatste twee jaar voor EPS hoger 
(p=0.09). Lokaal geproduceerde VEGF toonde geen verschil tussen de groepen. 
De combinatie van de AR CA-125<33 U/min en de AR IL-6>350 pg/min had een sensitiviteit 
70% en een specifi citeit van 89% voor het voorspellen van de EPS diagnose. Recente artikelen 
toonden dat ultrafi ltratie falen een vroeg dominante aanwijzing is voor ontwikkelende EPS. 
De voorspellende waarde van het predictieve model nam toe als dit ultrafi ltratie falen werd 
meegenomen. De specifi citeit werd 100%, waarmee het potentieel bruikbaar werd voor het 
voorspellen van EPS. In de dagelijkse praktijk zou het nuttig kunnen zijn om patiënten te iden-
tifi ceren die meer kans hebben op EPS. Dit is belangrijk, aangezien preventieve interventies 
om de morbiditeit en mortaliteit te reduceren mogelijk eff ectiever zijn in deze fase dan na het 
vaststellen van de ziekte. Daarom wordt het aangeraden om de peritoneale functies longitudi-
naal te vervolgen met jaarlijkse peritoneale equilibratie testen met 3.86% glucose. 
Er zijn enkele beperkingen aan de studie. Niet alle analyses werden gedaan in alle patiënten 
en ondanks dat er gestreefd was naar een controle voor PD duur, bleek er toch een klein verschil 
in de gemiddelde PD duur aanwezig te zijn.
TAMOXIFEN EN OVERLEVING
Hoofdstuk 5 beschrijft het mogelijke gebruik van tamoxifen in de behandeling van EPS. Tot 
op heden is er geen consensus over de behandeling van het ziektebeeld. Aandacht voor de 
voedingstoestand is belangrijk en chirurgie met een uitgebreide adhesiolyse wordt aangera-
den. Dit laatste wordt zelden uitgevoerd in West Europa, waarschijnlijk komt dit door de kans 
op complicaties. Er zijn nog geen gerandomiseerde studies die een eff ect laten zien van een 
medicamenteuze therapie, inclusief tamoxifen. Tamoxifen beïnvloedt de activiteit van het 
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profi brotische cytokine TGF-β en heeft al aangetoond eff ectief te zijn in fi brotische aandoe-
ningen als retroperitoneale fi brose. De hypothese was dat tamoxifen zou resulteren in een 
lagere mortaliteit in behandelde patiënten. We verrichtten een retrospectieve analyse in de 
multicenter EPS studie om te onderzoeken of tamoxifen was geassocieerd met een toegeno-
men overleving in deze patiënten. EPS patiënten die behandeld waren met tamoxifen werden 
vergeleken met patiënten die niet behandeld waren. De studie laat zien dat de mortaliteit lager 
was in tamoxifen behandelde EPS patiënten vergeleken met EPS patiënten die niet behandeld 
waren met tamoxifen (45.8% vs. 74.4%, p=0.03). Beide groepen hadden vergelijkbare demogra-
fi sche en klinische karakteristieken. Nog belangrijker, de behandeling van EPS patiënten met 
tamoxifen was geassocieerd met een trend naar betere overleving, onafhankelijk van andere 
mogelijke goede behandelingsopties (HR 0.39, p=0.056). Ondanks dat verschillende mogelijke 
confounders werden meegenomen in de multivariate analyse, is het mogelijk dat er een ‘con-
founding by indication’ is. 
Indien overwogen wordt om tamoxifen te gebruiken in de behandeling van EPS, zullen ook 
de mogelijke nadelige eff ecten, als tromboembolische complicaties en endometrium carci-
noom, meegenomen moeten worden. Gezien de mortaliteit en de beperkte levensverwachting 
van EPS patiënten, lijken de voordelen van tamoxifen op te wegen tegen de mogelijke nadelen. 
De combinatie van de pathofysiologische rationale achter tamoxifen gebruik en de bemoe-
digende resultaten van deze studie ondersteunt de aanbeveling tamoxifen te gebruiken als 
additionele behandelingsoptie.
MORTALITEIT NA EEN NIERTRANSPLANTATIE TEN GEVOLGE VAN EPS
Hoofdstuk 6 beschrijft de invloed van post-transplantatie EPS op de mortaliteit na niertrans-
plantatie. EPS presenteert zich veelal na een niertransplantatie, een fenomeen tegenwoordig 
bekend als post-transplantatie EPS. De prevalentie en invloed van post-transplantatie EPS op 
de overleving na niertransplantatie zijn onbekend. De hypothese was dat post-transplantatie 
EPS mogelijk een signifi cante bijdrage levert aan de mortaliteit na niertransplantatie, welke 
voorheen niet als zodanig herkend werd.
Van 1 januari 1996 tot 1 juli 2007 werden 1241 PD patiënten getransplanteerd in de vier deel-
nemende universiteit ziekenhuizen in Nederland. Er werden 38 patiënten met post-transplan-
tatie EPS (3%) geïdentifi ceerd in de Nederlandse multicenter EPS studie. Tweehonderd-en-een 
(16.2%) patiënten overleden na transplantatie, van welke 17 EPS patiënten. Na infecties (23.9%), 
cardiovasculaire ziekte (21.9%) en maligniteit (10.9%), was EPS (8.5%) de vierde bekende oor-
zaak van dood na transplantatie. Kaplan-Meier analyse toonden een signifi cante afgenomen 
overleving van getransplanteerde patiënten met EPS. De meerderheid van de EPS patiënten 
werd waargenomen in de eerste twee jaar na niertransplantatie, echter sommige patiënten 
ontwikkelden EPS pas vele jaren na transplantatie. Concluderend, post-transplantatie EPS is 
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zeldzaam, maar heeft een hoge mortaliteit. Derhalve is een verlengde klinische waakzaamheid 
en verhoogde verdenking op de diagnose noodzakelijk, voornamelijk in PD patiënten met 
een relatieve lange PD duur. Tenslotte dragen de bevindingen bij aan de discussie of jonge PD 
patiënten vroegtijdig over moeten gaan op HD na enkele jaren van PD, terwijl ze wachten op 
een niertransplantatie of na een falend niertransplantaat.
CONCLUSIES
1. De incidentie van ernstige EPS is signifi cant toegenomen in de periode 1996-2006 in de 
Nederlandse populatie.
2. PD duur, leeftijd, niertransplantatie, tijd na niertransplantatie, verlengd gebruik van icodex-
trin en ultrafi ltratie falen (UFF) zijn onafhankelijk geassocieerd met EPS ontwikkeling. Elk 
jaar van PD heeft een toegenomen relatief risico op EPS van 40%.
3. De combinatie van de AR CA-125<33 U/min en de AR IL-6>350 pg/min heeft een sensitivit-
eit van 70% en een specifi citeit van 89% voor het voorspellen van EPS.
4. Tamoxifen reduceert de mortaliteit van EPS patiënten behandeld met tamoxifen in vergeli-
jking met patiënten die niet behandeld werden met tamoxifen. Behandeling van EPS 
patiënten met tamoxifen was geassocieerd met een trend naar toegenomen overleving, 
onafhankelijk van andere goede behandelingsopties.
5. Na infecties (23.9%), cardiovasculaire ziekten (21.9%) en maligniteiten (10.9%), was EPS 
(8.5%) de vierde bekende oorzaak van dood na niertransplantatie. De overleving van 
getransplanteerde patiënten met EPS is signifi cant afgenomen in vergelijking met getrans-
planteerde patiënten zonder EPS.
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List of abbreviations
AGE Advanced Glycation Endproducts
AR Appearance Rate
AT II Angiotensin II Inhibitors
CA 125 Cancer Antigen 125
CAPD Continuous Ambulatory Peritoneal Dialysis
CNI Calcineurin Inhibitor
CsA Cyclosporin
CTGF Connective Tissue Growth Factor
D/S Dialysate over Serum ratio
EMT Epithelial Mesenchymal Transition
EPS Encapsulating Peritoneal Sclerosis
ESRD End Stage Renal Disease
FGF Fibroblast Growth Factor
FSGS Focal Segmental Glomerulosclerosis
GDP Glucose Degradation Product
HD Hemodialysis
HPMC Human Peritoneal Mesothelial Cell
HR Hazard Risk
HUS Hemolytic Uremic Syndrome
Il-6 Interleukin-6
IQR Interquartile Range
ISPD International Society Of Peritoneal Dialysis
K Potassium
MMF Mofetil Mycophenolate
MMP Metalloprotease
MPGN Membranous Proliferative Glomerulonephritis
OR Odds Ratio
PAI-1 Plasminogen Activator Inhibitor 1
PD Peritoneal Dialysis
PDGF Platelet Derived Growth Factor
PET Peritoneal Equilibration Test
RAGE Receptor of AGE
RENINE Renal Replacement Registry in The Netherlands
RRT Renal Replacement Therapy
SD Standard Deviation
SERM Selective Estrogen Receptor Modulator
SMAD Proteins that transduce extracellular signals from TGF-β ligands to the nucleus
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SPA Standard Peritoneal Permeability Analysis
TGF-β Tumor Growth Factor-β
TNF-Α Tumor Necrosis Factor-Α
Tpa Tissue-Type Plasminogen Activator
TPN Total Parental Nutrition
UFF Ultrafi ltration Failure
VEGF Vascular Endothelial Growth Factor
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Dankwoord 
Een ieder die mij kent, weet dat ik altijd geroepen heb, dat een proefschrift niets anders is dan 
een aantal artikelen met een kaft erom heen. Dat vind ik na deze jaren nog steeds. Het zou meer 
moeten gaan om de onderzoeksvraagstukken en niet zo zeer om het afronden van het boekje 
zelf. Nu de onderzoeken eenmaal gebundeld zijn in dit boekje, durf ik echter wel toe te geven 
dat dit toch een mooie voldoening geeft.
In de afgelopen jaren is het onderzoek verlopen, zoals ik me altijd had voorgesteld, hoe een 
ideaal onderzoek zou verlopen. Het begon met het constateren van een echt klinisch relevant 
probleem, in dit geval de indruk dat EPS toenam in ernst en voorkomen. Daarna hebben we 
hypothesen geformuleerd en een onderzoeksvoorstel geschreven. Van begin tot eind hebben 
we het daarna als ons eigen onderzoek beleefd. We hopen hiermee te hebben bijgedragen aan 
de zorg van patiënten met EPS, want uiteindelijk is dit toch het belangrijkste doel!
De uiteindelijke publicaties zijn met veel hulp tot stand gekomen. Er zijn dan ook veel mensen, 
die ik dankbaar ben voor hun bijdrage aan de onderzoeken.
Allereerst, mijn co-promotor, Michiel Betjes; veel goede ideeën ontstaan op merkwaardige 
momenten. Zo geldt dat ook voor dit onderzoek. De basis voor onze belangrijkste ideeën voor 
het gehele EPS onderzoek is ontstaan terwijl we stonden te brainstormen buiten de HRU naast 
de enorme (en stinkende) prullenbak. Ik was me op dat moment al bewust van de combinatie 
van een merkwaardige omgeving en de goede ideeën. Het mooie is dat al deze ideeën uit-
eindelijk uitgewerkt zijn. Ik vind onze samenwerking erg plezierig, buitengewoon stimulerend 
en eff ectief. Daarnaast ben je gewoon een hele prettige vent om mee te ouwehoeren of om 
bubbels mee te drinken. Dank je wel!
Het eerste initiatief voor het onderzoek kwam tijdens de grote visite op 3 Noord van de 
professoren Weimar en Zietse. Willem en Bob, jullie gaven de eerste belangrijkste aanzet tot 
wat uiteindelijk heeft geleid tot dit onderzoek. Jullie ongeruste waarneming werd vergezeld 
van een wens tot nadere analyse van het probleem. Ik nam “de opdracht” met een zekere 
vrijwillige interesse aan met uiteindelijk dit proefschrift als gevolg. Willem, veel dank dat ik bij 
je mocht promoveren. Bob, niet alleen was je een belangrijke sparringpartner in het begin van 
het onderzoek. Maar ik ben je vooral ook dankbaar voor de opleiding nefrologie, die ik met veel 
plezier heb kunnen doen, ondanks dat we toch uiteindelijk nooit die subsidieaanvraag hebben 
gekregen.
Marien Fieren, jij liet met jouw PD expertise veelvuldig de noodzakelijke kritische noot 
horen. Dank hiervoor en ik wens je veel plezier met je pensioen.
Professor Krediet, beste Ray, het koste me wat energie om je erbij te krijgen, maar ik ben heel 
blij dat we hebben samengewerkt. Het heeft geresulteerd in twee mooie proefschriften. Dank 
je wel hiervoor! Jouw aanwezigheid in mijn promotiecommissie is een mooie afsluiting van 
deze unieke Rotterdamse-Amsterdamse samenwerking.
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Jan van Saase, jij was mijn polibegeleider in de Clara en (met René) partner in crime voor 
eerste stappen in wetenschappelijk onderzoek, namelijk de interessante vraag naar “seasonal 
variation of blood pressure in HD patients”. Daarom is het bijzonder voor mij dat je nu in de toga 
aan de andere zijde plaats neemt, dank je.
Professor Lindholm, I am most grateful that you were willing to join us for this ceremony. I 
am looking forward to our further collaboration in the EPS/PD study group.
Professor Ewout Steyerberg, met Hester heb je een goede troef voor dit soort onderzoek. 
Ik heb het bijzonder gewaardeerd dat wij de nodige epidemiologische en statische steun van 
jullie kregen, die we als dokters toch ontberen. Dank voor het plaatsnemen in mijn commissie 
en ik hoop nog fi jn te kunnen samenwerken in het kader van EPS registratie.
Professor Tilanus, nadat u in 2008 bereid was om plaats te nemen in de promotiecommissie 
van mijn vrouw, neemt u nu ook in die van mij plaats. Dank u wel.
In dit deel van het dankwoord, kom ik met de bekentenis dat (ook) ik dit niet zonder hulp van 
vrouwen had kunnen voltooien. Hiervoor wil ze danken.
Allereerst, Denise Sampimon, deze “rare” Rotterdammer heeft ons unieke Rotterdamse-020 
initiatief ook bijzonder en plezierig gevonden. Je hebt een bepaalde eigenwijze volhardend-
heid (al die vragen over het multicenter stuk) en doorzettingsvermogen die uiteindelijk tot 
verbetering van de stukken hebben geleid. Daarnaast heb je een mooi streven naar een com-
binatie van serieus onderzoek doen en plezier hebben. Ik hoop dat je weer veel (dans)plezier 
hebt op het feest. Veel dank voor het fi jne samenwerken!
Hester Lingsma, je werd door Wilma aan mij geïntroduceerd als superslim, handig en ook 
nog erg aardig. Dat is inderdaad zo! Je hebt het vermogen om ingewikkelde statistische zaken 
uit te leggen alsof het lesstof voor een zesjarige is. Dank voor je hulp!
Aline Hemke (van RENINE en NOTR), ondanks dat ik je nog nooit gezien heb, ben je van 
onschatbare geweest voor de onderzoeken. Zelfs tijdens mijn vakantie in Italië spraken wij 
elkaar, omdat ik je weer bestookt had met één van mijn verzoeken voor nog wat extra data. Je 
bereidheid en snelle service waren een zegen. Dank je wel!
Zoals in elk onderzoek en eigenlijk ook in de dagelijkse praktijk zijn dialyse verpleegkun-
digen en secretaressen onmisbaar. Voor hen in alle deelnemende centra, veel dank. In het 
bijzonder, Saida en Natalie dank voor jullie hulp in de laatste fase van dit boekje.
De studies werden uitgevoerd in samenwerking met een aantal top centra. Frans van Ittersum, 
Ad Zanen, René van den Dorpel, Marieke Yo, Walther Boer, Ruud de Sévaux, Stijn Konings, ik 
ben jullie dankbaar voor de tijd en energie, die jullie met jullie centra in de verzameling van de 
gegevens en de interessante discussies hebben gestoken.
Meelad Habib, jij kwam er op het laatst bij, maar was gelijk heel belangrijk voor het transplan-
tatiestuk. Dank je wel! Je hebt een gezonde ambitie en ik kijk met veel plezier en vertrouwen uit 
naar jouw onderzoekstraject.
Mario BW v4.indd   160 25-03-11   11:11
Dankwoord 161
All the members of the EPS study group, both in The Netherlands and in the international 
working group; I am looking forward to our further collaboration and am convinced that 
the registry will be successful and lead to an improved management of the EPS patient. Els 
Boeschoten, jouw aandeel als de initiator van de EPS registratie is niet te onderschatten. Ik 
waardeer de fi jne samenwerking. 
Sinds 2008 mag ik deel uitmaken van de maatschap Interne Geneeskunde van het Albert 
Schweitzer ziekenhuis in Dordrecht. Ik wil mijn maten danken voor hun interesse. En in het 
bijzonder Eric, Gijs en Peter; jullie hebben mij de vrijheid gegeven om dit onderzoek verder te 
voltooien. Onze samenwerking ervaar ik als bijzonder plezierig, eerlijk en stimulerend. Peter, 
dank voor je kritische review op het transplantatie stuk (it payed off ).
Iedereen weet dat mijn prioriteit altijd zal liggen bij mijn familie en vrienden. Daarom wil ik 
hen allen danken. Niet zozeer voor de bijdrage aan het proefschrift, maar simpelweg omdat 
dit altijd een goede manier is om hen te danken voor hun vriendschap! Ik hoop dat er nog vele 
mooie momenten van samenzijn en plezier zullen zijn. Van de beste vrienden die ik heb, zullen 
er twee mij bijstaan op deze dag als paranimf. 
Tundi, we hebben al mooie dingen gedaan en beleefd (samen met de mannen en tegen-
woordig ook vrouwen). Wij weten dat we niet veel nodig hebben om elkaar te begrijpen. Jij zult 
de voorkant van dit boekje hebben herkend. Want ook daar was de uitwisselingen van blikken 
onderaan de MB top voldoende om de gevoelens weer te geven. Dat gaf toen veel steun en 
goede moed, want ik had het moeilijk. Op dat soort momenten wordt alleen maar bevestigd 
wat voor vriend je bent. Daarom vind ik het ook super dat je vandaag naast mij wilt staan. 
Bas, samen hebben we gestudeerd in de bieb, afgewisseld met wat basketballen op de 
Kade. Het is veelzeggend voor onze band, dat jij met mij in een te smalle roeiboot kan zitten, 
terwijl ik zit te tieren en te vloeken (en jij alleen maar lacht)! De afgelopen jaren hebben we 
fi jne, bijzondere en moeilijke momenten gedeeld. Het is mooi dat we de lijn mogen doorzetten 
en jij mijn paranimf bent. Dank voor je vriendschap!
Dit proefschrift is voor mij niet los te zien van een aantal andere life events, waaronder het 
verbouwen van een huis. Dit bleek een lastige combinatie, maar werd behaald met veel hulp. 
Tineke, Paul, Ria, Karel, Mam en Pa, veel dank!
Pap en mam, dit proefschrift is ook voor jullie. Jullie hebben er uiteindelijk voor gezorgd 
dat Mariska en ik zijn, wie we nu zijn. In de laatste jaren van het onderzoek vond ik het grappig 
dat jullie na een tijdje ook door hadden hoe dat werkt met artikelen en reviseren van artikelen, 
vooral dat ene irritante stuk. Dank jullie wel voor jullie liefde.
Essie, voor ons geen promotie clichés! Dit soort boekjes betekende namelijk een goed 
excuus voor samen relaxen (in het bijzonder in de bergen). Jouw afronding in Chamonix 
betekende gelijktijdig mijn wetenschappelijk begin en wat volgde waren fi jne “werkweken” in 
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onder andere Tubbergen en Odoorn. Heel graag wil ik samen met jou nog veel meer genieten 
van die letterlijke en fi guurlijke toppen. Om in onze stijl af te sluiten: …“Somewhere over the 
Rainbow”…HvJ en DZ, Chico
Mario
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Mario werd op 21 november 1972 geboren in ’s Gravenhage. Vanaf zijn derde jaar woonde hij 
samen met ouders en zusje in Maassluis. Voor de middelbare school fi etste hij elke dag naar 
Vlaardingen. Hij deed het VWO op de Prof. Casimir school, hoewel zijn grootste aandacht uitging 
naar het judo. In Rotterdam werd er vanaf 1991 onder andere ook geneeskunde gestudeerd, en 
op 16 april 1999 werd het artsexamen behaald.
Na twee jaar als AGNIO in “de Clara”op Rotterdam-Zuid gewerkt te hebben, begon aldaar op 
1 januari 2002 ook de opleiding interne geneeskunde onder de leiding van dr. Albert Groot-
endorst. Na vijf jaar Clara werd de opleiding afgerond in het Erasmus MC. Aanvankelijk was dit 
onder leiding van prof.dr. Huib Pols als opleider, later werd hij opgevolgd door prof.dr. Jan van 
Saase. Vanaf 2005 kon hij onder leiding van prof. dr. Bob Zietse de nefrologie leren. Vanaf juni 
2008 is hij werkzaam als internist-nefroloog in het Albert Schweitzer ziekenhuis, in Dordrecht.
Na vele jaren in de energieke stad, Rotterdam, woont hij nu aan de Waal in Her…wijnen. In 
2007 mocht hij trouwen met Esther.
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Encapsulating Peritoneal Sclerosis in the Netherlands
A study on incidence, risk factors and clinical consequences
The picture on the cover of a book is not only attractive, but also tells a lot about the 
author and the path he has travelled to complete the book. Performing scienti c re-
search mimics mountaineering in many ways. The way to the top is sometimes di  cult 
and can be dangerous. At each attempt one encounters new problems which have 
to be overcome. Only by careful planning and having the guts to take the necessary 
steps the summit can be achieved. The journey to the summit is di  cult but at the 
same time the undiscovered territory is fascinating and tremendously appealing to 
mountaineers and scientists. Once on the top it is as if one is in an unknown surround-
ings like nothing seen before.
As Everest conqueror Sir Edmund Hilary stated 
”It’s not the mountain we conquer, but ourselves”.
Encapsulating Peritoneal Sclerosis in the N
etherlands
A
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